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The Lander College of Arts and Sciences
at Touro College of Flatbush
Throughout its 38-year history,Touro’s Lander College of Arts and Sciences of Flatbush (with separate
men’s and women’s schools) has provided cohorts of aspiring high school graduates from well-regarded yeshivas and seminaries with a foundation of academic excellence for professional career growth,
in an environment that is supportive of the religious values of its students. Graduates have assumed
leadership roles and continue to strengthen Jewish communities throughout the world.
Lander College of Arts and Sciences–Flatbush offers more than 25 majors and preprofessional options, and three joint undergraduate/graduate degree programs in occupational therapy, physical therapy and physician assistant studies with the School of Health Sciences. Honors tracks in biology, the
health sciences, political science and psychology are currently offered.
Students are also required to complete a carefully designed core curriculum that emphasizes the development of communications skills, critical thinking and analytical competencies, computer literacy
and quantitative reasoning. Enrollment in science courses, notably biology and chemistry, continues to
increase, reflecting the career interests of premedical and health science students.
Faculty members continue to earn recognition for outstanding achievements, including Joshua November, Assistant Professor of Languages and Literature, who was selected as a finalist for the Los
Angeles Times Poetry Book of the Year Prize in 2011; Karen Sutton, Assistant Professor of History,
whose significant Holocaust analysis, The Massacre of the Jews of Lithuania, 1941-44, was published
in 2008; and Atara Grenadir, Assistant Professor of Art, whose works were displayed at the Art Expo
2011 show in New York City.
Notable alumni distinctions of Touro’s Lander College of Arts and Sciences of Flatbush include: David
Greenfield (JD, Georgetown), elected to the New York City Council (44th Council District) in 2010;
Dr. Israel Deutsch (MD, Einstein), appointed as Director of Brachytherapy at New York-Presbyterian
Hospital/Columbia University; Yossi N. Heber (MBA, Wharton), President, Oxford Hill Partners; Dr.
Haim Mozes (PhD, NYU), Asso- ciate Professor, Graduate School of Business, Fordham University;Vivian Schneck-Last, Managing Director, Goldman Sachs; and Sara Grossman Wiederblank, who published
her fourth novel, Pass or Fail, in 2010. Alumni have published articles in the New York Law Journal,
Bloomberg Law Reports, Institutional Investors Journal and other peer- reviewed journals.
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Abstract
Influential American medical organizations and publications have published guidelines for the treatment of acute migraine
headaches that omit antiemetics, usually suggesting triptans as the first line of treatment. A review of the few comparative
studies directly contrasting clinical outcomes of triptans and antiemetics in the treatment of acute migraines suggest that
both treatment options are relatively equal in efficaciousness. The added burden of triptan usage, including an added risk
of adverse effects and a high cost per dose, would seem to warrant an antiemetic-first approach to migraine treatment,
as recommended by several international health communities. Possible reasons for the prominent omission of antiemetics
from leading publications may include medical parochialism and pharmaceutical funding of medical research.
Introduction
In January 2002, the New England Journal of Medicine published a
paper entitled “Migraine-Current Understanding and Treatment,”
written by several leading neurologists. The paper reviewed
all the current treatment options for migraine headaches, and
strongly emphasized triptans, a relatively new class of drugs
developed by drug companies specifically to address migraines
(Goadsby et. al., 2002). One of the most notable aspects of the
paper was that it completely omitted the drug class antiemetics,
which is increasingly used nationally and internationally, mostly
among emergency medicine practitioners, to treat acute migraine
headaches (Seguil & Lax, 2014). One factor for this omission may
have been the varied perspectives which can often develop between members of different specialties of medicine, with neurologists recommending one therapy and emergency medicine
doctors recommending another (Newman, 2009). Nevertheless,
it is likely that the authors were aware of the therapeutic history
of antiemetics for migraine headaches, and they chose to omit
it. In fact, the papers recommendations are completely consistent with the guidelines published by the American Academy of
Neurology (n.d.).The purpose of this review is to assess whether
these influential omissions are in fact warranted by clinical observation and meta-analysis, or if antiemetics should be considered
an efficacious treatment for acute migraines with the right clinical
indications. Possible biases that could have caused conscious or
subconscious influences on the recommendations of different
groups will also be analyzed as a method of understandings them.

Methods
In order to assess antiemetics as an efficacious treatment option
for acute migraines, a meta-analysis of the published literature
was undertaken. Comparative studies between the effectiveness
of triptans and antiemetics is the main focus. In assessing clinical
value, both primary effectiveness and secondary side-effect prevalence were surveyed to accurately portray an overall picture of
patient outcomes. Clinical trials were obtained using the National
Institute of Health’s PubMed search engine, and only studies published in reputable academic journals were included.

Migraine Headaches
A migraine headache is defined as a headache that usually affects

one specific area or side of the head and is frequently accompanied by nausea, sensory sensitivity, and possible neuralgia (Ferrari,
2013). Headaches accompanied by neuralgia have been recorded
since ancient times, as far back as the ancient Egyptians (Miller,
et. al. 2005). The difference between a normal headache and a
migraine is often one of degree and thus cannot always be definitively assessed; however, chronicity can be an important indicator
of migraines. The first modern treatment for migraines was ergotamine (Woakes, 1868), which was originally hypothesized to
slow the stimulation of sympathetic nervous pathways (although
its mechanism is now contested). The pathogenesis of migraines
was illuminated in the 1940s, when serotonin was isolated as a
potent cause of migraines (Wolff, 1948).This discovery led to the
serotonin-inhibiting class of migraine treatments, starting with
methylsergide, which was first used in the middle of the 20th
century (Sicuteri, 1959).
This paper focuses on two modern therapies for migraine headaches: triptans, of which the prototype drug is sumatriptan, discovered in 1988, and antiemetics, which are primarily anti-nausea medications, including domperidone, metoclopramide, and
prochlorperazine. These drugs are typically given together with
an analgesic, usually aspirin. Other commonly used pain-relieving
drugs, such as NSAIDs, caffeine, and codeine should be noted, but
are not of specific interest to this discussion.

Triptans
Triptans were first used in the treatment of migraines during the
1980’s, when interest surged in examining the role of serotonin
(5-HT) in the pathogenesis and pathophysiology of migraines
(Bateman, 2000). Triptans are a class of drugs that affect serotonin receptors, commonly called 5-HT receptors, of which there
are many subtypes. Triptans are 5-HT agonists, binding with high
affinity to many 5-HT subtypes that cause potent vasoconstriction of many intracranial blood vessels. They also affect various
neurotransmitters and chemical mediators, but no specific effect has been conclusively tied to theiranti-neuralgic properties.
Because of a variety of concerns regarding the effectiveness of
the original triptans, such as variable bioavailability, variable absorption, and significant adverse effects, new classes of triptans
have been continuously developed by drug companies. Some of
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the most recent triptans typically prescribed for migraine headaches include almotriptan, frovatriptan, and avitriptan (Loder,
2010). Although the mechanism of the therapy remains unclear, it
is generally recognized in the United States as a first-line therapy
for patients unresponsive to analgesics. Triptans provide relief of
symptoms within the first 10-60 minutes of use, depending on
route of entry (Loder).

Antiemetics
Antiemetics are drugs that relieve symptoms of vomiting and
nausea. They are usually used to treat motion sickness and to
relieve the side effects of nausea-causing therapies. The use of
antiemetics as a direct therapy for migraine headaches was a
serendipitous discovery. Originally, antiemetics were used to
allow sufferers of migraines to ingest drugs given to relieve the
headaches. However, physicians soon began to notice that the
symptoms of the migraine headaches were relieved before the
primary therapy could be given. Thus antiemetics soon became
the drug of choice, especially among emergency medicine practitioners, to treat analgesic-resistant headaches (Newman, 2009).

Comparative Studies
Unfortunately, and for possible reasons that will be addressed
further, there are very few studies that directly compare the
efficaciousness of triptans and antiemetics in the treatment of
migraine headaches (Gupta et. al., 2002). However, a number of
studies have been completed globally that directly contrast these
two treatment options.
The first comparative study was published in 1995, comparing
oral sumatriptan (a triptan) with lysine acetylsalicylate plus metopramide (an aspirin plus an antiemetic) in their effectiveness
in treating migraines (Tfelt-Hanson et. al., 1995). This study was
conducted between October 26, 1993 and July 18, 1994 at over
68 medical centers in Belgium, Denmark, the Netherlands, and
France, and included only patients with significant histories of
migraine headaches. It was a randomized, double-blind study,
which included follow-up for up to as eight weeks, as needed.
Four hundred twenty-one patients participated in the study. The
study showed that in numerous benchmarks for effectiveness,
the two treatment options were virtually identical, including improvement in immediate headache severity, control of adverse
effects, headache recurrence, and patient satisfaction.The authors
concluded that “there is no difference in primary or secondary
efficacy between LAS+MTC and oral sumatriptan…because of
its high price physicians should consider whether the routine use
of sumatriptan as the initial treatment of a migraine attack really
is preferable to the use of cheaper drugs such as analgesics combined with an antiemetic.” Indeed, in Europe and in many other
countries, these recommendations are generally considered best
practice (Newman, 2009).
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A subsequent study was performed in three medical centers in
France, with a total of 666 participating patients (Geraud et. al.,
2002). It was a multicenter, double-blind, randomized study, and
follow up was performed until fifteen days after the last migraine
attack took place. Each patient was given one of the following: acetylsalicylic acid plus metoclopramide, zolmitriptan, or a
placebo. The patients were then requested to keep an hourly
diary to record headache relief, overall pain relief, nausea levels, any adverse effects, and overall satisfaction with the therapy. The study results seemed to be inconclusive initially, as the
authors wrote: “Both treatments reduced migraine-associated
nausea, vomiting, phonophobia and photophobia. There were no
important inter-group differences with respect to the onset of
meaningful migraine relief, the frequency of headache recurrence,
the usage or efficacy of a second dose of medication or the use
of escape medicine.” However, the authors preceded to perform
what they called a “post hoc analysis,” in which they found certain benefits to triptan use, including a greater overall patient
satisfaction, overall pain-free reporting (as opposed to headache
pain), a greater efficacy in patients with “migraine associated with
menses,” and the fact that triptan use was “unaffected by age,
weight, or gender.” They thus concluded that “Although evaluation using the primary end point in this study was inconclusive,
other end points such as freedom from pain, now identified as
more clinically relevant end points, showed zolmitriptan 2.5 mg
to be significantly better that the standard analgesic-anti-emetic
combination of acetylsalicylic acid and metoclopramide.” In summary, this study found slight benefits to triptan use, although it is
important to note that for all the primary end points designated
before the study was completed, the therapies were identical.
Only after the data was collected did the authors find certain
benchmarks that could be identified as benefits to triptan use.
This is generally considered a far less objective method of gathering data, as it allows the investigator considerable latitude in
actively picking specific data sets. In what may be an important
note, the study concludes with an acknowledgement that “this
study was supported by AstraZeneca Pharmaceuticals.”
A third study, performed in New York City, compared aggressive
metoclopramide treatment, consisting of four infusions within
the first two hours, to subcutaneous sumatriptan treatment of
migraine headaches (Friedman et. al., 2005). Two hundred two
patients participated in the trial. Patients were not followed after
the initial twenty-four-hour period, which can be considered a
weakness in their overall assessment of the therapies; in fact, only
37 of the patients completed the twenty four-hour follow-up
protocol. In addition, the patient population studied was almost
completely comprised of individuals of Latino origin, making extrapolations to general populations uncertain.Another concern is
that the study excluded those suffering chronic migraines, which
may be a population which reacts differently to specific therapies.
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The study concluded that there were no significant differences
between the two therapy options in reaching the primary end
points of the study, including headache relief, nausea relief, and
overall well-being. However, in their own post hoc analysis, the
authors find certain benefits to metoclopramide use, including
twenty-four-hour symptom relief.
A fourth comparative evaluation was performed in Iran at the
Isfahan University of Medical Sciences, comparing metoclopramide to sumatriptan for migraine headache treatment (Talabi
et. al., 2013). This study was performed on emergency room
patients. One hundred twenty-one subjects were included in
this randomized, double-blind study. Several introductory notes
should be mentioned about this study. First, the command of the
English language displayed by the authors is competent overall
but nevertheless displays signs of possible grammatical and idiomatic peculiarities which may or may not result in important,
altered connotations (for example, the authors wrote that their
study included a “controlled study design and patient blindness”).
Second, the study noted that “it is surprising that no subjects in
both groups complained of adverse effects.” This is a significant
deviation from other comparable studies, which may be a cause
for concern. The authors attempt to explain this discrepancy as
“a result of slow metoclopramide injection and the way the question about these effects were phrased.” It also may be a reflection
of cultural differences in the way side effects are described, or
how often, or upon what level of acuteness, they are remarked
upon. The patients were all observed during the initial hour after
they were treated. The results of this trial were that metoclopramide was superior to sumatriptan in headache relief (Talabi).
In summary, there are very few studies that directly compare
triptans to antiemetics for acute migraine headache relief. The
few that have been performed suggest that the therapies are relatively similar in effectivity for all primary end points.

Triptans vs Antiemetics: Other Differences
The fact that triptans and antiemetics have been shown to have
similar outcomes in treating migraines does not necessarily mean
that they are equally sound treatment options. In fact, there are
several reasons why triptans may be a less advisable treatment
option. The first is adverse effects. Triptans are known to cause
several negative effects in patients. The most common set of adverse side effects, affecting almost half of all triptan users, is often
referred to as triptan sensations, and includes upper chest pressure or pain and epithelial flushing. Rare cardiovascular events
have also been reported and triptans are thus contraindicated in
those with possible cardiac disease. This stands in contrast to antiemetics, and specifically to metoclopramide, which have minimal
reported adverse effects. The second shortcoming of triptans is
their often high price, with the average cost of a single triptan pill

typically exceeding ten dollars, while a single dose of antiemetics
can cost less than ten cents (Adelman et. al., 2004). The benefits
of antiemetics are thus both in terms of adverse effects, which
are minimal, and cost, as they are extremely cheap therapy to
provide to patients. Therefore, if antiemetics can be shown to
be comparably effective to triptans in specific clinical settings,
which seems to be the case, they can plausibly be considered
a superior therapy overall under those conditions. Thus it remains puzzling how the 2002 review article in the New England
Journal of Medicine completely omitted antiemetics in its review
of migraine relief protocols, and why it is omitted from the recommendations of the American Academy of Neurology on the
treatment of migraines.

Medical Parochialism
Parochialism in research has been a phenomenon long noted and
lamented by meta-researchers (March, 2005). It is often based
on nationality, with different countries’ research communities
favoring different approaches. These differences can have cultural,
ideological, or experiential origins. Parochialism can also be of
disciplinary origin. In the medical field, this has often been the
case; for example, medical doctors and nurse practitioners often
find themselves at odds over a variety of disciplinary differences
(Phillips et. al., 2002). In the specific case of the triptan vs. antiemetic debate, the difference in recommendations may have arisen from the different perspectives that neurologists and emergency medicine doctors have of migraine sufferers. Emergency
medicine practitioners generally see patients who are in the midst
of acute migraine attacks. Therefore, their perspective is geared
toward therapies that are most efficacious at immediate migraine
relief, and this may factor into their preference of antiemetics to
triptans (Friedman et. al., 2014). Neurologists, on the other hand,
see mostly patients who are chronic migraine sufferers, and may
therefore strongly favor treatments that provide longer-lasting
relief. Nevertheless, it must be emphasized that the review in
the New England Journal of Medicine was a complete review of
both acute and chronic migraine treatments, and thus explicitly
included the medical protocols in which emergency medicine
practitioners are most experienced. It is therefore quite possible
that parochialism is at fault for the varying guidelines proposed to
treat migraines, where one field’s inherent biases led it to ignore
or be unfamiliar with the practices of other fields. (It should be
noted, however, that the 2005 study that found that antiemetics
were comparable to triptans was authored by emergency room
doctors and was published in the journal Neurology.)

Pharmaceutical Funding
Surveying the comparative studies of triptans and antiemetics
brings to the fore the often uncomfortable question of relationships between for-profit companies and medical institutions and
research facilities (Smith, 2003). Although many regulations have
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been passed over the last few decades, which have helped prevent the more egregious practices of pharmaceutical companies,
many interactions remain that might possibly compromise clinical
objectivity (Brody, 2005). It is certain that drug companies would
favor the use of expensive, patented triptans over the cheap antiemetic drugs, and it is thus distressing that a drug company was
the primary funder of the single comparative study that found, in
post hoc data examination, that triptans were a superior treatment option. The other studies were free of any reportable conflict of interest, and came to different conclusions. In addition, the
review article from the New England Journal of Medicine, which
strongly focused on and recommended triptan use, closes with
a fine-print disclosure that all the authors have been recipients
of grant funding or have acted as consultants for many different
drug companies, including all those that currently manufacture
triptan medications (Newman, 2009). This fact may explain why
the authors, consciously or not, were especially focused on triptan therapy. Of course, this does not mean to slander the authors
in any way or to impugn their professional reputation, but rather
to bring into focus the problems associated with industry funding
of scientific enterprises. Certainly, the fact that such funding is
indispensable to many research projects cannot be ignored, but
perhaps other remedies, such as the mandatory authorship of
one author without reportable conflicts of interest, can be advanced to protect the integrity of these studies.
Another important question regarding pharmaceutical company
funding of medical research is the types of studies performed.
For example, if a pharmaceutical company deems a therapy to
be dangerous toward its bottom line, it may simply withdraw all
funding for studies pursuing that therapy, leaving little incentive
for researchers to pursue it. This may explain why so few studies
have actually been performed comparing triptans directly with
almost any other therapy, including antiemetics, and instead most
research in the field consists of large studies, including thousands
of patients (Ferrari et. al., 2002), which look solely at the benefits
of triptans.
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Abstract
Many studies examine the effects of vigorous cardiovascular exercise on the heart. Intense exercise causes frequent
muscle contractions in the heart and specific biomarkers that usually signify a myocardial infarction are released into
the bloodstream. However, studies indicate that there might not be a correlation between the release of biomarkers
and cardiac function. Another study shows that long term vigorous exercise negatively affects the heart by dramatically
increasing the mass and volume of the right and left ventricles, thereby resulting in hypertrophy. The cardiac hypertrophy
is still evident even after the subjects have stopped exercising. Cardiac hypertrophy results in myocardial fibrosis and
scarring. The percent of myocardial fibrosis in those engaging in long term vigorous exercise was significantly higher than
that of the control group. After intense training, tests found a reduced right ventricle ejection fraction due to dilation of
the right ventricle while there was no dilation in the left ventricle. In addition, a correlation was found between reduced
right ventricle ejection fraction and ventricle arrhythmias. The mortality rate of vigorous exercisers was slightly higher in
comparison to those who moderately exercised. Animal studies showed that rats who exercised developed left ventricle
hypertrophy, impaired diastolic function, and right ventricle dilation, the symptoms found in humans with an “athlete’s
heart.” Additional research on the effect of vigorous exercise on the heart needs to be conducted to verify these findings.
Introduction
In 490 BCE Pheidippides, a 40 year old courier ran 24.8 miles
from Marathon to Athens to announce the Spartan victory over
the Persians, and then dropped dead from what is believed to be
cardiac arrest.This is the earliest mention of death due to aerobic
activity (Trivax & McCullough, 2012). It was not until the 1970s
that jogging would become a popular form of aerobic exercise.
The many physical and physiological benefits of aerobic exercise
caused this phenomenon to grow. In 2010, statistics indicated
around 36 million people jog daily. In 2013, 541,000 people completed a marathon (which is an intense aerobic event of 26.2
miles) in the United States alone (Schnohr, et.al. 2013 & Martin,
2014). It has been hypothesized that a person capable of completing a marathon is immune to coronary heart disease (Bassler,
1974). This hypothesis is not fully supported since a six year
study from 1975-1980 showed that eleven men died in Rhode
Island while running; the cause of death being coronary heart
disease (Thompson et. al. 1982). In addition, a study conducted
from 2000-2010, shows that out of 10.9 million people who have
completed marathons or half-marathons, only 59 have suffered
cardiac arrest, majority due to coronary heart disease. (Kim, et.al.
2012).
The World Health Organization endorses at least 150 minutes a
week of moderate demanding aerobic activity (such as walking,
water aerobics, and bicycling) or 75 minutes a week of vigorous-intensity aerobic physical activity (such as jogging, running,
and swimming laps) for significant health benefits (Prevention
and Health Promotion, 2014). People may think that exercising
vigorously for longer periods of time would increase the health
benefits. However, it is unclear whether more intense exercise
improves the efficiency of the cardiovascular health or if it overexerts the heart and thereby puts the individual’s health at risk.
By examining the data and studying trends associated with extreme exercise and productivity of the heart, this review will try
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to determine if prolonged vigorous exercise is detrimental to a
person’s cardiovascular health.

Methods
This comprehensive review was written through the critical analysis of clinical research papers and peer reviewed journal articles.
The necessary material was found using Touro College’s online
databases, such as Pubmed, Medline and EBSCO. Google and
Google Scholar were used to search specific keywords related
to the topic.

Discussion
The Mechanism of Cardiac Contraction
Cardiac muscle contraction and relaxation has been studied
on the cellular and molecular level. The overall mechanism for
muscle contraction is known as excitation–contraction coupling.
In excitation–contraction coupling, an electrical stimulus (action
potential) transforms into a mechanical response (muscle contraction). In cardiac muscle, excitation–contraction coupling
occurs by a more specific mechanism of calcium-induced calcium
release, a positive-feedback system where calcium induces the
release of more calcium from intracellular Ca2+ supplies. The
internal conduction system initiates an action potential that progresses along the t-tubules of the cardiomyocytes, resulting in
the opening of voltage-gated L-type calcium channels. This allows
extracellular calcium to flow into the sarcoplasmic reticulum
causing a stimulation of the ryanodine receptors (RyR) of the
sarcoplasmic reticulum which results in a bulk release of calcium
into the cytoplasm. Binding of the cytoplasm calcium to troponin
C (a subunit of the troponin complex), results in conformational
changes of the tropomyosin complex allowing for cross bridging
to occur between the actin and myosin (excitation–contraction
coupling mechanism). Contraction occurs as the actin filaments
are pulled toward each other. All this transpires through the
hydrolysis of ATP in the mitochondria mainly found around the
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ryanodine receptors. The cardiac muscle cell relaxes/repolarizes
once there is not any calcium left in the cytosol; this is achieved
through the different ion channels that sequester the calcium
back into the sarcoplasmic reticulum, an ATP dependent action.
The more intense the exercise, the more frequently this process
happens and a variety of toxic molecules are produced (Bers,
2001).

Biomarker Release
The troponin complex comprises of three subunits of proteins:
troponin I (TnI), troponin T (TnT), and troponin C (TnC). Each
of the three subunit proteins has specific interactions with the
actin filaments that help regulate muscle contraction. Necrosis of
myocardiocytes results in loss of membrane integrity, resulting in
the release of cardiac troponin T and cardiac troponin I into the
bloodstream. Troponin T and troponin I are considered leakage
markers since cardiac muscle has a different isoform than skeletal
muscle does for each of these respective troponins. Usually, an
increase in troponin T and troponin I in the blood is an early
warning sign of a myocardial infarction. It has been hypothesized
that the elevated cardiac troponin markers found in the bloodstream after vigorous exercise is from the cytosolic pool rather
than from physically bound cardiac troponin (the breakdown of
the myocyte). This means that cardiac muscle contraction is not
affected by the increase in troponin levels in the bloodstream
due to vigorous exercise since the damage to the membrane is
reversible (Wells & Sleeper, 2008). A study examined the relationship between cardiac troponin T and left ventricle function
in 52 runners who just completed a marathon. The 52 runners
were screened with an echocardiogram to determine left ventricle function and a blood sample assessing for cardiac troponin
T before and after the race. The 99th percentile for cardiac troponin T in the serum assay of normal subjects is 0.01 micrograms per liter. The cardiac troponin T was not detected in all
the participants before the race. However, significant increases of
cardiac troponin T levels were observed after the race in all the
marathon runners. Twenty runners had values above the acute
myocardial infarction cut off of 0.05 micrograms per liter. The
study did not find a link between these elevated levels of cardiac
troponin T and left ventricle function. This supports the notion
that the cardiac troponin T released into the bloodstream during
extreme exercise is from the cytosolic pool (Whyte, et.al. 2005).
A study of fourteen amateur runners who completed a marathon
were tested pre and post marathon for myoglobin, creatine kinase (both also biomarkers for detecting a myocardial infarction)
and cardiac troponin T along with a cardiac magnetic resonance
to detect myocardial necrosis. The study was performed to determine whether elevated biomarkers due to vigorous exercise
had a relation to myocardial necrosis. Before the race, myoglobin,
creatine kinase, and cardiac troponin T serum levels were normal.

Post marathon there was a significant increase in the assay serum
levels of all the three biomarkers. If these results were found in
a person who did not partake in vigorous exercise it would be
cause for alarm. When cardiac magnetic resonance imaging was
done there was no evidence of myocardial edema on T2 imaging
or delayed enhancement of the left ventricle myocardium.Within
one week of the race, all the biomarker levels returned to normal. Some might say vigorous exercise is fine since there is not an
immediate relationship found between elevated biomarker levels
and cardiac function. However, constant vigorous exercise might
affect cardiac function in the future depending on whether the
increased biomarker levels are from the cytosolic pool or from
physically bound cardiac troponin (Mousavi, et.al. 2009). These
two studies provide some evidence to the above hypothesis
however further studies must be conducted to understand the
exact reason for the increase in biomarker levels.

The Heart Rate Effect
The body’s cardiac output increases during aerobic activity, due
to the greater demand for oxygenated blood that the body has
during exercise. The two defining qualities of cardiac output is
stroke volume (the amount of blood forced out of a ventricle
during one contraction [mm/Hg]) and heart rate (the amount of
times the heart contracts in one minute [beats/min]). The stroke
volume is determined by three factors: the blood that fills the
heart during diastole (preload), the force with which the blood
leaves the heart during systole (afterload) and, the resistance of
the aorta or pulmonary arteries. Cardiovascular exercise causes more blood to be pumped out of a ventricle, resulting in an
increased stroke volume. There is a maximum capacity that the
stroke volume can increase to before it levels off. At this point,
the heart rate responsible for the cardiac output pumps blood to
the rest of the body (McArdle, et. al. 2006).
In a recent study, fifty healthy females ages 18 to 24 were randomly selected to examine the benefits that moderate and vigorous exercise training has on a person’s heart rate and blood pressure (systolic and diastolic). Participant’s heart rate and blood
pressure were measured before and after actively engaging in an
exercise regimen. The exercise regimen included a thirty minute
combination of walking (moderate exercise) and running (vigorous exercise) over a three month period. The heart rate and
blood pressure was considerably lower after the three months
of aerobic training (see Figure 1 on next page) (Munisekhar, et. al.
2014). This data shows that moderate exercise training is beneficial for improved cardiovascular health due to a decreased resting
heart rate and blood pressure. In addition, there is reduced stress
on the heart and artery walls. A slower heart rate also gives the
coronary arteries more time to fill with blood and oxygenate all
the heart cells (Harvard, 2008).
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Figure 1

the average deconditioning period of six years, the
dimensions of the left ventricle during end-diastolic
shrunk by seven percent. The left ventricle cavity
size still remained enlarged; more than 55mm in
Before
After
Before
After
Before
After
85 percent of the athletes and more than 60mm
Training Training Training Training Training Training
in 22 percent of them. The average wall thickness
Mean
Mean
Mean
decreased by fifteen percent from 12mm at peak
Resting
78.1
68.1
66.2
62.15
99.6
95.1
training to 10.1mm after deconditioning. There was
not any difference between the fifteen that stopped
Walking
126.2
106.58
76.65
67.75
115.88
102.5
all physical activity and the other twenty five that
Running
169.25
127.93
77.7
72.3
144.85
124.35
changed from intense to moderate exercise. The
study showed that once there is substantial left
Mean heart rate, blood pressure (diastolic & systolic) of the 40 participants before and after
ventricle dilation (hypertrophy), there is only a
their training: Modified from (Munisekhar, et. al. 2014).
slight reversal in left ventricle hypertrophy, even
after ceasing to do exercise for a long period of time (Pelliccia,
Long Term Exercise Conditioning
et.al. 2006).
To attain the physiological condition of “athlete’s heart” there
must be a decrease in heart rate and an increase in hemodynamic
demands, which modifies the stroke volume loading. As a result
Myocardial Fibrosis
of increased hemodynamic demand there is a change in the left
La Gerche et al. (2012) found that five of the participants (13%)
and right ventricle mass and volume; the result of which is carwho had greater prior exposure to vigorous exercise displayed
diac hypotrophy. Due to the limitation of imaging tools, this has
delayed gadolinium enhancement (DGE) in their cardiac magnetbeen shown in the past to be predominately on the left ventricle.
ic resonance imaging baseline test. More specifically, they showed
Echocardiography and MRI were used in order to study the effect
fibrosis and scarring in the interventricular septum. Another
that prolonged vigorous exercise has on both the right and left
study which contained 102 healthy male runners between 50
ventricles’ mass and volume. Twenty-one healthy male endur–72 years were matched with 102 control subjects who were
ance athletes, with a history of exercise and a control group of
non-runners. In order to be included in the experiment the runtwenty one untrained males were used in the study. In order
ners had to have completed at least five marathons in the past
to meet the criteria of an “athlete’s heart”, the heart volume of
three years. The results showed that 12% of marathon runners
the twenty one endurance athletes had to be at least 13 ml/
had myocardial fibrosis and patchy scarring, as demonstrated
kg. Results showed that in the hearts of endurance athletes, the
by delayed gadolinium enhancement with cardiac magnetic resmass of the left ventricle was 200 grams while in the control
onance imaging. This rate was three times higher than in the
group the mass of the left ventricle was 148 grams. In the hearts
control group, who had a 4% occurrence of myocardial scarring.
of endurance athletes, the mass of the right ventricle was 77
The study also did a 21 month follow up on all the participants
grams while in the control group the mass of the right ventricle
and found the rate of coronary heart disease was higher in the
was 56 grams. This is a significant increase in the mass of the left
runners with myocardial scarring and fibrosis then in the conand right ventricles and reaches the criteria for hypertrophy. The
trol group. Even though the percentage of marathon runners
left ventricle and right ventricle end-diastolic volumes were also
with scarring or fibrosis is low, compared to the control group,
substantially increased in the endurance athletes compared to
the incidence of scarring is greatly higher. This author proposes
the control group (Figure 2) (Scharhag, et.al. 2002). This study
that the development of myocardial scarring may be correlated
shows that an “athlete’s heart” has a balanced enlargement of the
Figure 2
left ventricle and right ventricle, which in turn indicates a benign
Endurance Athletes
Untrained Control
balanced cardiac hypertrophy.
HEART RATE
(BEATS/MIN)

DIASTOLIC BLOOD
PRESSURE (mm/Hg)

SYSTOLIC BLOOD
PRESSURE (mm/Hg)

In another study echocardiography and electrocardiography was
used to look at left ventricle hypertrophy remodeling in forty elite
endurance male athletes after termination of systematic training
(deconditioning). Of the forty endurance athletes, fifteen stopped
all physical activity and the other twenty five changed from doing
intense exercise to doing moderate exercise. The forty athletes
had left ventricle cavity enlargement of more than 60mm or wall
thickness of more than 13mm at the beginning of the study. After
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Comparison of volume and mass of both ventricles in endurance athlete’s vs
untrained Control (Scharhag et.al. 2002.)
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to prolonged engagement in vigorous exercise; in this case, the
marathon running (Breuckmann, et.al. 2009).
A study on myocardial fibrosis resulting from extreme training
was performed on twelve lifelong veteran male endurance athletes, twenty age-matched controls and seventeen younger male
endurance athletes. Veteran male athletes had to have 35–52
years of continuous intense training and younger male athletes
had to have 11–31 years of intense continuous training. Just as in
the previous study, delayed gadolinium enhancement with cardiac
magnetic resonance imagining was performed to evaluate myocardial fibrosis. Results showed that in six of the twelve veteran
athletes (50%), the existence of myocardial fibrosis and scarring
was present. There was no sign of myocardial fibrosis found in
the age-matched veteran controls or the younger athletes. The
extensiveness of myocardial fibrosis in veteran athletes was not
correlated to the age of the athlete, but rather to the amount of
years spent training and to the amount of marathons completed.
Even though the previous two studies were a small sample size,
they still add validity to the correlation between extreme exercise and myocardial fibrosis (Wilson, et.al. 2011).

Forty healthy endurance athletes were studied following a vigorous event (duration of between 3-11 hours) to assess cardiac
function at baseline, immediately post-race, and 1 week postrace. The authors found a reduced right ventricular ejection
fraction after the race, which was connected to the dilation of
the right ventricle after the event. This follows the Frank–Starling
mechanism, which states that an increase in the volume of blood
stretches the ventricle causing the heart to contract more forcefully. Thus, in these extreme conditions it causes a dysfunctional
heart which is evident by the right ventricular ejection fraction.
A greater dilation of the right ventricle caused a slight decrease
in left ventricle volume (figure 3) (La Gerche, et.al. 2012). This
may be explained because the increase in ventricular load due
to intense exercise is greater for the right ventricle then the left
ventricle (La Gerche, et.al. 2010). The study also showed that the
extent of right ventricle deformation is directly correlated to the
event period. A week after the event, all of the cardiac dysfunction returned to their baseline readings (La Gerche, et.al. 2012).
Figure 3

Right Ventricle Dysfunction Immediately
After Exercise
Vigorous aerobic activity increases the average cardiac output of 5
liters per minute to a maximum of 35 liters per minute (McArdle,
et. al. 2006). This increase puts a strain on the heart causing the
right atrium (RA) and right ventricle (RV) to dilate. A one-time
event will not have a negative impact since the heart will return
to its normal size. However more consistent vigorous exercise
can cause myocardial scaring due to the volume load and cardiac
strain because of the chronic dilation of the right atrium and right
ventricle. In fact, a study using cardiovascular magnetic resonance
(CMR) showed that running a marathon causes acute right atrium
and right ventricle dilation and reduces the right ventricle ejection fraction (RVEF).The participants in the study were randomly
selected; 25 healthy participants from a pool of 425 volunteers.
Cardiovascular magnetic resonance imaging was conducted four
weeks before and after the race.The mean age of the participants
was 38 years and the mean time for completing a marathon was
256 minutes. “Cardiovascular magnetic resonance showed before
and after marathon left ventricular ejection fractions were comparable, 57.7 ± 4.1% and 58.7 ± 4.3%. Right atrial volume index
increased from 46.7 ± 14.4 to 57.0 ± 14.5 ml/m2 . Also, right ventricular end-systolic volume index increased from 47.4 ± 11.2 to
57.0 ± 14.6 ml/m2 whereas the right ventricular ejection fraction
dropped from 53.6 ± 7.1 to 45.5 ± 8.5%”. This data shows that
marathon running causes a decrease in right ventricular ejection
fraction due to a dilation of the right atrium and right ventricle.
However, according to the study it does not appear to result in
ischemic injury to any of the chambers (Trivax, et.al. 2010).

Intense exercise effect on right and left ventricle. The change in volume from
baseline is showed on the left (La Gerche, et.al. 2012).

There was a correlation found between a decrease in right ventricular ejection fraction and ventricular arrhythmias (VA) in endurance athletes. This was a result of right ventricle dysfunction
in 82 percent of the cases. The study performed right ventricle
angiography on three groups: 22 athletes with ventricular arrhythmias, 15 athletes without ventricular arrhythmias and 10
control non-athletes. The study defines an athlete as one who
has 6 hours a week of endurance exercise (running or cycling)
for more than 5 years. Results showed that those athletes with
ventricular arrhythmias showed a substantial decrease in right
ventricular ejection fraction versus athlete without ventricular
arrhythmias (49.1 ± 10.4 vs. 63.7 ± 6.4%). It was also revealed
that the athletes who participated in vigorous exercise have
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enlarged right ventricles while the control group right ventricles
were normal, these findings are consistent with previous studies
(Ector, et.al. 2007).

Mortality Rate
The positive effects of exercise on health are numerous. The
greatest benefit is the overall decrease of the mortality rate due
to physical activity. A 21 year study observed 55,157 adults from
the age of 18 to 100 (mean age 44) to determine the correlation of running with all-cause and cardiovascular mortality risk.
Individuals with any health issues prior or present were excluded
from the experiment.There was a questionnaire that was distributed to participants which asked specific questions regarding a
person’s exercise training (figure 4). Of the 55,157 participants
24% of them were involved in weekly running of some sort.
The study found that runners had a 30% lower all-cause and
45% lower cardiovascular mortality rate then compared with
non-runners. The cardiovascular mortality life expectance decreased in non-runners by 4.1 years. These results were similar,
as long as the weekly running time was kept under 175 min/week
(less than 1840 MET -min/week). Exercising more than 175 min/
week slightly increased the mortality rate but was still less than
the non-runners mortality rate. This was not only the case for
time spent running but also for speed, frequency, and distance
(Figure 3) below for the given data (Lee, et.al. 2014).
In the Copenhagen heart study, similar results were found after
it was adjusted to a comparable set of confounders found in the
previous study. The authors reported with less than 150 minutes
of exercise a week there was a decrease in all-cause mortality.
However, exercise time greater than 150 min/week did not make
a difference in all-cause mortality between runners and non-runners. These results produced a U-curve with regard to jogging
time versus mortality rate (figure 5) (Schnohr, et.al. 2013). One of
the reasons may be because in this study there were only 1,878
joggers which caused wide confidence intervals since there were
not enough runners to equally distribute in all the different exercise categories. On the other hand in the previous study by Lee
et.al. there were approximately 13,000 joggers which allowed an
equal distribution in the different dose running times.
Another observational study was done by the British Regional
Heart Study in 1978 on the decreased risk of coronary heart
disease due to physical activity. There were a total of 7,735 male
participants aged between 40 and 59. The male participants were
randomly chosen from general practices in 24 British towns without distinguishing whether they had pre-existing coronary heart
disease. A typical questionnaire was conducted which asked questions on exercise and leisure activities (such as walking, weight
lifting, and jogging). After eight years, results showed that the male
participants without any pre-existing coronary heart disease who
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partook in moderate exercise (such as walking at 4 miles per hour)
had decreased the risk of coronary heart disease by 50 percent,
compared to those who were inactive. The participants with coronary heart disease conditions in the past showed a comparable
inverse relationship: decreased risk of coronary heart disease with
increased moderate exercise. However, those partaking in vigorous
aerobic activity (such as jogging or running) had a higher rate of a
heart attack than those participating in moderate exercise (Shaper,
et.al. 1991).These three studies show that those who participate in
weekly moderate exercise versus those who do not do any exercise have less of a risk of developing coronary heart disease, and a
lower all-cause and cardiovascular mortality rate. However these
studies also show that there is an upper limit to these benefits
and over exercising slightly reverses these positive effects and the
mortality rate is similar to those who do not exercise.
Figure 4

Hazard ratio of all-cause mortality versus the amount of time spent exercising
per week. Graph produces a U shaped curve with an optimal exercise time
between 1-2.4 hours per week (Schnohr, et.al. 2013).

Animal Studies
In order to achieve a post-mortem look at the effect intense
exercise training has on cardiovascular health, it is necessary to
perform studies using animals. Rats were used to examine the
long term intense exercise effect on cardiac function; more precisely fibrosis, which can induce cardiac arrhythmias. The Wister
rats were separated for 16 weeks (this is equivalent to around
10 years in humans) into exercise and sedentary control groups.
After the 16 week experiment, some of the rats from the exercise
group were held for another eight weeks without exercise. This
was done in order to see if the effect that intense exercise has on
the heart is reversible.At the end of the experiment, all of the rats
were euthanized and their hearts were removed for dissection.
The exercise rats were put on a treadmill for five days a week, at
60 centimeters per second. In order to keep the rats running, a
small shock was provided however, it was extremely low so that
a stress response would not be elicited. Results showed that after
16 weeks of training, the exercise rats developed left ventricle
hypertrophy, and impaired diastolic function; which is related to
the left atrium dilatation. There was also right ventricle dilatation,
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impaired diastolic and systolic dysfunction. All these symptoms
are also found in humans with “athlete’s heart”. Right ventricle
fibrosis was found in the histological sections. This can be due to
the higher loading conditions on the right ventricle versus the
left which is also consistent in humans. TGF-β1, a fibrotic marker,
was found in high levels in both atrium and right ventricle. TGFβ1 is a collagen stimulator that leads to development of fibrosis.
Another component that was observed was the surge in collagen-I [determines stiffness of cardiac muscle] protein expression
in the right atria and ventricle, collagen-III [distensible] remained
unchanged. This shows that the diastolic dysfunction of the right
atria and ventricle could be due to the increased cardiac stiffness.
Intense long term exercise effect on cardiac arrhythmias was
evaluated in vivo, by attaching a modified catheter to the right
ventricle apex. Inducible ventricle tachyarrhythmia was found in
42% of the exercise rats compared to 6% of the control rats. A
possible explanation for the higher prevalence of arrhythmias in
exercise rats could be linked back to cardiac fibrosis. After the
eight week deconditioning period, all the exercise rats had almost
all the cardiac remolding mentioned above revert to the control
rats levels. (Benito, et.al. 2011) There have been other animal
studies conducted that show similar results to this one. Even
though there are some similarities between cardiac remodeling
in animals and humans, researchers cannot be certain that cardiac
remodeling in both is exactly the same.

Conclusion
After intense exercise immediate testing resulted in dilatation of
the right ventricle and atrium, reduced right ventricular ejection
fraction, and elevated levels of biomarkers found in the blood.
Even though there was a correlation found between reduced
right ventricular ejection fraction and ventricle arrhythmias, the
sample size was too small to fully determine the validity of the
correlation. Further research needs to be conducted on the effect
and mechanism of elevated biomarkers found in the bloodstream
after vigorous exercise. Testing after many years of intense aerobic activity show that balanced cardiac hypertrophy is normally
found in a person with the condition known as “athlete’s heart.”
Even after many years of deconditioning, the heart does not return to its normal size. A result of cardiac hypertrophy is myocardial fibrosis and scarring. The percent of myocardial fibrosis in
those participating in prolonged vigorous activity is low; however,
compared to the control group, the percent is significantly greater. Studies also show that while moderate exercise is beneficial
to lowering a person’s all-cause mortality rate and cardiovascular mortality rate, intense exercise reverses this positive effect
slightly. Humans share similar results found in dissections of rats
that underwent exercise training. Though intense exercise does
not have a positive effect on cardiovascular health, more studies
involving a greater sample size have to be conducted to determine the extent to which vigorous exercise damages the heart.

In addition to the negative effects that intense exercise has on the
heart one has to consider the adverse effects that it has on the
body and more specifically the skeletomuscular system.
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Abstract
Ethical questions with regard to treatment arise when pregnant women are diagnosed with cancer. Does the health of
the mother or the health of the fetus take priority? However, research suggests that concern over transplacental transfer
should not deter those seeking treatments since avoidance of favorable transfer drugs can allow chemotherapy to be
a viable option if properly administered. Doctors highly contraindicate the use of chemotherapeutic drugs in the first
trimester due to high risks such as teratogenesis and fetal death. However, they reassure that treatment can be given in
the final two trimesters. It presents minimal consequences as long as the drug is not favorably transferred, treatment is
not given after thirty five weeks, and delivery is not less than three weeks after chemotherapy administration. Iatrogenic
prematurity should also be avoided. Additionally, long term risks are minimal, but further research needs to be performed
with longer follow ups and larger sample sizes in studies in order to obtain more conclusive data.
Introduction
There has been an increase in treating pregnant women with
cancer and scientists suggest that the change in trend is due to
older women conceiving. Reports indicate that cancer is diagnosed in approximately 1 in 1000-1500 pregnancies (Voulgaris,
et al., 2011). If cancer treatment cannot be postponed until after
birth, ethical concerns arise with regard to the health of the
mother and fetus, and so the benefits and side-effects need to be
discussed by patient, oncologist, and obstetrician. Factors that impact treatment include cancer type and stage, gestational age and
consequences of treatment on the mother and fetus. In addition,
risks, treatments and, if necessary, the option of abortion must be
determined. The goal is to determine if and at what gestational
age treatment should be given, whether cytotoxic drugs administered to the mother impacts the development of the fetus and
results in long-term risks for the child.

Methods
Information and research was obtained through Ebsco, Proquest
and Pubmed. Access was provided by Touro College library. Main
key words included pregnancy, short-term, long-term, transplacental, in utero, fetus, and chemotherapy.

Discussion
Transplacental Transfer
To first address the impact of transplacental transfer, it is essential to determine if there is drug transfer between the mother
and the fetus, and if so, to what extent. A mouse model using 40
pregnant mice was studied to determine the amount of transplacental transfer of chemotherapeutic agents, doxorubicin, epirubicin, cytarabine, paclitaxel, carboplatin and vinblastine. Due to
the difference of drug metabolism in mice, the drugs were given
at proportionately higher dosages than when given to humans.
Fetal and maternal blood was collected on day eighteen and a
half, during the phase of fetal development. The mice were delivered by caesarean section ninety minutes (an arbitrary amount
of time) after chemotherapeutic drugs were intravenously given
to the mother. At this point in time, an increase in plasma levels

ensured drug detection and was the first phase of distribution
after the drugs were intravenously administered. The drug levels in the maternal and fetal plasma were detected using two
methods. High performance liquid chromatography determined
the amount of the five chemotherapy drugs and Atomic absorption spectrometry determined carboplatin levels, based on the
amount of platinum in the blood.

Plasma Drug Analysis
Paclitaxel was found in maternal plasma, but was not detected
in fetal plasma. It has a high molecular weight, is highly protein
bound and is a substrate of P—glycoprotein (ATP-binding cassette transporters) and multidrug resistance protein. P—glycoprotein is found in fetal-derived epithelial cells which forms the
maternal-fetal blood exchange border and protects the fetus.
Vinblastine and anthracyclines, which includes epirubicin, a
4′-epimer of doxorubicin, and doxorubicin, only presents as a
small transfer ratio due to being P-glycoprotein substrate, which
protects the fetus against xenobiotics’ harmful effects. Another
factor is that it possesses pharmokinetic properties that contrast
to the substances that cross the placenta. Thus, one can imply
that vinblastine, anthacyclines and paclitaxel present a safe option
for treatment when given in small dosages during the last two
trimesters.
However, both carboplatin and cytarabine have high transfer rates
and can penetrate the membranes barriers since they are slightly
bound and have a low molecular weight. Therefore, researchers
recommended, if possible, avoiding these drugs (Calsteren, et al.,
2010;Van Calsteren et al., 2010)
The transplacental transfer is generally through passive diffusion
and is typically penetrable. However, there are three factors that
influence the maternal-fetal transfer. They are: (1) maternal and
fetal circulation concentration gradient, (2) the placental blood
flow, and (3) chemotherapy’s drug properties. The pharmokinetics of chemotherapy that favor transplacental transfer are
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uncharged, low molecular weight, lipid soluble, and unbound or
low protein bound compounds (Calsteren, et al., 2011).

Maternal- Fetal Transfer in a Baboon Model
The data obtained from the previous experiment, however, is
limited in its clinical application due to the differences of human
and mouse metabolism and permeability and formation of the
placenta (Van Calsteren, et al., 2011). This elicited further investigation of the effects of maternal-fetal transfer of chemotherapeutic agents given in second and third trimesters. Two studies,
using the same subjects, examined the results of different chemotherapeutic drugs on a group of nine pregnant baboons. Data
more relevant to humans can be obtained from baboon models
as compared to mice models due to the greater similarity of
human and baboon embryological development, placental structure and function, reproductive physiology and endocrinology of
pregnancy and drug metabolism. Based on the outcome, since
only low levels were detected, the authors were reassured that
the use of doxorubicin, epirubicin, vinblastine, taxanes (docetaxel
and paclitaxel) and active metabolite of cyclophosphamide (4OHPC) were not damaging to the fetus. However, they were
concerned with the results of trastuzumab and carboplatin since
they were transferred in large or complete amounts. The study
was limited since there was no record of long term results, and
it was suggested that further research needed to be performed
(Calsteren, et al., 2010). Furthermore, other medical professionals contraindicate trastuzumab since it has been correlated with
oligohydramnios, reduced production of amniotic fluid resulting
from the drug binding to fetal renal receptors (Gziri, et al., 2012).

Placental Perfusion Model
As it would be unethical to perform human testing on pregnant
women to determine whether there is maternal-fetal transfer
due to fetal risk of fetal blood sampling from the umbilical cord
known as cordocentesis, Van Calsteren et al. (2011) suggested
that they can be applied to a single cotyledon models that have
separate fetal and maternal circulations. Unfortunately, some
complications with this proposal included difficulties obtaining
absolute physiological conditions in a perfusion system, temporary status of tissue viability, and the differences in data between
in vivo and placenta perfusion model with some drugs (Myllynen,
Vhakangas, 2002;Van Calsteren, et al., 2011).
An attempt was made, however, to examine the effects of maternal-fetal transfer of taxanes (paclitaxel and docetaxel) to determine whether it can be a viable treatment option. The single
cotyledons were taken from twelve placentas from uneventful
pregnancies with each test group containing six models. The test
groups were further divided into two groups of three, with one
group containing high concentration of albumin (30 g/L) and the
other group with low concentration of albumin (2 g/L). In the
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intervillous space two catheters were inserted to begin the perfusion and the twelve placentas were perfused for ninety minutes. The results indicated that taxanes have a low transplacental
transfer due to their chemical properties and added that there
was no difference in amount of drug transfer between paclitaxel
and docetaxel. Furthermore, the outcome between the groups of
high and low levels of albumin reinforced the theory that protein
levels affect the maternal-fetal transfer. This was supported with
the observation of less transfer of both docetaxel and paclitaxel
with high levels of albumin. Although this reinforced previous
studies of placental transfer, sample size was too small and further investigation should be performed (Berveiller, et al., 2012).

Factors and Effects of Chemotherapeutic Drugs
Based on research that positively indicated transplacental transfers of chemotherapeutic drugs, studies were initiated to determine the drug effect on the developing fetus.There are four main
drugs that are typically administered to pregnant cancer patients.
They are: anthracyclines (e.g., doxorubicin, epirubicin), platinum-based antineoplastics (e.g., cisplatin, carboplatin), cyclophosphamide and taxanes (e.g., paclitaxel, docetaxel). Anthracyclines
result in cardiotoxicity and inhibit topoisomerase, interfering
with DNA replication. Platinum based antineoplastics result in
neurotoxicity and ototoxicity if given at high doses. It also allows
for apoptosis to occur since it binds to and causes crosslinking of
DNA. The effect of cyclophosphamide is permanent infertility if
given at high dosage. Lastly, taxanes disrupt the microtubule function in cell division thereby inhibiting mitosis (Vandenbroucke, et
al., 2014). The overall similarity between them is that they halt
normal cell proliferation cycles which results in interrupting crucial cell processes. Studies on somatic cell mutations report that
some adverse effects of chemotherapy are gene mutations, chromosomal breaks and rearrangements, and aneuploidy (Arnon, et
al., 2001).
The impact of chemotherapy on the fetus can vary due to physiologic changes in the pregnant patient. Some examples that may
occur include an increase in glomerular filtration, which increases
the amount of elimination or drug excreted by the kidney, and an
increase of drug metabolization in the liver, which might impact
the presence of active drugs. Additionally, there is an increase in
entero-hepatic circulation in pregnant women. This causes active
metabolites to return to the liver and then colon after being
secreted from bile into the colon and reabsorbed by enterocytes.
The circulation prolongs the drug exposure since it lengthens
the time needed to eliminate the drug from the body because it
returns to the blood stream.The amount of active drugs available
can decrease due to an increase in protein binding which results
in a greater impact of cytotoxic drugs. However, plasma levels
of cytotoxic drugs may be reduced as a result of an increase in
plasma concentration (Amant, et al., 2008). The third space that
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develops in pregnant women resulting from an increase of amniotic fluid can also impact the distribution volume of chemotherapy, causing a slow release of drug which results in an increase
of fetal chemotherapy exposure (Williams, Schilsky, 2000). Other
factors that impact the maternal chemotherapy on the fetus are
metabolic activity and excretion of the placenta, increase of body
fat of the pregnant patient and pH difference between maternal
and fetal fluids (Gedeon, Koren, 2006). When creating a treatment plan, these physiologic changes must be considered.
Various other factors can also result in teratogenic risks to the
fetus. Although the placenta can excrete fetal waste products and
assist in fetal drug elimination, some antineoplastic agents may
not be eliminated from the fetus if drugs are administered close
to delivery time. Additionally, due to the fetus’s immature liver
and kidney, the fetal metabolism and excretion of the chemotherapeutic drugs may be abnormal.This can result in an increase
of chemotherapy exposure and acute toxicity (Williams, Schilsky,
2000).

there is a 10-20% chance of teratogenicity, fetal malformation,
occurring if agents are administered in the first trimester. An increase of embryonic death can occur if there is damage to the
embryo in the first month of gestation resulting from chemotherapy exposure (Voulgaris, et al., 2011). Spontaneous abortion and
major malformations are also possible risks that can occur. The
fetus is more susceptible to malformations two to eight weeks
after conception, the period of organogenesis. Specifically, the
heart, neural tube, and limbs are more vulnerable, preceding the
palate and ears of the fetus. If chemotherapy exposure continues
after eight weeks, the eyes, genitalia, hematopoietic and central
nervous system still remain at risk (Cardonick, Iacobucci, 2004).
This strongly reinforces that maternal chemotherapy should be
avoided in the first trimester.

Chemotherapy Exposure- Fetal Phase of
Development

The effect on the fetus is not only dependent on drug type and
performance, but is also based on dose, route and gestational
age. Studies have proven higher toxicity can develop from short
infusions, topically applied cytotoxic agents and intraperitoneal
administration.¬ Drugs given orally may be absorbed less due
to a decrease of elimination from the stomach and intravenous
administration can result in fetal risks. As mentioned previously,
prolonged drug elimination from the mother also impacts the
toxicity on the fetus (Wiebe, et al., 1994).

Based on observations of the fetus exposed to maternal chemotherapy during the final two trimesters, researchers have
suggested that these exposed fetuses did not exhibit more
congenital malformations than fetuses from untreated mothers.
Nevertheless, intrauterine growth restriction, low birth weight
and neonatal myelosuppression have been detected in neonates
exposed to chemotherapy in the second and third trimester
(Cardonick, Iacobucci, 2004; Van Calsteren, et al., 2011). From
week eleven until delivery, functional damage will frequently
occur as a result of cell death. In addition, some organs may later
develop structural anomalies. For instance, the fetus can develop
neuropsychological impairment since the central nervous system
is progressing throughout gestation (Vandenbroucke, et al., 2014).

Chemotherapy Exposure- Fertilization/
Implantation

Short-term Effects -Obstetric and Neonatal
Outcomes

To determine the effect of chemotherapy on the developing
embryo and fetus, observations were performed during the
three stages of pregnancy. The three phases of fetal development are fertilization/implantation, organogenesis, and the fetal
phase. Chemotherapy is cytotoxic, thereby inhibiting cell growth.
Therefore, exposure during the first ten days of pregnancy, the
stage of fertilization/implantation, results in an all-or-nothing phenomenon. Cells are omnipotent and may develop into the three
different embryological layers, ectoderm, mesoderm and endoderm. However, their ability to develop normally is dependent
on the impact of maternal chemotherapy. If there is a sufficient
amount of cells, the embryo will develop normally, but a miscarriage can occur if too many cells are destroyed by the chemotherapeutic drug (Reed, et al., 2010).

One study reported on 62 patients who were treated predominantly in the last two trimesters with chemotherapy alone or
combined with other treatments, such as radiotherapy. These
patients were part of a sample of 180 pregnant women who received various treatments for cancer. The results were analyzed
to determine the fetal risks of treated and untreated mothers
diagnosed with cancer.

Administration Variables

Chemotherapy Exposure- Organogenesis
During the first trimester, it is highly inadvisable to treat the
mother with cytotoxic drugs. Voulgaris et al. reports (2011) that

Regarding patients treated with chemotherapy, there was a significant increase in preterm labor, but not in the rate of preterm
premature rupture of membranes (PPROM) when compared to
neonates not exposed to maternal chemotherapy. However, the
only incidents of preterm labor and PPROM that occurred in the
180 cases analyzed involved patients treated with chemotherapy.
Preterm labor can occur from the activation of hypothalamic-pituitary-adrenal axis of either the mother or fetus resulting from
physical or psychological stress. Scientists propose that PPROM
can result from apoptosis in amnion epithelial and chorion
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trophoblast layers of the membranes after maternal chemotherapy exposure (Van Calsteren, et al., 2010).
The risks of preterm labor include intraventricular hemorrhage,
bradycardia, apnea, respiratory insufficiency, necrotizing enterocolitis, sepsis, seizures, hypoglycemia, and feeding problems (Van
Calsteren, et al., 2010). Additionally, Johnson (2007) reported
that preterm births are associated with a decrease in IQ scores,
cognitive delay, behavioral problems and higher risk for psychiatric disorders, primarily ADHD. Preterm labor in this research was
preventable since several of the neonatal issues were iatrogenic.
Therefore, researchers suggested that patients that can delay
treatment until after delivery should do so to avoid prematurity
(Van Calsteren, et al., 2010).
Data of small-for-gestational-age children was available for only
175 neonates. Regarding those treated with cytotoxic treatments
(chemotherapy and/or radiotherapy), 16 of 66 children were
small- for- gestational age as opposed to 10 of 109 children who
were not exposed to maternal chemotherapy/radiotherapy.
The malformation outcome in comparison to normal pregnancies reveals that there was no significant increase in rate. The
range of physical abnormalities of neonates exposed to maternal
chemotherapy was still within normal range, with 2 of 66 (3.0%)
inflicted with major malformations and 5 of 66 (7.5%) affected
with minor malformations. The average rate of major and minor
malformations was 4.1% to 6.9% and 6.5% to 35.8%, respectively.
This suggests that the concern of malformation defects due to
chemotherapy is not applicable and should not deter patients
from avoiding treatment (Van Calsteren, et al., 2010).
Another fetal risk that may occur is transient neonatal myelosupression (TNM). Elburg et al. (2008) defined TNM as “leukopenia
and/or neutropenia combined with anemia and/or thrombocytopenia, during the first weeks of life in newborns exposed to
maternal chemotherapy during pregnancy.” The disease is rare,
potentially life-threatening and may not necessarily develop
right after birth. Additionally, it may pose a risk for developing
infections. The development of TNM may result from a short gap
between chemotherapy administration and birth, maternal neutropenia at delivery, type of chemotherapy and maternal disease
and dosage given. Treatments for TNM include thrombocyte and/
or erythrocyte transfusions, bedside isolation, erythropoietin,
and recombinant human granulocyte colony stimulating factors
(G-CSF). In a study of fifteen neonates diagnosed with TNM,
only one died due to infection resulting from TNM. However,
the other fourteen neonates’ physical and neurological developments were normal by the age of one and their TNM was
resolved between two to ten weeks after birth. Generally, there
is no difference detected in short term outcomes and survival
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rates between neonates exposed to chemotherapy that develop
TNM and those not diagnosed with TNM. Researchers stated
that this is true as long as the disease is recognized and aggressive
treatment is given. However, the long-term consequences are still
unknown (Udink ten Cate, et al., 2009).
Another study performed by Aviles et al. (1991) consisted of
43 infants exposed to maternal chemotherapy. The infants were
examined from age three through nineteen years old and it was
observed that only eight were pancytopenic at birth, which characterizes them as being deficient in red and white blood cells
and platelets. However, the mothers of these neonates were
treated with chemotherapy in the last three weeks prior to delivery which disputes the suggestion that a short gap between
chemotherapy administration and delivery results in TNM. There
were no congenital anomalies and neurological abnormalities reported and like the findings of the Udink ten Cate et al. (2009)
study, the TNM resolved 2-10 weeks after birth. In addition, in a
study of 62 patients, two children suffered postnatal hematologic toxicity (leukopenia and pancytopenia) when born ten days
after maternal chemotherapy administration for acute lymphatic
leukemia and required hematologic growth factors as treatment
(Calsteren, et al., 2010). This study supports the theory, unlike
Aviles et al. (1991) that a short interval between the chemotherapy administration and delivery can result in hematologic toxicity.
As seen with these results, hematologic toxicity can present a
slight concern for pregnant women with cancer, yet the risks are
minimal if proper treatment is given.
Cardonick and Iacobucci (2004) have studied the impact of chemotherapy given after the first trimester on 376 fetuses. Of the
376, nineteen of the fetuses and four of the neonates died, 28
neonates were born with intrauterine growth restriction and 18
were born prematurely (iatrogenic cases excluded). Additionally,
two were diagnosed with transient neonatal cardiomyopathy due
to maternal idarubicin treatment, fifteen neonates developed
transient neonatal myelosuppression. Eleven malformations were
also reported with the majority resulting from chemotherapy
exposure in the first trimester.
Another study was performed which was composed of 61 patients receiving chemotherapy during the second and third trimesters. Of the 61 patients, 32 were treated with neoadjuvant
chemotherapy and 2 received adjuvant chemotherapy. The 61
neonates that were exposed to maternal chemotherapy were
examined and compared to 60 neonates who were born prematurely and were not exposed to maternal chemotherapy. Results
suggested that there were no differences in birth weight, admissions to the NICU, and neonatal survival. No malformations were
reported in either group. Nonetheless, one contrast between the
groups was the considerable difference in Apgar score, which
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tests the future neurobehavioral development first at one minute
after birth, then five minutes after and after ten minutes after
birth. The results favored the group of children not exposed to
chemotherapy at one and five minutes, but there were no significant difference at ten minutes. Although it reflects positive
short-term outcomes, it’s limited in long-term follow up on these
children and researchers suggest further studies need to be performed (Abdel-Hady, et al., 2012).
Fetal cardiotoxicity was also researched to determine whether
it can develop from maternal chemotherapy and pose a threat
to neonates. One study consisted of ten pregnant patients treated with anthracyclines in the last two trimesters to investigate
whether these drugs, which are thought to cause fetal cardiotoxicity, can result in fetal cardiac abnormality. The results indicated
that one fetus was diagnosed with fetal supraventricular tachycardia, but researchers believed it was unrelated to maternal chemotherapy. Additionally, differences in myocardial performance
index and in the tricuspid inflow pattern were detected, but were
considered clinically insignificant. The neurological development
and weight, height, and clinical examination of the fetuses in the
study group were within normal limits. Significant cardiac abnormality and intrauterine growth restriction were not detected, although low birth weight was observed. Although the researchers
gathered data systematically, the study was small and therefore
limited (Gziri, et al., 2012).

Long Term Effects
A concern of maternal chemotherapy is the long-term cardiotoxic
effects on the fetus.A study used tissue Doppler and strain imaging
to identify any specific changes in cardiac performances that might
result from chemotherapeutic drug.The study focused on children
exposed to anthracylines, a drug shown to cause cardiomyopathy
and cardiac dysfunction. The children’s ages ranged from 1-9 years
old, with the mean age being 1.7 years old.Those exposed to anthracyclines were observed to have minor changes in left ventricular
(LV) wall thickness that might have occurred from the effect of
anthracycline’s toxicity. Anthracycline is known to lead to loss of
cardiac muscle. There was also indication that there might be a
lower, but normal ejection fraction and left ventricular ejectional
fractional shortening, which is not clinically important since there
is no change in functionality. Since there were no differences in tissue Doppler and strain imaging between the control group and patients, researchers indicated that there was no change in myocardial function. They stated that changes recorded could have resulted
from the fact that the majority of the neonates born were preterm.
Overall, their observation showed that there was no significant
change between the 62 patients and 62 age gender-matched controls. Researchers recommended further research to observe any
future irregularities and suggested performing further studies with
larger patient groups with proper follow up (Gziri, et. al., 2013).

Further research was performed to assess the neurodevelopment, cardiac function, and general health of 70 children who
were exposed to chemotherapy in utero. Seventy children from
68 pregnancies (two twin pregnancies) were assessed at age 18
months and at ages 5–6, 8–9, 11–12, 14–15, or 18 years. The median gestational age at birth was 35.7 weeks, with a median follow-up period of 22.3 months. Most of the children had normal
cognitive development. However, children who were born prematurely had lower cognitive development scores albeit within
normal range of cognition. Moreover, for each additional month
of gestation, the IQ score increased by an average 11.6 points.
Therefore, iatrogenic preterm delivery is not suggested since it
significantly impacts the cognitive development.
Additionally, because the CNS continues to develop after the
first trimester, the possibility that maternal chemotherapy may
adversely affect neurological development is a serious concern
(Gziri, et al., 2012). However, only one set of twins of 70 children
observed experienced severe neurodevelopmental delay. This
cannot be completely attributed to the exposure to a chemotherapeutic drug (Amant, et al., 2012). The cortex of the fetal
brain develops surface sulci and gyri at 14 weeks gestational age
and doesn’t remain the original smooth cerebral surface.The formation of polymicrogyria, in which the cerebral cortex develops
abnormally before birth in the deeper layers and excessive gyri
form, removes some of the probability that chemotherapy exposure after 15 weeks instigated the developmental delay observed
in the twins (Amant, et al., 2012; Barkovich, et al., 2010). Yet, the
researchers did acknowledge that although the neurodevelopment was normal in the overall researched group, subtle changes
could occur and further research on longer follow-ups should
be conducted.
Nonetheless, the average results of the children’s behavior, general health, hearing, and growth were within the normal range,
along with their cardiac dimensions and functioning. No increase
in CNS morbidity was recorded. Although there were no congenital cardiac abnormalities detected, further study was recommended on the cardiac function since there were clinically small,
but statistically significant changes in ejection fraction, fractional
shortening and diastolic variables. They did detect, however, a
higher incidence of disharmonic intelligence profiles. The results
of the Wechsler test depicted a discrepancy between verbal
and performance IQ values. This was seen in 39% of patients in
comparison to 15% in the normal population. The discrepancy
has been associated with several neurological disorders, learning
problems and behavioral issues.
The study was limited due to the small sample size, short follow-up periods, and lack of children born at the same gestational
age and similarly assessed, who were not prenatally exposed to
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chemotherapy. Additionally, researchers could not predict if secondary malignancy and infertility would have developed due to
time constraint of the experiment. Only one twin, who also had
congenital malformation, was diagnosed with secondary malignancy and suffered from papillary thyroid cancer at age eleven
and neuroblastoma at age fourteen.
Nonetheless, the researchers suggested that chemotherapy not
be administered after 35 weeks since this can trigger spontaneous labor. Delivery, they stated, should be arranged to be no
less than three weeks after the last chemotherapy cycle. This ensures that the bone marrow recuperates properly, prevents the
development of fetal and maternal sepsis and hemorrhage and
hematological toxicity. As mentioned, preterm delivery should be
avoided due to the impact on cognitive development. Preterm
neonates are limited in their capacity to metabolize and eliminate drugs since they have immature liver and kidneys.Therefore,
if delivery can be postponed, the fetus can excrete the drug
through the placenta instead.

it provides concrete evidence that the fetus can escape harm and
develop normally into a healthy accomplishing adult.

Conclusion
Overall, transplacental transfer of cytotoxic drug is not detected in all of the treatments and its impact varies based on the
physiologic changes in pregnant women and the pharmokinetics
of drugs administered. Many emphasize that chemotherapeutic
agents should certainly be delayed and only be given after the
first trimester since the fetus is highly vulnerable to teratogenicity. When given in the final two trimesters, risks can still persist.
However, this should not prevent the mother from seeking treatments due to insignificant short-term and long-term effects.
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Abstract
Prostate cancer is the most common form of cancer found in American males. Breaking technological advances in prostate
cancer treatment continue to develop to help fight this disease, one such is proton beam therapy. Proton beam therapy
is theorized to spare even more healthy tissue than photon radiotherapy because it delivers a majority of its radiation
during the Bragg peak. Since this technology is substantially costlier than any other form of radiation therapy, physicians
are assessing its effectiveness and determining if it is worth the cost. Currently, there is no significant difference seen in
patient quality of life between recipients of proton or photon therapy. This can possibly because of secondary neutrons
that are generated when protons exit the nozzle. Pencil beam scanning, a recent advancement in proton therapy delivery,
is theorized to make protons have much better treatment outcomes than photons and would eliminate the issue of
secondary neutrons. More studies need to be conducted to determine if pencil beam scanning ensure better quality of
life over photon therapy.
Introduction
Carcinoma of the prostate, more commonly known as prostate
cancer, is a malignant tumor that develops on the prostate –a
male organ that wraps around the urethra. Prostate cancer can
occur in many different forms, such as carcinoid, small-cell tumors, and ductal carcinoma, however, these types are extremely
rare and little is known about which treatment most effectively
eliminates them. The vast majority of cases are adenocarcinoma,
a tumor that originates in the gland cells. Prostatic adenocarcinoma is observed in over 95 percent of patients (National Cancer
Institute 2014) and affects 15 percent of men predominantly
above the age of 66, making it the most common cancer among
American males (SEER 2014). Fortunately, prostate cancer tends
to grow extremely slowly, and early treatment can often yield
high survival rates. The most common treatment interventions
for prostate cancer include surgery or radiation therapy. Within
radiation therapy there are two methods, external beam radiation therapy (EBRT) and internal radiation therapy.The latter, also
referred to as brachytherapy, involves the placement of radioactive pellets within the prostate gland that release a highly concentrated dose of radiation to eliminate the cancerous growth.
External beam radiation therapy is employed by using a linear
accelerator to accelerate electrons close to the speed of light
and strike them against a metal plate. On impact, high-energy,
ionizing photons are produced, which travel towards the targeted
cancerous cells. The high amount of energy in the photons can
irreparably damage vital structures in the cell such as DNA, RNA,
or protein. Photons are able to directly harm the cancerous cells’
DNA by energizing its electrons and pulling them out of their
orbits. This produces free radicals, causing irreversible damage by
altering the chemical structure of the nucleotides. Ionizing radiation can also delete, fragment, and translocate the nucleotides.
Radiation can also indirectly harm DNA when photons collide
with a cell’s water molecules and energize its electrons. When
a water molecule’s excited electrons bounce out of their orbits
it produces a hydroxyl ion (OH-). The hydroxyl ion is then able
to extract a hydrogen atom from the deoxyribose part of the
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DNA, ruining the nucleotide’s chemical configuration. Direct or
indirect radiation damage to a cancerous cell’s DNA is usually
lethal. This is because the uncontrollable growth of the prostate
cancer involves the mutation of the tumor suppressor gene TP53
(Wang et al. 1997). The protein that TP53 codes for is not only
responsible for regulating the cell cycle, it is also responsible
initiating DNA repair. As a result, cancerous cells are ineffective
at repairing radiated DNA, and the cell’s ability to proliferate is
practically destroyed. Damaging 1000 nucleotides in DNA only
takes one cobalt grey equivalent –the unit measure of radiation
used during treatment.
Although external beam is an effective form of treatment, it also
delivers radiation to surrounding healthy tissue. This is because
before the advent of image guided treatment, physicians had to
target the entire prostate to ensure that the entire tumor was
radiated. Additionally, since the dose of radiation is gradually reduced as the beam passes through the patient, tissue directly in
front of the tumor must be radiated to the prescribed dose. This
leaves a track of radiation damage as the photons enter the body
until it reaches the tumor. Furthermore, photons are massless
particles and are not stopped or slowed down when they impact
body tissue. This causes healthy tissue behind the tumor to receive radiation when photons travel past the tumor. Radiation to
nearby healthy tissue often causes gastrointestinal and genitourinary toxicity, which can impair the patient’s quality of life.
Advances in radiotherapy have greatly reduced these problems.
The advent of three-dimensional conformal radiotherapy (3DCRT) helps radiation oncologists treat prostate cancer more effectively.This sophisticated computer program creates a three-dimensional map to conform the radiation beam to the shape of
the cancer and its surrounding normal tissues. Concentrating the
beam more accurately to the cancerous area reduces the exposure of normal tissue to radiation, further reducing side effects
after treatment. More recent advances in high precision targeting have led to intensity-modulated radiotherapy (IMRT), where

Proton Beam Therapy

there is an even more effective manipulation of the radiation
beam.The beam in IMRT is divided into multiple ‘beamlets’, aimed
at the target from different directions. The ‘beamlets’’ shape and
intensity are adjusted to avoid radiating nearby healthy tissue. By
taking advantage of intensity-modulated ‘beamlets’, IMRT is able
to deliver higher doses of radiation to the prostate. This arguably
ensures greater eradication of cancerous cells while sparing even
more healthy tissue than 3D-CRT. Additional advances include
image-guided radiotherapy, which provides more accuracy to the
targeted area in the event that patients or the organs inside them
move during treatment.
Despite all the improvements in radiotherapy healthy tissue behind the tumor is still getting bombarded with radiation. Proton
therapy is able to stop this. Proton therapy involves the therapeutic use of protons to radiate the DNA of cancerous cells.
Protons are positively charged heavy particles, approximately
1800 times the mass of an electron. Therefore, protons need a
particle accelerator to strip hydrogen atoms of their electrons,
accelerate them to nearly the speed of light, and shoot them into
tumors. Particle accelerators, either cyclotrons or synchrotrons,
require an enormous amount of space, which makes the cost
of a particle accelerator exceed 100 million dollars (National
Association for Proton Therapy 2010). Upon entering the body,
protons slow down due to their heavy weight and their attraction to the electrons in the body’s cells. Consequently, physicians
must program the particle accelerators to provide the protons
with enough energy to reach the cancerous cells. After traveling
the specified distance protons stop abruptly, depositing most
of their energy at the targeted cells, sparing harmful radiation
to the healthy cells behind the tumor. This biologic phenomenon, of depositing high dose and energy of the beam within the
tumor while having minimal energy deposited beyond the tumor
is known as the Bragg Peak Effect. During radiation treatment,
physicians modify the Bragg peak and extend its distance to cover
the entire depth of the tumor, ensuring that the entire tumor
is radiated. Extending the distance of the Bragg Peak is accomplished by treating the tumor to different energies, which sends
multiple sprays of protons to different depths of the tumor. This
manipulation of the proton beam is called the Spread-Out Bragg
Peak. Additionally, protons do not deposit much radiation when
they enter the body. Taking advantage of the Bragg Peak Effect
and the low entrance dose, proton therapy should theoretically
achieve less exposure of radiation to normal tissue. This is believed to lead to higher prescribed doses, reduced complications
of therapy, and greater efficacy in eradication of the tumor than
any other form of radiotherapy.

Methods
Literature for this article was obtained using the Touro College
Online library, in particular PubMed.

Figure 1

The graph compares the Bragg peaks of IMRT vs. Proton beam therapy.
Protons, unlike photons, are clearly seen to delivery most of the radiation at
the targeted cell.
(Mohan et al. 2013)

Discussion
Over the past decade, intensity-modulated radiotherapy has become the standard form of radiation treatment for prostate cancer, accounting for more than 80% of all radiotherapy (Nguyen
2011). Although IMRT is the most common method of radiation
treatment, new forms of treatment are still emerging, most notably proton beam therapy. Proton therapy is currently being
implemented at various cancer centers across America because
of the excitement over the radiological advantages protons seem
to offer. Even though there is a lot of enthusiasm over PBT, no
factual evidence to prove protons are better than photons has
been found. The lack of evidence in conjunction with the enormous cost of delivering the treatment is compelling physicians
to determine if protons are more beneficial. To date there has
been no clinical study that establishes that protons have a major
advantage in cancer cure rates. This is because it is difficult to
conduct cure rate trials, since such differences take many years to
manifest.Therefore, the initial studies on proton therapy focus on
treatment related toxicity and quality of life (Pearson et al. 2007).
The organs most frequently affected by radiation toxicity after
treatments are the bladder and rectum.

Dosimetric Analysis
A dosimetric analysis is the estimated measurement of ionizing
radiation from the dose that is absorbed by nearby organs and
is projected before treatment is delivered. This analysis helps
physicians determine if there will be toxicity to nearby healthy
tissue, which can downgrade the patient’s quality of life. A study
comparing the dosimetry of intensity-modulated radiotherapy
and proton therapy was conducted to discover if protons spare
more healthy tissue than photons on the bladder and rectum.Ten
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patients were planned with both three dimensional conformal
proton therapy and intensity-modulated radiotherapy. The prescribed dose for both treatments was 79.2 cobalt gray-equivalent
(CGE) to the prostate gland. The study concluded that protons
reduce the area of nearby healthy tissue that inadvertently receives low to medium, but not high doses of radiation. In contrast,
intensity-modulated radiotherapy spreads more low and medium doses of radiation over a larger area of the pelvis (Table 1)
(Trofimov et al. 2007). IMRT likely ‘bathes’ the pelvis with low to
medium doses of radiation because it uses multiple ‘beamlets’ to
target the tumor from different directions. As a result, there are
more entry points into the patient’s body as radiation is shot
from the linear accelerator to the tumor.
More significant results were reported by a study from the
University of Florida.The study also used 10 patients to compare
proton beam therapy treatment with intensity-modulated radiotherapy, but with a prescribed dose of 78 CGE (Table 1) (Vargas et
al. 2008). The difference in results between the study by Trofimov
et al, in comparison to Vargas et al, can most probably be attributed to the difference in beam margins and arrangement. To be
certain the cancerous growth was completely radiated, Trofimov
et al, added a 10 mm margin around the clinical target volume,
Vargas et al, only added 5 mm by 8 mm. By minimizing the margins, Vargas was able to better conform the beam to the tumor.
When IMRT was delivered both studies used 7 beams, 52° apart
from each other. However, for proton therapy, only Vargas et al
optimized the beams. Beam angle optimization means physicians
determine the ‘beamlet’ angles and intensities, so that the beams
strike the tumor while sparing as much normal tissue as possible.
Two steps are taken when determining the correct beam angle
Table 1

Author
Trofimov

Vargas

Chera

Dosimetric

Value

Bladder

A clinical investigation conducted by Chera et al, did not use
beam angle optimization, but used the same prescribed dose and
similar margins to Vargas et al (Table 1). Chera et al, concluded
that the, “use of PBT significantly reduced the dose to normal
tissues in the pelvis while maintaining adequate target coverage
compared with IMRT” (Chera et al. 2009). Although the absolute difference between the two treatments was greater in the
study by Chera et al,Vargas et al, managed to spare slightly more
healthy tissue. One can conclude that beam margins play a more
important role in limiting radiation from healthy tissue than beam
arrangement.
In a recent study about the dosimetric impact on anatomical
movements, Zhang et al, noted that the proton beam is affected
by compensators that shape the beam at the end of the nozzle.
As a result, protons experience more scatter than photons and
minimizing the margins is extremely crucial. Although a dosimetric analysis was not the main focus of their study, Zhang et al
reported that, “The proton therapy plan was better at sparing the
rectum at doses of less than 50 Gy. However, above 50 Gy, IMRT
was better at sparing the rectum” (Zhang et al. 2007). Clearly, all
studies confirm that proton therapy reduces the amount of low
to medium radiation unintentionally delivered to nearby healthy
tissue. Yet, IMRT can sometimes yield better conformity to the
target area in cases where high doses are delivered.

Rectum

Absolute Difference
Bladder / Rectum

30% CGE

44.5%(IMRT) / 32.8%(PBT)

65.3%(IMRT) / 43.8%(PBT)

11.7% / 21.5%

70% CGE

11.4%(IMRT) / 17.3%(PBT)

9.7%(IMRT) / 10.3%(PBT)

5.9% / 0.6%

30% CGE

42.8%(IMRT) / 27.7%(PBT)

55.4%(IMRT) / 20.7%(PBT)

15.1% / 34.7%

78% CGE

—

5%(IMRT) / 2.9%(PBT)

- / 2.1%

30% CGE

73.1%(IMRT) / 29.3%(PBT)

71.8%(IMRT) / 22.5%(PBT)

43.8% / 49.3%

70% CGE

9.7%(IMRT) / 9.8%(PBT)

11.5%(IMRT) / 7.9%(PBT)

0.1% / 3.6%

Dosimetric Analysis Comparing IMRT Versus PBT (Pearlstein et. al 2013)
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and intensity. “First, the physicians through their experience and
intuition decide the arrangement of the beams. Secondly, based
on the orientation of the beams and the shape of the cancer,
computer software optimizes the beam intensities.” (Bertsimas
et al. 2013).

Proton Beam Therapy

Toxicity and Quality of Life
Radiation poisoning of healthy tissue caused by protons can irritate the bladder, cause frequent urination, rectal bleeding, and
sexual dysfunction. The question is, does toxicity to surrounding
normal tissue result from the combined low and medium dose
areas or the high dose area? A clinical investigation compared the
rate of second cancers between IMRT and 3D-CRT. The study
found that IMRT almost doubles the amount of second malignancies from 1% to 1.75%. This is because IMRT increases the
amount of low dose radiation absorbed by surrounding healthy
tissue (Hall et al. 2003). With this information it should follow
that proton therapy, which substantially reduces low to medium
unintentionally absorbed radiation should have significantly lower
toxicity rates than IMRT.
A study was launched to discover if proton therapy causes less
toxicity to nearby organs than intensity-modulated and three-dimensional conformal radiotherapy. There were 95 proton therapy patients, 153 IMRT patients, and 123 3D-CRT patients. Every
patient’s bowel and urinary functions were assessed 3, 12, and 24
months after treatment. The Expanded Prostate Cancer Index
Composite (EPIC) was used to grade patients that received IMRT.
Patients that received PBT or 3D-CRT were evaluated with the
Prostate Cancer Symptom Indices, a similar scale to EPIC. In
both tests scoring lower signifies lower quality of life. At three
months following treatment, patients who received 3D-CRT or
IMRT scored lower on the indices. They reported symptoms of
urinary irritation, obstruction, incontinence, and a decrease in
bowel quality of life. Proton therapy patients only reported minimal bowel and urinary morbidity. At 12 months all groups were
equal on the indices when they reported decreased bowel quality
of life. Only proton therapy patients reported a slight decrease
in quality of urinary functions, such as irritation and obstruction,
in comparison to the other groups. By 24 months all groups
reported minor but clinically meaningful decrements in bowel
and urinary functions quality of life. Proton therapy had a slight
advantage for toxicities after 3 months and IMRT and 3D-CRT
only had a slight advantage for urinary toxicities at 12 months. All
groups had the same level of toxicity 24 months later. However,
there are problems with this study. Firstly, each group received a
slightly different dose to the prostate: 75.6 to 79.2 CGE for the
IMRT patients, and 74.0 to 82.0 CGE for PBT patients. Different
doses of radiation could have caused the different patterns of
toxicity reported by the patients. Also, treatment was delivered
according to each center’s preferred practice and planning target
volume margins were not explicitly mandated (Gray et al. 2013).
Another study on whether PBT can control the incidence of rectal toxicity only comprised of patients receiving the same dose,
74 CGE. Patients were followed up with after treatment to collect data on the toxicities at 1 month and once every 3 months

for the first two years and once every 6 months thereafter. The
rectal toxicities observed included anal pain at defecation and
rectal bleeding. The bladder toxicities were urinary frequency,
painful urination, and urinary retention.The patients were graded
with the Common Toxicity Criteria 4.0, a scale created by the
National Cancer Institute Grade 1 toxicity usually means minor
toxicity. Grade 2 means symptoms requiring medications and
grade 3 means symptoms requiring minor corrective surgery.The
results revealed that PBT can achieve a low occurrence of grade
2 rectal toxicities and no major late toxicity was seen. (Nihei et al.
2011).The study by Nihei et al, takes care of some of the issues of
the trial by Gray et al, that were mentioned earlier. Each patient
had the same dose of radiation. In both studies a low amount of
rectal toxicity is seen early on.
More significant results were found by a study conducted by
Mendenhall et al. The authors used image-guided proton therapy
to target the cancerous tissue. They discovered low amounts of
grade 2 genitourinary and gastrointestinal toxicities (Mendenhall
et al. 2012). These toxicity results do appear more favorable than
results commonly reported with IMRT. There was a high incidence of grade 1 and 2, and some patients experienced grade 3
toxicity. (Valeriani et al. 2014). Even more surprising was the fact
that Valeriani et al, used image-guided IMRT and the prescribed
dose was much lower, 68 CGE. The image guided radiation and
the low amount of radiation should have curtailed the amount of
toxicity that was reported.
Only one study reported overall worse gastrointestinal toxicity rates for protons than photons. The study used data from
Surveillance, Epidemiology, and End Results (SEER), a Medicare
linked database. Sheets et al, analyzed patient reported outcomes
based on billing claims for diagnoses and procedures from sixteen cancer registries. There were 684 patients treated with
proton therapy and 6666 with IMRT. The authors observed that,
“proton therapy–treated patients were more likely to receive a
diagnosis of gastrointestinal morbidity and undergo gastrointestinal procedures” (Sheets et al. 2012). However, this investigation
did not report information on the prescribed dose and target
margins. If the dose and margins differed between the two groups
it could have caused a difference in toxicity rates. Another issue
with this study is that Sheets et al, used claims for colonoscopy
to measure gastrointestinal toxicity rates. This would be an imprecise surrogate for any population. This is the same population
that might also be more concerned about colonoscopy screening,
and therefore would receive more gastrointestinal procedures.
This study should not be used to relay any important morbidity
information to inquiring patients. The few studies on quality of
life have only shown modest advantages associated with proton
therapy in comparison with other forms of radiotherapy.
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Problems with Scatter Beam Proton Therapy
Theoretically, protons should be the superior form of radiation
treatment because of the Bragg Peak Effect. However, this phenomenon also makes the protons extremely sensitive to uncertainties during treatment. If a physician is unsure how deeply
situated the tumor is, protons will not destroy the cancerous
cells if it is not given even energy to reach that area. In contrast,
photons continue to deposit a substantial amount of radiation
as they transverse the entire body. As a result, physicians end
up programming the Spread-Out Bragg Peak to extend deeper
into the body, irradiating nearby healthy tissue. Additionally, the
Spread-Out Bragg Peak requires multiple shots of protons to be
passed through the body to completely radiate the entire depth
of the tumor. This causes the tissue in the front of the prostate
to be exposed to many doses of radiation. Additional concerns
have recently been raised that organ toxicity can also be a result
of secondary neutrons. Secondary neutrons are created when
protons collide with the collimator –a metal piece that shapes
the beam. The collimator is made out of brass and when struck
by protons it sends off secondary neutrons. Low secondary neutron radiation can cause patients receiving treatment to develop
a high chance for contracting second malignancies (Brenner et al.
2008). These neutrons could be stopping PBT from having better
toxicity results. Although there are simple fixes to reduce the
amount of neutrons, such as using a material with a low mass
number, these techniques do not substantially curtail the amount
of neutrons (Gould 2009).

Pencil Beam Scanning
Recently, a newer method of delivery has been added to proton therapy. The older method, Scatter beam uses thick beams
of passively scattered protons. The beams are shaped through
slits in metal plates that form a relatively large beam as it exits
the particle accelerator. The latest improvement to proton beam
therapy is pencil beam scanning. Also known as spot scanning, this
method is more accurate version of proton therapy. Pencil beam
employs an extremely narrow beam that is brushed from side to
side, ‘painting’ the dose on the tumor spot by spot. Because no
apertures are needed, the protons do not collide with any metal
and secondary neutrons are not produced with the collimator.
The beam targets each spot on the tumor with a specific dose
of radiation. Pencil beam scanning can even adjust the Spread-out
Bragg Peak for every individual cancerous cell. “Scattered beam
and pencil beam can be compared to a painter spraying with a
spray can versus an airbrush. Instead of needing a stencil to master the shape, the proton beam is made ultra fine to define the
contours and landscape of a tumor” (MD Anderson 2009). With
pencil beam protons are turned into an intensity-modulated type
of treatment.This is projected to give protons more conformation
to the cancer and its surrounding healthy tissues. Recently, a small
number of cancer centers that deliver proton therapy introduced
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this new technology (Weisenbaugh 2014).To date, it is premature
to determine if pencil beam is the most optimal method to use
in the fight against prostate cancer. Only one study concluded
that there is no toxicity or quality of life differences between
passively scattered and pencil beam. The clinical investigation was
comprised of 226 men who received passively scattered proton
therapy and 65 men who received pencil beam proton therapy.
Both groups reported similar gastrointestinal toxicity results,
grade 2, throughout the 24-month trial. Genitourinary toxicity
was also grade 2 and occurred mostly in the first 12 months
following treatment. Yet, the authors acknowledged that, “Future
comparative analyses between spot-scanning and passively scattered are warranted in a larger cohort” (Pugh et al. 2013).

Conclusion
Proton beam therapy can cure prostatic adenocarcinoma as efficiently as IMRT. If proton therapy would not be extremely expensive this therapy would be less controversial. Protons would have
been regarded as another type of treatment used to eradicate
cancerous cells. However, because proton therapy is considerably more expensive it draws criticism to the fact that it only
has a meager benefit over IMRT. PBT is slightly more effective
in curtailing the amount of low to medium dose of radiation to
the nearby organs. However, this only translates into a modest
advantage in early toxicity over intensity-modulated radiotherapy. Currently, there is no clinical evidence that proves scatter
beam proton therapy is a significantly better form of treatment
than IMRT. However, since there are limited centers that deliver
proton therapy and relatively few patients that received it, more
studies need to be conducted to solidify this claim. Although
scatter beam might not be so advantageous in comparison to
intensity-modulated radiotherapy, pencil beam proton therapy is
theorized to turn protons into the ultimate form of treatment.
More clinical trials need to be conducted to find out if pencil
beam technology gives proton therapy the edge in the battle
against prostate cancer.

References
Bertsimas D, Cacchianib V, Craftc D, Nohadani O. A hybrid approach
to beam angle optimization in intensity-modulated radiation therapy.
Computers & Operations Research. September 2013;40(9):2187-97
Brenner DJ, Hall EJ. Secondary neutrons in clinical proton radiotherapy: a
charged issue. Radiother Oncol. February 2008;86(2):165-70.
Chera BS,Vargas C, Morris CG, Louis D, Flampouri S,Yeung D, Duvvuri
S, Li Z, Mendenhall NP. Dosimetric study of pelvic proton radiotherapy
for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. November
2009;75(4):994-1002.
Gould P. Simple solution to secondary neutron dose. Available at: http://

Proton Beam Therapy

medicalphysicsweb.org/cws/article/research/40637. Published October

Review. 2007. Available at: http://www.icerreview.org/wpcontent/up-

2009. Accessed November 30, 2014

loads/2013/04/Management_Options_for_Low-Risk_Prostate_Cancer_
Final-2.pdf. Accessed December, 2014.

Gray PJ, Paly JJ,Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott
JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman

Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo

JE, Efstathiou JA. Patient-Reported Outcomes After 3-Dimensional

N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA,

Conformal, Intensity-Modulated, or Proton Beam Radiotherapy for

Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of Life and Toxicity

Localized Prostate. Cancer. Cancer May 2013;119(9)

from Passively Scattered and Spot-Scanning Proton Beam Therapy for
Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. December

Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-

2013;87(5):946-953.

CRT and IMRT. Int J Radiat Oncol Biol Phys. May 2003;56(1):83-8.
Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, Holmes
Mendenhall NP, Li Z, Hoppe BS, Marcus RB Jr, Mendenhall WM, Nichols

JA, Reeve BB, Godley PA, Carpenter WR, Chen RC. Intensity-Modulated

RC, Morris CG, Williams CR, Costa J, Henderson R. Early outcomes from

Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and

three prospective trials of image-guided proton therapy for prostate

Morbidity and Disease Control in Localized Prostate Cancer. JAMA : the

cancer. Int J Radiat Oncol Biol Phys. January 2012; 82(1):213-21.

journal of the American Medical Association. July 2012;307(15):1611-20.

Mohan R, Mahajan A, Minsky BD. New Strategies in Radiation Therapy:

Surveillance, Epidemiology, and End Results Program. SEER Stat Fact

Exploiting the Full Potential of Protons. Clinical Cancer Research.

Sheets: Prostate Cancer. http://seer.cancer.gov/statfacts/html/prost.html.

December 2013;19(23)6338-48

December 25, 2014

MD Anderson Cancer Center. Advances in Proton Therapy, Pencil Beam

Trofimov A, Nguyen PL, Coen JJ, Doppke K, Schneider R, Adams,

Technology Reach Patient Care. MD Anderson Cancer Center. Availible

J, Bortfeld T, Zietman AL, DeLaney TF, Shipley WU. Radiotherapy

at: http://www.mdanderson.org/newsroom/news-backgrounders/03-30-

treatment of early-stage prostate cancer with IMRT and protons: a

09-advances-in-proton-therapy-pencil-beam-technology-reach-patient-

treatment planning comparison. Int J Radiat Oncol Biol Phys. October

care.html. March 30, 2009

2007;69(2):444-53.

National Association for Proton Therapy. Background Information.

Valeriani M, Carnevale A, Osti MF, De sanctis V, Agolli L, Maurizi enrici R.

Available at: http://www.proton-therapy.org/backgrou.htm March 2010

Image guided intensity modulated hypofractionated radiotherapy in highrisk prostate cancer patients treated four or five times per week: analysis

National Cancer Institute. General Information About Prostate Cancer.

of toxicity and preliminary results. Radiat Oncol. September 2014;9:214.

Available at:http://www.cancer.gov/cancertopics/pdq/treatment/prostate/
HealthProfessional/page1#Section_1679. Accessed November 28, 2014

Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, McKenzie
C, Lawlor P, Henderson R, Li Z, Lin L, Olivier K, Keole S. Dose-volume

Nihei K1, Ogino T, Onozawa M, Murayama S, Fuji H, Murakami M,

comparison of proton therapy and intensity-modulated radiotherapy for

Hishikawa Y. Multi-institutional Phase II study of proton beam therapy for

prostate cancer. Int J Radiat Oncol Biol Phys. March 2008;70(3):744-51.

organ-confined prostate cancer focusing on the incidence of late rectal
toxicities. Int J Radiat Oncol Biol Phys. October 2011;81(2)390-6

Wang YZ, Wong YC. Oncogenes and Tumor Suppressor Genes in
Prostate Cancer : a review. Urol Oncol. March 1997;3(2):41-6.

Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE,
Hu JC. Cost Implications of the Rapid Adoption of Newer Technologies

Wisenbaugh ES, Andrews PE, Ferrigni RG, Ferrigni RG, Schild SE, Keole

for Treating Prostate Cancer. Journal of Clinical Oncology. April

SR, Wong WW,Vora SA. Proton Beam Therapy for Localized Prostate

2011;29(12):1517-24.

Cancer 101: Basics, Controversies, and Facts. Reviews in Urology.
2014;16(2):67-75.

Pearlstein KA, Chen RN. Comparing Dosimetric, Morbidity, Quality of
Life, and Cancer Control Outcomes After 3D Conformal, Intensity-

Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y,

Modulated, and Proton Radiation Therapy for Prostate Cancer. Seminars

Newhauser WD, Gillin M, Mohan R. Effect of anatomic motion on proton

in Radiation Oncology. June 2013;23(3):182-190

therapy dose distributions in prostate cancer treatment. Int J Radiat
Oncol Biol Phys. August 2007;67(2):620-9.

Pearson SD, Ladapo, Prosser L. Intensity modulated radiation therapy
(IMRT) for localized prostate cancer. Institute for Clinical and Economic

31

Mechanisms, Potential Therapies, and the Role of TGF-β in
the Formation of Scars
Isaac Traube

Isaac will graduate in June 2015 with an Honors Biology B.S. degree.

Abstract
Scarring is the inevitable outcome of wound healing.This review looks at some of the underlying mechanisms of this complex process with the aim of identifying targets for therapeutic manipulation that could result in reduced scarring or even
scarless wound repair. Fetal wounds are shown to heal without scars primarily due to low levels of TGF-β1 and TGF-β2
and high levels of TGF-β3 as compared to adult wounds which heal with scars. Abnormal excessive scarring in keloid and
hypertrophic scars are also attributed to TGF-β. Clinical manipulation of TGF-β ratios showed promise as a therapeutic
means of controlling scar formation. The effect of the COX enzyme and PGE2 levels remains controversial and more
research is needed to understand the exact roles these molecules play in the wound healing process before they can be
exploited in a clinical setting.
Introduction
Scarring, both as a component and complication of, wound healing affects millions of US citizens every year at a cost of more
than 7 billion dollars (Wilgus, et al. 2003). In addition to esthetic
concerns, scar formation is also implicated clinically in fibrotic
diseases that some reports suggest are responsible for up to 45%
of deaths in the industrial world (Wynn, 2008). Despite such a
heavy toll on the healthcare system, current treatment options
are limited. Further research is needed to understand the underlying causes and mechanisms of scar formation so that effective
treatments and even methods of prevention can be developed.
Cellular response to tissue damage and the consequent formation of fibrotic tissue is a complex process that is still not very
well understood. Current paradigms include the contribution of
such varied cells as epithelial cells, macrophages, T-cells and, of
course, fibroblasts. Initial response to tissue wounds involves the
rapid recruitment of clotting factors and immune inflammatory
moderators to stem blood loss and reduce potential infection
by pathogenic microbes. Later, the relatively extended process of
wound healing begins. Injured epithelial cells undergo a process
of reprogramming, initiation, and propagation of mesenchymal
pathways that includes the ubiquitous TGF-β related pathways.
Macrophages also contribute to the inflammatory response and
secrete profibrotic cytokines as well as growth factors, including
TGF-β, that recruit and activate fibroblasts. Fibroblasts accumulate and ultimately produce and deposit new extracellular matrix
and collagen that replaces normal tissue architecture. It is this
deposition that characterizes scar formation and clinical fibrosis.
Interestingly, the development of scar tissue differs greatly between adult and embryonic wounds. Contrary to the normal
fibrotic result in adult wounds, fetal wounds have been shown to
exhibit scarless healing. Many cellular and molecular differences,
including differences in key inflammatory mediators and various
cytokines and growth factors, have been studied and documented
to attempt to explain this phenomenon.
In addition to expected scarring as a result of injury, there exist
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two clinical examples of atypical wound healing that result in abnormal scar formation. The etiology of hypertrophic scars and
keloids is not well-understood, and although important differences between them have been detailed, both clearly involve the
deposition of excessive amounts of collagen even as compared
to normal scarring.
Such anomalous results, from the scarless healing of fetal wounds
to the excessive scarring of keloid and hypertrophic scars, may
serve as paradigms for understanding the mechanisms behind the
wound healing and scarring processes and the ability to prevent
undesired outcomes.

Methods
Literature searches were chiefly performed using the PubMed
database. After relevant literature was found, related articles
were accessed using the Related Citations feature on the PubMed
website. Additionally, references in these articles were retrieved
and then served as additional points of reference for further research. Review articles relevant to the research topic were helpful in providing references to source material. The Touro College
Online Library and Google Scholar proved to be valuable for
finding and accessing the necessary relevant articles. Moreover,
conversation with plastic surgeons led to additional searches for
source material on the website of the Plastic and Reconstructive
Surgery journal.

Discussion
The formation of scar tissue in the process of wound healing is
both a positive construct that effectively patches breaks in damaged tissue and a negative consequence that can have dire effects.
Scar tissue production is intended to increase the tensile the
strength of wounds but never surpasses 70% of the strength of
the original undamaged tissue (Wilgus, et al. 2003). Scar tissue
also can impede tissue function, restricting mobility in joints and
impairing normal growth in the case of external injuries involving
the skin. The issue is even more problematic in the case of scar
deposition as a result of internal organ damage. In such cases,
scars can dramatically reduce function of vital organs as with
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victims of myocardial infarctions whereby normal heart tissue is
replaced with nonfunctional scar tissue. However, the problem
of scar formation is perhaps greatest with respect to its role in
devastating fibrotic diseases where scar tissue often times fatally
overtakes normal tissue function.
Scars are essentially large deposits of extracellular matrix and
collagen that are deposited by activated fibroblasts in response
to tissue damage. After an injury, inflammatory mediators are
immediately recruited and activated. Numerous cell types are
involved in this response which includes the production and
excretion of various growth factors and cytokines such as the
well-studied TGF-β, IL-6, IL-8 and others.
Tissue injury involves disruption of capillaries and immediately triggers activation of platelets which begin a clotting cascade. Inflammatory events follow with recruitment of neutrophils which secrete a variety of growth factors and cytokines.
Monocytes arrive to facilitate changes in the wound matrix and
macrophages release factors that activate fibroblasts to begin
adding hyaluronate and glycoproteins such as fibronectin to the
extracellular matrix (ECM). Gradually, these fibroblasts shift to
producing proteoglycans and collagen which are then deposited
at the wound site. Over the course of several days, macrophages
and fibroblasts work to remodel the matrix and thus convert the
granulation tissue into scar tissue (Harty, 2003).
Studies comparing scarless fetal wounds to adult wounds have
found significant differences in the levels of proinflammatory cytokines such as IL-6 and IL-8. Liechty et al. (1998) grafted adult
and fetal skin subcutaneously into SCID mice, wounded the site
and subsequently excised the wound after varying lengths of time.
The presence of IL-8 was confirmed using reverse transcription
polymerase chain reaction (RT-PCR). Their results showed that
fetal fibroblasts produced significantly less IL-8 at baseline (50
+/- 6 pg/mL versus 450 +/- 115 pg/mL, P < 0.001). IL-8 mRNA
was detected in unstimulated adult fibroblasts but not in fetal
fibroblasts and much less IL-8 mRNA was detected in stimulated
fetal fibroblasts than in adult fibroblasts. IL-8 mRNA was detected 4 hours after wounding in both fetal and adult wounds but by
12 hours no IL-8 mRNA was detected in fetal wounds, whereas
IL-8 mRNA persisted for up to 72 hours in adult wounds.
In a similar experiment, Liechty et al. (2000a) excised incisional
wounds and examined them for IL-6 mRNA quantification by RTPCR. As with IL-8, fetal fibroblasts produced less IL-6 protein and
mRNA at all points examined (P < 0.01 vs adult). IL-6 mRNA was
detected 4 hours after wounding in both fetal and adult wounds.
By 12 hours there was no IL-6 mRNA in the fetal wounds but the
adult wounds had IL-6 mRNA persisting to 72 hours. In this experiment, another set of grafts had 5 micrograms of IL-6 injected

at wounding and the wound subsequently harvested at 7 days for
analysis. The wounds with administered IL-6 resulted in scar formation. Since these cytokines are responsible for the recruitment
and activation of various leukocytes including macrophages, the
diminished inflammatory response by fetal tissues may explain
the lack of cellular recruitment and inflammation in fetal wound
healing and further suggests that the inflammatory response
plays a key role in the process of scar formation.
One well studied growth factor, TGF-β, exists as three known
isoforms and is involved in many aspects of wound healing, from
the immediate inflammatory response to matrix deposition
(Adzick & Lorenz, 1994). In response to tissue injury, macrophages release TGF-β which stimulates the deposition of collagen
and other matrix components by fibroblasts, thus implicating it in
the etiology of fibrosis. Specifically, the TGF-β1 and TGF-β2 isoforms have been directly implicated in the fibrotic response and
formation of scar tissue. Whitby and Ferguson (1991) detected
both TGF-β1 and TGF-β2 isoforms with immunolocalization in
adult wounds but not in fetal wounds. In a pioneer study, Shah et
al. (1992) studied the effect of reduced levels of TGF-β in adult
rodent wounds by using various neutralizing agents. The results
of that experiment indicated inhibited fibrosis and scar formation. In another similar experiment, Shah et al. (1994) injected a
polyclonal neutralizing antibody to TGF-β1, 2 into full-thickness
cutaneous wounds of adult rodents just prior to wounding or
within 24 hours of wounding and repeated daily for two days
post-wounding. The effect was successful reduction in scarring.
Numerous similar studies have been performed that confirm
these results with more or less comparable data (Singer, et al.
2009; Shah, et al. 2000). Conversely, up-regulation of these TGF-β
isoforms via exogenous application resulted in excessive scar
formation in a number of animal models (Lin, et al. 1995; Wang,
et al. 1999; Lanning, et al. 1999). Thus direct evidence exists that
increased levels of TGF-β1 and TGF-β2 play an important role in
the fibrotic response and suggests that manipulation of TGF-β
levels may provide an efficient strategy of reducing scar formation.
The culpability of TGF-β in the formation of scar tissue is further supported by studies that have investigated the cellular and
molecular differences abnormal scar formation such as keloid
and hypertrophic scars. Experimental evidence suggests that
upregulation of TGF-β is necessary for the excessive scarring
characteristic of these pathologies (Lee, et al. 1999; Campaner,
et al. 2006). Wang et al. (2000) compared the levels of TGF-β1
mRNA in hypertrophic scar tissue and normal skin and found
that hypertrophic scar tissues expressed five-fold more TGF-β1
mRNA than normal skin per unit of wet weight. TGF-β1 mRNA
expression in 5 pairs of fibroblast cultures derived from hypertrophic scar tissue also was found to be significantly elevated as
compared to those derived from normal cells (116 +/- 6 vs. 97

33

Isaac Traube

+/- 7, p = 0.017). Additionally, Schmid (1998) demonstrated by
immunohistochemistry and in situ hybridization, that hypertrophic scars exhibit unresolved persistent overexpression of TGF-β
receptors by fibroblasts leading to overproduction of matrix protein and subsequent fibrosis.
Table 1

TGF-β Isoform

Scarless Fetal
Healing

Scar-forming
Adult Healing

TGF-β1

low/absent

high

TGF-β2

low/absent

high

TGF-β3

high

low

Summary of relative TGF-β isoform differences in scarless fetal wound healing
and scar-forming adult wound healing. (Ferguson, O’Kane, 2004).

However, although the TGF-β1 and TGF-β2 isoforms have been

implicated in scar formation, a third isoform has been shown to
reduce scarring. Whitby and Ferguson (1991) demonstrated that
fetal wounds express low levels of TGF-β1 and TGF-β2 but high
levels of the third isoform, TGF-β3 (Table 1).
This implied that the ratio of TGF-β isoforms in wounded tissue
may be the key to understanding the mechanism of wound healing and whether or not a scar forms. Shah et al. (1995) confirmed
this hypothesis when they demonstrated that pan-neutralization
of all three known TGF-β isoforms in linear incisions made on
rats did not improve scarring, while exogenous application of
TGF-β3 resulted in marked improvement in scarring and even
scarless healing. Numerous studies have exploited this therapeutic approach of increasing the relative ratio of TGF-β3 to TGF-β1
and TGF-β2 with novel pharmaceutical agents (Ferguson, O’Kane,
2004) (Figure 1).
The first clinical application of human recombinant TGF-β3,
avotermin (Juvista; Renovo, UK) administered as an intradermal
injection at the time of surgery, had shown promise in reducing scarring in controlled, double-blind, randomized phase I/
II clinical studies (Durani, et al. 2008). So et al. (2011) studied
sixty patients (35 men and 25 women; age, 19 to 78 years; 53
Caucasians; scar length, 5 to 21 cm) who received intradermal

Figure 1
macroscopic: black
dots indicate ends of incision
(a)
normal scar
histological score - 4

scar: dense abnormally
organized dermis
histology

(b)
no visible scar
histological score - 0.5

improved dermal organization
similar to normal skin
histology

(a) Placebo-treated incisional rat wound compared with (b) scarless healing in TGF-β3-treated wound 84 days post-wounding (Ferguson, O’Kane, 2004).
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avotermin (200 ng/100 μl/linear cm wound margin) and placebo
to wounds immediately after scar revision surgery and again 24
hours later. Primary efficacy was measured as a total scar score
derived from a visual analogue scale and scored by a lay panel
from standardized photographs from 1 to 7 months following
treatment. Profilometry showed a greater reduction in scar surface area from baseline with avotermin treatment compared with
placebo and histologic analysis showed collagen organization that
more closely resembled normal skin. However, an earlier study
of dermal ulcers on the ears of female rabbits had demonstrated only that exogenous topical TGF-β3 had accelerated wound
healing but with no improvement in scar morphology and prominence. Wu et al. (1997) showed that the use of TGF-β3 (0.3-0.75
microgram per wound) increased granulation tissue formation
by more than 100% (P < .005) but no significant difference in the
hypertrophic index was noted as compared with controls. In fact,
phase III trials of avotermin failed to meet primary and secondary
endpoints, suggesting that the difference between scarless and
scar-forming wound healing is perhaps more complex than simply
altering the ratio of TGF-β isoforms (Penn, et al. 2012) .
Interestingly, a number of studies have demonstrated that even
in fetal wounds, exogenously applied TGF-β can induce fibrosis.
McCallion and Ferguson (1996) applied exogenous TGF-β1 to
fetal wounds and observed a profound fibrotic response with
scar formation. Krummel et al. (1988) showed that the addition
of TGF-β to polyvinyl alcohol sponges implanted in fetal rabbits
produced fibrosis. Sullivan et al. (1995) also examined human scarless fetal wounds transplanted subcutaneously into adult nude
mice. Immunohistochemistry performed on the wounds did not
show TGF-β staining. In a second part of the study, a slow-release
disk with varying amounts of TGF-β1 was placed beneath the
fetal skin graft at the time of wounding. Marked scarring in these
fetal grafts was observed fourteen days post-wounding with the
size of the scar proportional to the amount of TGF-β1 applied.
These data suggest that the cellular mechanism of scar formation
characteristic of adult wound healing is present in fetal wounds.
The absence of scar formation in fetal wounds thus implies active
suppression of these inflammatory mediators that have been implicated in scar formation.
The concept of immune inflammatory suppression as the mechanism of scarless healing has been investigated further by testing
with the known anti-inflammatory cytokine IL-10. IL-10 deactivates macrophages and inhibits expression of both IL-6 and IL-8.
Liechty et al. (2000b) hypothesized that the diminished levels of
IL-6 and IL-8 they had revealed in a previous study were in fact
due to the effects of IL-10. They developed a new syngeneic murine model of fetal wound repair in which 15-day-gestation skin
from either normal or transgenic IL-10 knockout mice was grafted to the back of the same strain adult mice. Incisions were made

in the grafts after 5 days, which were then harvested at 1 week
and analyzed for inflammatory response and scar formation. The
normal fetal skin grafts showed minimal inflammation and were
histologically consistent with scarless healing.The IL-10 knockout
fetal skin grafts, in contrast, displayed significant inflammation and
scar formation. Thus, the anti-inflammatory effects of IL-10 are
necessary for active suppression of the inflammatory response
leading to the observed paucity of macrophages, less TGF-β release, and consequently, less scarring.
The impact of IL-10-induced immune suppression is a key factor in scarless wound healing. Yamamoto et al. (2001) performed
Northern blot analysis to show that IL-10 differentially regulates
collagen deposition by downregulation of TGF-β1-induced collagen mRNA. In a phase II randomized controlled clinical trial,
Kieran et al. (2013) demonstrated that exogenous IL-10 applied
to human incisional wounds reduced scarring and generally improved scar appearance.
In a recent study, Wise et al. (2014) studied the effects of a purified IL-10 homolog derived from orf virus (ovIL-10). Orf virus
infections induce persistent skin lesions that are reminiscent of
sustained wound healing, yet surprisingly resolve with minimal
scarring (Gurel 2002), and genetic studies have discovered that
orf virus encodes for a variety of factors that allow it to subvert
host immune responses, including an IL-10 homolog (Fleming
2007). Wise et al. made excisional wounds in mice and divided
them into four groups. The first three groups were treated with
either recombinant murine IL-10 (mIL-10) or ovIL-10 in a buffered saline solution (PBS), or PBS alone, while the fourth group
received no treatment. The wounds were biopsied at varying
times and analyzed. Histological analysis revealed that wounds
treated with ovIL-10 exhibited accelerated healing as evident
by increased wound reepithelialization as compared to controls.
Reduction in visible scarring was also evident and quantitative
PCR confirmed decreased levels of key proinflammtory mediators. Thus supporting evidence exists that limiting the inflammatory response in wound healing can improve the quality of
wound repair.
TGF-β is an upstream regulator of the cyclooxygenase (COX)
pathway (Wilgus, et al. 2004). COX enzymes catalyze the conversion of membrane phospholipid-derived arachidonic acid into
prostaglandins which are known mediators of the inflammatory
response. Western blot analysis and immunohistochemistry of
biopsied hypertrophic and keloid scar lesions revealed significant
overexpression of COX-1 and COX-2 isoforms, respectively, in
comparison to normal dermal tissue which further suggests a significant role these enzymes play in the pathogenesis of these abnormal scarring processes (Rossiello, et al. 2009). Indeed, TGF-β
was shown to induce prostaglandin production in cultured
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fibroblasts via COX-1 overexpression (Diaz, et al. 1998).
The significance of COXs in the etiology of pathological scarring
such as keloids and hypertrophic scars has led to the investigation of its role in wound healing in general. Wilgus et al. (2003)
examined the role of COX inhibitors in reducing scar formation.
Celecoxib belongs to the family of nonsteroidal anti-inflammatory drugs (NSAIDs) which target the COX enzymes. Specifically,
celecoxib selectively targets COX-2 and prevents its enzymatic
activity and subsequent production of prostaglandins including
prostaglandin E2 (PGE2). Wilgus et al. made full-thickness incisions in mice and closed the wounds with stainless steel wound
clips to mimic surgical wounds. The staples were removed after
5 days. The wounds were treated topically immediately after
wounding and for up to 14 days daily with either 200 µl of the
vehicle control (K-Y Jelly; Ortho Pharmaceutical Corp., Raritan,
NJ) or with 1 mg of celecoxib capsules (Celebrex®, Searle, St.
Louis, MO) dissolved in 200 µl of vehicle such that 200 µl contained 1 mg of the drug.
Skin sections were excised and analyzed. Immunohistochemical
analysis using an antibody specific for the neutrophil surface
marker Ly-6G, revealed a stark contrast between vehicle-treated
and celcoxib-treated wounds. While a major inflammatory response, manifested as a massive infiltration of neutrophils, was
observed in the vehicle-treated wounds in comparison to unwounded tissue, wounds treated with celecoxib were virtually
devoid of neutrophils.
Additionally, Biotrak enzyme immunoassays (EIA; AmershamPharmacia, Piscataway, NJ) were used to quantify the concentration of PGE2. An approximately 50% decrease in wound PGE2
levels was observed in wounds treated with celecoxib (p < 0.05).
Levels of TGF-β1 were examined by Western blot analysis which
revealed significantly lower levels in celecoxib-treated wounds
compared to vehicle-treated wounds. These data were substantiated by the observation of reduced scarring later on.
Wilgus et al. (2003) also reported that PGE2 promotes fibroblast
proliferation and collagen synthesis consistent with known findings (Lupulescu 1975) as well as their data showing decreased
scar tissue deposition in treatment with celecoxib. This seems to
be corroborated by the fact that lower levels of the proinflammatory fibrogenic TGF-β1 were detected. A similar result was
presented by Miyajima et al. (2001) who also showed the ability
of COX-2 inhibitors to reduce TGF-β levels and thus fibrosis.
The demonstrated effect of treatment with topical celecoxib in
reducing scar formation in adult wound healing led Wilgus et al.
(2004) to examine the role of COX-2 in scarless fetal wound
repair. Incisions were made in the dorsum of fetal mice at either
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15 (E15) or 18 (E18) days after the detection of a vaginal plug
using microsurgical scissors.These time points represent the ages
at which either scarless or fibrotic healing occurs. Normal E15
and E18 skin were harvested as controls along with the wounded
samples at varying times for examination. Immunohistochemical
staining at 24 hours post-wounding demonstrated COX-2 protein expression only in wounded E18 skin but not in E15 skin.
Western blot was also used to detect COX-2 protein and the
levels were analyzed by image analysis software. Levels of COX-2
protein as well as PGE2 were higher in wounds introduced at E18
compared to those at E15, implying that COX-2 is involved in the
process of scar tissue formation.
It is thought that one mechanism by which PGE2 contributes to
scar deposition is by increasing the rate of fibroblast proliferation. Indeed, Wilgus et al. showed that exogenous PGE2 applied
to fetal fibroblast cultures resulted in statistically significant (p
< 0.05 compared to untreated cells) dose dependent increased
proliferation.
However, conflicting data suggest that fibroblasts from other organs do not respond in the same way to increased PGE2 levels.
For example, PGE2 reduces proliferation and collagen synthesis by lung fibroblasts. This suggests that PGE2 can have varied
effects perhaps resulting from differences in the expression or
activity of various PGE2 receptors (Wilgus 2004).
Thus, the mechanism of PGE2-induced scarring could involve a
number of plausible options. PGE2 could be contributing to the
inflammatory response which has already been implicated in scar
formation. Alternatively, PGE2 could be promoting scar deposition through increases in the profibrotic TGF-β. Lastly, PGE2
could be directly encouraging scar formation by stimulating fibroblast proliferation.
Of note, however, is that although keloid and hypertrophic scars
were found to express high levels of COX proteins, Yeh et al.
(2006) found that fibroblasts derived from keloid patients exhibited diminished capacity to produce PGE2, in line with the studies
that identified PGE2 as an antifibrotic agent. In this experiment,
fibroblast cultures were stimulated using the proinflammatory
cytokine IL-1 which is known to activate fibroblasts and induce
the formation/release of COX pathway products such as PGE2
(Elias, et al. 1987). The effects of PGE2 on the synthesis of collagen were determined using enzyme-linked immunosorbant assay
(ELISA) kits. According to these data, the excessive deposition of
collagen characteristic of keloids may in fact be due to decreased
levels of PGE2 rather than increased.
The conflicting and perhaps confounding data surrounding PGE2
and its effect on fibroblast proliferation and collagen synthesis
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necessitate further investigation into the exact mechanisms by
which this enzyme affects the healing process. Such contradictory
data does not now lend to sufficient understanding that can lead
to exploitation and development of therapeutic clinical applications in the treatment or prevention of scarring. In fact, some
have suggested that the use of NSAIDs and COX-2 inhibitors
may even exacerbate wound scarring because of their ability to
decrease PGE2 production (Su, et al. 2010).
Until such time as the role of PGE2 and its effect on wound
healing becomes better understood, a more promising approach
to treatment and/or prevention of scarring would seem to be
manipulation of the various TGF-β isoforms, which perhaps play a
more direct role in the process of scar formation .
Already, clinical trials that manipulated the ratio of TGF-β isoforms have proven efficacy in the controlling scarring, although
not without some failure. Further investigation into the exact
role the various isoforms of TGF-β play in the process of wound
healing can hopefully lead to the development of better targeted
therapies to reduce scarring and perhaps even cure the numerous fibrotic diseases.
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Conclusion
In this review, the underlying mechanisms of scar formation in
wound healing were explored. The various TGF-β isoforms (and
their ratio) seem to play a vital role by regulating the inflammatory response although the process is undoubtedly more complex.
The role of COX and PGE2 remains unclear with contradictory
evidence pointing either to a reduction in scarring or perhaps
exacerbation of the problem. The focus of potential therapeutic
agents should for now remain dedicated to TGF-β as past studies
have already proven potential in reducing scarring, while the other
options reviewed here remain clouded in uncertainty. Research
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therapy (Liu, et al. 2004).These and other efforts show promise in
the development of successful clinical means of controlling scarring and perhaps even fibrotic disease.
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Abstract
Alzheimer’s disease is a neurodegenerative disease that causes dementia and ultimately death. Currently, there is no
treatment available for this disease. The aging of the population will only increase the incidence of Alzheimer’s disease,
making it ever more important to find an effective method of prevention. Dietary intervention is a practical and affordable
method of intervention. The brain is a fat rich organ, and dietary fats are critical for proper development of the brain.
A literature review was conducted to determine whether there is a link between saturated fat intake and Alzheimer’s
disease. According to the literature reviewed, saturated fat increases the amount of amyloid beta in circulation, and is
linked to blood brain barrier dysfunction. Consistent with this, high saturated fat diets lead to cognitive decline in animals.
Epidemiologic studies have yielded conflicting results, but most studies show a link between increased intake of saturated
fat and increased incidence of Alzheimer’s disease. Lipid lowering agents and anti-inflammatory drugs have been found to
attenuate the effect of a high saturated fat diet in animals. An examination of medical records has also shown that patients
who had been prescribed statins were less likely to be afflicted with Alzheimer’s disease.The literature reviewed indicates
that lowering intake of saturated fat as part of a healthy diet may reduce the risk of Alzheimer’s disease later in life. There
is also evidence that lipid lowering agents and anti-inflammatory drugs may slow the progression of Alzheimer’s disease.
Introduction
Alzheimer’s disease is a neurodegenerative disease that causes
severe memory loss and ultimately death. The first part of the
brain affected by Alzheimer’s disease is the hippocampus, a region
of the brain associated with memory. Memory loss is usually the
first symptom of Alzheimer’s disease. As the disease progresses
the degeneration spreads to other parts of the brain leading to
the loss of other cognitive skills such as language skills and the
ability to plan. Eventually, damage to the basal nucleus of Meynert
leads to a sharp drop in the amount of the neurotransmitter
acetycholine present in the brain, leading to further deficiencies
(Peterson, 2002). Approximately ten percent of the population
over the age of 65 and fifty percent of those above 85 suffer
from Alzheimer’s disease (Carlson, 2011). Currently, there is no
medication that can cure Alzheimer’s disease or stop its progression. Patients suffering from Alzheimer’s disease are treated with
medications that alleviate the symptoms. Acetylcholinesterase
inhibitors are prescribed to alleviate the cognitive symptoms.
Anxiolytics and antipsychotics may be prescribed to treat behavioral symptoms. These drugs, however, may worsen cognitive
deficiencies. Ultimately, the inexorable progression of Alzheimer’s
disease leads to death (Peterson, 2002).
Although the cause of Alzheimer’s disease has not been definitively determined, two pathological conditions have been linked
to Alzheimer’s disease, amyloid plaques and neurofibrillary tangles. The amyloid plaques are extracellular deposits of the protein beta amyloid (sometimes referred to as amyloid beta). These
plaques are surrounded by degenerating neurons and activated
microglia, the phagocytotic cells of the central nervous system.
Activated microglia are a sign of inflammation or immune response. The neurofibrillary tangles are intracellular accumulations of hyperphosphorylated tau proteins. These tangles disrupt
transport within the neurons eventually killing the cell and leaving
behind the tangle of filaments (Carlson, 2011).

Alzheimer’s disease is split into two categories: early onset, also
called familial, and late onset, also called sporadic. Alzheimer’s
disease occurring before the age of 65 is considered familial
whereas Alzheimer’s disease occurring after the age of 65 is considered sporadic. Familial Alzheimer’s shows a clear pattern of
inheritance. In different families the disease is caused by different
genetic mutations. Three genetic mutations have been identified:
a mutation in the amyloid precursor protein gene (APP) gene, a
mutation in the presenilin 1 (PS1) and a mutation in the presenilin 2 (PS2) gene. All three of these mutations have been shown
to increase the relative amount of amyloid beta 42 in the brain.
Amyloid beta 42 is “stickier” than the wild type variant, amyloid
beta 40. Consequently, amyloid beta 42 is more likely to conglomerate and form plaques. Sporadic or late onset Alzheimer’s
disease does not show any clear pattern of inheritance. However,
a variant of the apolipoprotien E gene, apolipoprotein epsilon
4, has been linked to increased occurrence and earlier age of
onset of Alzheimer’s disease. Apolipoprotein E is a carrier protein
for cholesterol. The epsilon 4 variant of this protein has been
linked to an increase in the amount of amyloid beta in the brain.
The mechanism behind this relationship is unknown. Researchers
suspect that apolipoprotein E is involved in the clearance of amyloid beta from the brain and that the epsilon 4 variant is not as
effective the epsilon 2 or epsilon 3 variants in clearing amyloid
beta (Peterson, 2002).
Researchers have recently begun to examine the role of diet in
the etiology of this disease (Heude et al 2003, Kalmijn et al 1997,
Engelhart et al 2002, Luchsinger et al 2002, Morris et al 2003
and Laitnen et-al 2006). Diet is a particularly interesting field for
research because dietary interventions are relatively cheap and
easy to initiate. This research hopes to provide the public with
a cost effective method for preventing Alzheimer’s disease, or
at least delaying its onset. Dietary fats in particular have been
the focus of much research. The central nervous system has a
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very high concentration of lipids, second only to adipose tissue.
Additionally, lack of essential fatty acids has been shown to be a
limiting factor in brain development (Winocur and Greenwood,
1993). It follows that intake of fatty acids would have a significant
impact on the health of the brain later in life. The link between
apolipoprotien E and Alzheimer’s disease also suggests a role for
lipid metabolism in the etiology of Alzheimer’s disease.
Dietary fatty acids are ingested as triglycerides, groups of three
fatty acids attached by an ester bond to a glycerol backbone.
In the small intestine, these triglycerides are broken down to
monoglycerides and fatty acids by the enzyme lipase. After being
absorbed by the epithelial cells of the small intestine, they are
recombined to form triglycerides. Because triglycerides are not
water soluble, they cannot be transported through the blood
stream without a carrier. Instead, they are combined with proteins to form lipoproteins. Lipoproteins are spherical particles
with an outer shell of proteins, phospholipids and cholesterol
surrounding an inner core of triglycerides.There are a number of
different types of lipoproteins, each with a different composition
and a different function. The lipoprotein formed in the epithelial
cells of the intestine is called a chylomicron. The chylomicron
passes from the intestinal epithelial cells to the lacteal, and is
delivered to the blood stream via the lymph system (Tortora and
Derrickson 2006).
Studies have shown that rats raised on a diet high in saturated
fat were impaired on behavioral tests (Winocur and Greenwood
1993). Changes in the morphology of the hippocampus consistent with a loss of dendritic integrity and immune response were
also observed (Granholm et al 2008). Additionally, animals that
were fed a diet high in saturated fat were found to have higher
concentrations of the protein amyloid beta (Galloway et al 2007),
the main component of amyloid plaques, and compromised blood
brain barrier integrity (Farrall and Wardlaw 2009, Taketchi et al
2010, Taketchi et al 2013a, Taketchi et al 2013b, and Freeman and
Granholm 2012). In humans, however, the link between saturated
fats and Alzheimer’s is not as clear. A number of studies have been
conducted, and they have yielded conflicting results. This paper
will review and elucidate the relevant research with the goal of
answering the following two questions: Is there a definitive link
between high intake of saturated fat and incidence of Alzheimer’s
disease? If yes, what is the mechanism of this relationship, and
does this suggest any possible interventions other than diet
modification?

Methods
A literature search was conducted using pubmed.gov.The following search terms were used: Alzheimer’s disease AND saturated
fat,Alzheimer’s disease AND dietary fat,Alzheimer’s disease AND
amyloid beta, Alzheimer’s disease AND blood brain barrier, and

Alzheimer’s disease AND statins.To exclude irrelevant papers the
search terms were restricted to the title and abstract. Of the
papers that were found using these search terms, relevant papers
were selected based on their abstract. Additional sources of information were found in the reference sections of these papers.

Discussion
Saturated Fat and Amyloid Beta
In 1992 Hardy and Higgins proposed that the deposition of amyloid plaques is the initiating event in Alzheimer’s disease. This
hypothesis, called the amyloid cascade hypothesis, suggests that
an influx of calcium caused by the toxic effects of amyloid plaques
leads to hyperphosphorylation of the tau proteins which then
form neurofibrillary tangles and kill the neurons. A number of
findings support this theory. Firstly, it has been observed that mutations of the gene encoding the tau protein lead to Parkinson’slike symptoms, but did not lead to the deposition of amyloid
plaques. Secondly, it has been observed that mice expressing mutant variations of both amyloid beta and tau protein experience
increased formation of tau protein tangles when compared to
mice expressing only the mutant version of tau protein, while the
number of amyloid plaques is the same. Both of these observations indicate that the deposition of amyloid plaques leads to the
formation of tau protein tangles, but not the other way around.
The discovery that familial Alzheimer’s disease is caused by a genetic mutation in the amyloid precursor protein also supports
the amyloid cascade hypothesis. It seems likely that both familial and sporadic Alzheimer’s disease share an underlying cause
(Hardy and Selkoe, 2002).
It has been shown that the degree of dementia is correlated with
the amount of amyloid beta present in the brain (Naslund et. al.
2000). However, there is no evidence of increased production
of the amyloid beta protein in the brains’ of Alzheimer’s disease
patients, indicating that the observed increase is caused by decreased clearance of amyloid beta from the brain or increased
uptake of this protein from circulation (Pallebage-Gamarallage et.
al. 2009). Using iodine-125 labeled amyloid beta, researchers have
shown showed that amyloid beta from circulation does indeed
cross the blood brain barrier (Mackic et. al. 2002) This suggests
that factors which increase the levels of circulating amyloid beta
may increase the level of amyloid beta in the brain, and lead to
the formation of plaques.
The protein amyloid beta is involved in the metabolism of lipids.
In vivo, it is associated with chylomicrons and lipoprotein B, and
it increases the uptake of triglyceride rich lipoproteins (TRLs)
by fat rich organs (James et. al. 2003). Consistent with this, it has
been found that a diet high in saturated fat increases the levels
of amyloid beta in enterocytes (Galloway et. al. 2007). The link
between lipid metabolism and the deposition of amyloid plaques
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in the brain is further strengthened by the finding that high serum
cholesterol induced by high cholesterol feeding is correlated with
increased levels of amyloid beta in the brain, as well as increases
in the number and size of amyloid plaques (Refolo, 2000). These
studies investigated the effect of cholesterol only, but not the
effect of saturated fat.
The link between saturated fat and amyloid plaques suggests that
reducing intake of saturated fat would reduce the incidence of
Alzheimer’s disease. However, it must be noted, that a ketogenic
diet, a diet very low in carbohydrate content and very high in fat
content, has been shown to lower the amount of amyloid beta
in a rat’s brain (Van der Auwera et. al. 2005). This indicates that
the increase in amyloid beta observed in rats fed a high saturated
fat diet is not simply because of the high fat content. Rather, it
is the result of a synergistic effect between saturated fats and
carbohydrates.

Saturated Fat and Blood Brain Barrier
Dysfunction
Saturated fat may also have a detrimental effect on the health of
the brain by disrupting the blood brain barrier. The blood brain
barrier was discovered more than 100 years ago by Paul Ehrlich
when he observed that blue dye injected into an animal’s blood
stream will not reach the spinal cord or the brain. The blood
brain barrier is formed by the endothelial cells of the blood
vessels in the central nervous system. In most capillaries there
are gaps between the endothelial cells that allow substances to
diffuse in and out of the blood. In contrast, the endothelial cells in
the central nervous system are tightly packed, and held together
by tight junctions. This prevents many substances that normally
diffuse out of the blood stream from diffusing into the central
nervous system (Carlson, 2011).
A disruption of the blood brain barrier can lead to Alzheimer’s
disease through two distinct pathways. As previously mentioned,
there is evidence that the increase in the amount of amyloid beta
in the brains of Alzheimer’s patients may be due to an influx of
amyloid beta from circulation. We previously explored the possibility that this is because intake of certain lipids increases the
amount of amyloid beta present in the blood. Another possibility
is that the influx of amyloid beta is due to the breakdown of the
blood brain barrier. In addition to affecting the level of amyloid
beta in the brain, a breakdown of the blood brain barrier would
allow toxins to enter the brain, possibly leading to Alzheimer’s
disease through a completely different pathway.
There are a number of methods by which blood brain barrier
integrity can be assessed. The levels of plasma derived proteins
in the brain can be measured, with a greater amount indicating influx through the blood brain barrier. Similarly, the levels of
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cerebrospinal fluid derived proteins in the plasma can also be
measured to determine efflux through the blood brain barrier.
Immunoflourescent antibodies can be used to detect the presence of tight junction proteins and other proteins integral to the
maintenance of the blood brain barrier. Imaging techniques such
as contrast CT, contrast MRI, and positron emission topography
(PET) have also been used.
Whether blood brain barrier dysfunction is linked to Alzheimer’s
disease has been debated for many years. A number of experiments have been performed using both biochemical and imaging
techniques. A meta-analysis of sixteen studies found that there
was a statistically significant link. There was, however, great heterogeneity among the results of individual studies (Farrall and
Wardlaw, 2009).
To examine the effects of saturated fat on the blood brain barrier,
researchers examined the brains of mice fed a diet high in saturated fat, high in unsaturated fat and a control group fed standard
laboratory chow. Immunoglobin G (IgG), and apolipoprotien B
(a hepatically derived lipoprotein) were used to measure influx.
The cerebrospinal fluid protein, S100B was used to detect efflux.
After three months, the mice were euthanized, and the relative
abundance of occludin, a tight junction protein, was also assessed.
It was observed that levels of immunoglobin G and apolipoprotien B were greatly elevated in the brains of mice in the saturated
fat group, indicating increased influx of proteins and lipoproteins.
The increased presence of apolipoprotein B, a lipoprotein that is
associated with amyloid beta in enterocytes, supports the theory that blood brain barrier dysfunction can cause Alzheimer’s
disease by increasing the influx of amyloid beta. Plasma levels of
S100B were also greatly elevated indicating efflux from the cerebrospinal fluid into the brain. Finally, levels of occludin were found
to be lower in the saturated fat group, indicating a breakdown of
the tight junctions that form the blood brain barrier. The effects
of the high saturated fat diet were exacerbated when the mice
were examined after six months of feeding (Taketchi et. al. 2010
and Taketchi et. al. 2013a).
Another experiment examined the effect of a high saturate fat/
high cholesterol diet on three blood brain barrier proteins. The
proteins investigated were endothelial barrier protein and the
tight junction proteins occludin, and ZO-1. Using immunoflourescent antibodies the high saturated fat/high cholesterol fed rats
were found to have markedly less endothelial barrier protein
in the cortex and the CA-1 region of the hippocampus. When
analyzed by western blot, a hippocampal homogenate of the experimental rats was found to have more occludin and the same
amount of ZO-1 as that of the control rats. However, immunoflourescent imaging showed that the localization of occludin
was markedly different in the two groups. In the control group
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occludin was found to be present mostly in the walls of blood
vessels, as would be expected for a blood brain barrier protein.
In contrast, the blood vessels of the experimental group stained
very weakly for occludin, while there was a strong signal in axon
fibers and granule cells of the dentate gyrus. It may be that the
increased level of occludin detected in the brain of the experimental group was because expression of occludin had been upregulated in response to blood brain barrier damage (Freeman
and Granholm, 2012).

Saturated Fat and Cognitive Decline in Animals
The evidence linking saturated fat to increased production of
amyloid beta and blood brain barrier dysfunction suggests a link
between saturated fat and Alzheimer’s disease. Indeed, a link
between saturated fat and cognition has been observed in rats.
Researchers found that rats fed a diet high in saturated fat performed worse on memory tests than rats fed a diet that had
unsaturated fat as its main fat component (Winocur and Gordon
1993). Again, it must be noted that rats fed a ketogenic diet did
not experience any cognitive decline, despite the extremely high
saturated fat content in their diets. This is consistent with the
finding that a ketogenic diet reduces the levels of amyloid beta in
the brain (Van der Auwera et al 2005).
In addition to memory impairment, researchers found that a
diet high in cholesterol and saturated fat significantly altered the
morphology of the hippocampus, one of the areas of the brain
responsible for memory and learning. After being fed a diet high
in saturated fat and cholesterol, sections of the hippocampus
were tested for Map2, an integral membrane protein that is considered a marker for dendrites, and Iba1 a marker for microglia.
Compared to the control group, rats fed a diet high in saturated
fat had significantly less Map2 and considerably more Iba1, indicating a loss of dendritic integrity and activation of microglia,
both hallmarks of Alzheimer’s disease (Granholm et al 2008).

Saturated Fat and Alzheimer’s Disease
A link between saturated fat and Alzheimer’s disease cannot be
definitively asserted unless there is evidence of such a link in
humans. A number of epidemiologic studies have been conducted to determine the link between dietary fats and Alzheimer’s
disease (Heude et. al. 2003, Kalmijn et. al. 1997, Engelhart et. al.
2002, Luchsinger et. al. 2002, Morris et. al. 2003, and Laitnen et.
al. 2006). Although the information gleaned from these studies is
enlightening, the results must be approached with caution. All of
these studies rely on self reporting. Because participants do not
know how much fat they have ingested, researchers use food
frequency questionnaires that ask participants about their dietary
habits.This information is used to estimate their intake of various
micronutrients. This method is an estimate at best. As with all
studies relying on self reporting there is an inherent inaccuracy.

Additionally, responses on a questionnaire reflect only the respondent’s current diet, but offer no information about their dietary habits in the past. Discrepancies among these studies can
arise from differences in the questionnaires used, length of follow
up time, the age of the population being studied, and the ethnicity
of the population.
In the Rotterdam study, 7,983 residents of a suburb of Rotterdam
over the age of 55 were administered questionnaires that were
followed up by clinical examinations. After a two year follow
up, researchers found a statistically significant link between increased intake of saturated fat and incidence of Alzheimer’s disease (Kalmijn et. al. 1997). Interestingly, the link was significant
even after eliminating patients with cerebrovascular disease, indicating that the mechanism mediating this link is not vascular in
nature. However, a six year follow up of the same group showed
no significant link between saturated fat intake and Alzheimer’s
disease (Engelhart et. al. 2002). An examination of the methods
used in the two studies does not reveal an obvious reason for
this discrepancy. Both studies used the same method of assessing
dietary intake of fats, and both adjusted their results for similar
confounding variables. The authors of the second study do not
address the discrepancy directly, but they do suggest that the
longer follow up may introduce selective survival. For instance,
it may be that subjects who live longer are less susceptible to
the detrimental effects of a high fat diet leading to a longer life
span, and a lower incidence of dementia as well (Engelhart et. al.
2002). It may also be that saturated fat lowers the age of onset
of Alzheimer’s disease, but does not increase overall incidence.
Using data from the Washington Heights-Inwood Columbia Aging
Project (WHICAP), researchers found a link between total intake
of fat and increased incidence of Alzheimer’s disease. Saturated
fat alone was linked to increased incidence of Alzheimer’s disease;
however, the hazard ratio was slightly lower than that of total fat
intake and was less than that of monounsaturated fats, indicating
that saturated fat is not more harmful than other fats. Although
increased intake of saturated fat overall was linked to increased
incidence of Alzheimer’s disease, no difference was found between those reporting moderately high intake and those reporting very high intake. When the data was analyzed using only
people who had tested positive for the apolipoprotien E epsilon
4 allele (both homozygous and heterozygous) the link between
total fat intake and Alzheimer’s disease was much stronger and
successively greater intake of saturated fat indicated successively
greater risk of Alzheimer’s disease (Luchsinger et al 2002).
Another study using data from the Chicago Aging Project and a
median follow up of 3.9 years found a strong link between saturated fat and Alzheimer’s disease. Participants in the top fifth of
saturated fat intake were 70% more likely to develop Alzheimer’s

43

Justin Konig

disease.This is in contrast to other fats, some of which seemed to
lower the risk of Alzheimer’s disease. Adjusting for confounding
variables led to 120% increase in risk. In contrast to the findings
of Luchsinger et al (2002), this study found that the link between
saturated fat and Alzheimer’s disease was not any stronger in participants possessing the apolipoprotein E epsilon 4 allele (Morris
et al 2003).
The previous studies focused on elderly people and had a follow
up between two and seven years. A short follow up can potentially underestimate the link because of the possibility of subclinical dementia (i.e. the patients who were discovered to have
dementia might have had subclinical dementia at baseline, and
the poor diet is a symptom rather than a cause of the disease).
In contrast, Laitnen et al (2006) studied the link between fat intake at midlife and the incidence of Alzheimer’s disease later in
life. In this study participants of the CAIDE study who had been
examined in either 1972, 77, 82, or 87 were called for reexamination in 1998. The mean follow up was 21 years. This study found
that participants with moderate fat intake (second quartile) had
a lower risk of Alzheimer’s disease than either low fat or high
fat intake. When broken down to specific fats, high polyunsaturated fats and monounsaturated fats were correlated with a
decreased risk of Alzheimer’s disease, while high intake of saturated fats was correlated with a higher incidence of Alzheimer’s
disease. Only the data for polyunsaturated fats and saturated
fats yielded results that were statically significant. When adjusted
for the Apolipoprotien E epsilon 4 allele, the results were similar; suggesting that effect of saturated fat is not related to the
Apolipoprotein E epsilon 4 allele. It is noteworthy that this study
calculated relative intake of fatty acids based only on intake of
different types of dairy, excluding two major sources of dietary
fatty acids, meat and fish.
As previously mentioned, studies that rely on self reporting food
frequency questionnaires are inherently inaccurate. To address
this problem, researchers studied the link between erythrocyte
membrane content and cognitive decline. This study found a significant link between saturated fatty acid content in erythrocytes
and cognitive decline. Interestingly, the results for polyunsaturated fatty acids were mixed; n-6 polunsaturated fatty acids were
linked to cognitive decline while n-3 polyunsaturated fatty acids
seemed to protect against decline. This study investigated only
the link between fatty acids and general cognitive decline. A link
between membrane composition and Alzheimer’s disease specifically was not investigated (Heude et al 2003).

Lipid-Lowering Pharmaceuticals
The link between saturated fatty acids and Alzheimer’s disease suggests that drugs that lower plasma lipids may prevent Alzheimer’s
disease, or slow its progression. Probucol is a lipid-lowering agent
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with anti-inflammatory and antioxidant properties that has been
used to treat cardiovascular disease (Santos, 2012). Experiments
with mice have shown that Probucol ameliorates the detrimental
effects of a diet high in saturated fat. It was previously mentioned
that mice fed a diet high in saturated fat and cholesterol were
found to have a greater abundance of the protein amyloid beta in
enterocytes. When Probucol was added to their diet, the levels
of enterocytic amyloid beta in the saturated fat group were comparable to those in the control group (Pallebage-Gamaramllage
et al 2012).
It was also found that Probucol prevented the damage to the
blood brain barrier normally associated with a high saturated
fat diet. Mice were randomly assigned either to a control diet, a
diet high in saturated fat, a diet high in cholesterol, or a high saturated fat/high cholesterol diet with Probucol for three months.
Consistent with previous experiments the mice in the high saturated fat and high cholesterol diets were found to have damage
to the blood brain barrier as measured by the concentrations of
immunoglobin G and apolipoprotien B in the brain, and the concentration of S100B in the blood plasma. High saturated fat and
high cholesterol mice were also found to have a greater abundance of activated microglia, a sign of inflammation. However in
mice treated with Probucol the levels of immunoglobin G, apolipoprotein B and S100B were comparable to that of the control
group. There was also no evidence of inflammation in mice treated with Probucol (Taketchi et al 2013a).
When the experiment was repeated and mice were kept on the
high saturated fat diets for 12 months the effect of the high saturated fat diet on blood brain barrier permeability and enterocytic
abundance of amyloid beta was even more pronounced. Yet, despite the long term exposure to saturated fat, the group treated
with Probucol was not effected (Taketchi et al 2014). In addition
to preventing damage to the blood brain barrier and lowering enteroctyic accumulation of amyloid beta, Probucol was also found
to increase synaptic density in mice (Poirier, 2008).
A pilot study examined the effect of Probucol on 12 patients with
mild-to-moderate Alzheimer’s disease. A clinical assessment after
six months of treatment found that Probucol led to a stabilization
of symptoms (Poirier, 2008). This was a small scale study that
did not include a control group. A long term controlled study is
needed to definitively determine whether Probucol is an effective
treatment for Alzheimer’s disease and whether its effect is long
lasting.
It is possible that the positive effects of Probucol are not related
to lipid metabolism. Probucol was found to attenuate the effects
of an injection of amyloid beta in mice. Mice injected with amyloid
beta exhibited cognitive decline, and a histological examination of
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their brains shows decreased synaptic density (as measured by
the presence of the presynaptic protein synaptophysin) and increased acetylcholinesterase activity. Injection with amyloid beta
does not increase plasma cholesterol. Treatment with Probucol
for 15 days attenuated the effects of the amyloid beta injection.
This is despite the fact that the pathological conditions observed
in these mice were not due to increased lipid intake or dysfunctional lipid metabolism. This suggests that Probucol may directly
affect the pathway responsible for Alzheimer’s disease pathology in addition to its positive effect on lipid metabolism (Poirier,
2008).
Statins (HMGCoA reductase inhibitors) are another group of
lipid lowering agents prescribed to treat cardiovascular disease.
Similar to Probucol, statins also have anti inflammatory properties. In an experiment similar to that performed with Probucol
it was shown that treatment with statins will reverse the blood
brain barrier damage caused by a high saturated fat diet. Mice
were fed either a low fat diet or a diet high in saturated fat.
Consistent with previous experiments the mice fed a diet high
in saturated fat were found to have significantly higher levels if
immunoglobin G and apoliprotien B in the brain parenchyma,
an indication of blood brain barrier damage. Treatment for two
weeks with Atorvastatin, a lipid soluble statin, led to a decrease
in the amount of immunoglobin G present in the brain.Treatment
with pravastatin, a water soluble statin did not lead to any reduction after two weeks. After eight weeks of treatment it was
found that both atorvastatin and pravastatin completely negated
the effects of the high saturated fat diet (Pallebage-Gamarallage
et al 2012). Unlike other studies, this study tested the effect of
the experimental compound after the mice had been on the saturated fat diet for an extended period of time. The effectiveness
of the compounds after the effects of the saturated fat diet had
presumably set in suggests that statins may be effective at reversing damage to the blood brain barrier as opposed to simply
preventing it.
An analysis of data obtained from the General Practice Research
Database in the UK revealed that individuals who had been prescribed statins had a significantly reduced incidence of Alzheimer’s
disease. This was true even for individuals who had taken statins
in the past, but were no longer taking these drugs. Interestingly,
use of other lipid lowering agents was not correlated with a
lower risk of Alzheimer’s disease (Jick et al 2000). Another study
used data from the databases of three different U.S. hospitals.This
study also found a statistically significant relationship between
use of lovastatin (Mevacor) or pravastatin sodium (Pravachol),
and a lower incidence of Alzheimer’s disease. Simvastatin (Zocor),
a different statin, was not correlated with decreased incidence of
Alzheimer’s disease in this study (Wolozin et al 2000).

Ibuprofen, a non-steroid anti inflammatory drug (NSAID) that
does not have any lipid lowering properties was also tested
alongside simvastatin and pravastatin in the previously described
experiment. After two weeks of treatment Ibuprofen was found
to be as effective as simvastatin, and eight weeks of treatment
completely reversed the effects of the high saturated fat diet
(Pallebage-Gamarallage et al 2012). Antioxidants are another
group of compounds that have been found to ameliorate the
effect of saturated fat. Inflammation is caused by reactive oxygen species (ROS). Anti oxidants combat the effects of reactive
oxygen species and prevent inflammation. Four compounds were
tested: aged garlic extract, alpha-lipoic acid, niacin, and nicotinamide. Mice were fed either a low fat diet a high saturated fat
diet or a high saturated fat diet containing one of the four compounds. All four compounds were found to prevent the blood
brain barrier dysfunction and inflammation caused by a high saturated fat diet (Takechi et al 2013b).These studies suggest that the
protective property of statins and Probucol that was observed
in humans and mice may be related to their anti inflammatory
properties and not their lipid lowering properties.

Conclusion
Saturated fat is clearly linked to an increase in amyloid beta and
to blood brain barrier dysfunction in animals. Although not definitive, epidemiologic evidence seems to indicate that increased
intake of saturated fat is a risk factor for Alzheimer’s disease.
Based on the evidence presented, it is reasonable to suggest limiting intake of saturated fat as part of an effort decrease the risk
of Alzheimer’s disease. In particular those with the apolipoprotein E epsilon 4 allele should limit their intake of saturated fat.
However, it must be noted that saturated fat is only one among
many micronutrients that make up our diet. Saturated fat alone is
not responsible for inflammation, blood brain barrier dysfunction,
or deposition of amyloid plaques. In fact, we have cited evidence
that a ketogenic diet, which is high in saturated fat, reduces the
amount of amyloid beta in the brain. When designing a diet low
in saturated fat one needs to ensure that saturated fat is not
replaced with an equally unhealthy substitute. Furthermore, there
is no evidence that limiting saturated fat intake after the onset
of Alzheimer’s disease will reverse or even slow the disease’s
progression. At best, limiting intake of saturated fat throughout
the course of one’s life will lower the incidence of Alzheimer’s
disease and delay its onset, but it will not cure it.
The use of Probucol, statins, and other anti-inflammatory medications in the treatment of Alzheimer’s disease is strongly supported by the evidence cited. Anti inflammatory medication
has been shown to reverse damage to the blood bran barrier
caused by saturated fat. Probucol has been shown to lower enterocytic accumulation of amyloid beta and to slow the progression of Alzheimer’s disease. Use of statins has also been linked
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to a decreased risk for Alzheimer’s disease. Further research is
needed to determine which of these drugs is most effective, and
whether these drugs can be effective in the long term.

Laitenen, M.H. et al (2006) Fat intake ad risk of dementia and
Alzheimer’s disease: A population based study. Dementia and Geriatric
Cognitive Disorders 22:99-107
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Abstract
Obesity is a mounting problem in America today. One major concern about obesity is that it is a risk factor for type 2
diabetes, a disease that impairs insulin sensitivity and secretion. This interferes with blood glucose levels and can cause
hyperglycemia, which is when there is too much circulating glucose in the blood. Ghrelin, an amino acid peptide responsible for appetite stimulation and energy balance, plays a direct role in insulin secretion and glucose metabolism. In many
experiments, elevated ghrelin levels are associated with decreased insulin secretion from pancreatic islet cells. Although
ghrelin concentration is decreased in obese individuals and diabetics, researchers attempt to use the ghrelin system as a
treatment option for these people. It seeks to accomplish this by regulating the ghrelin produced by the body, diminishing
its activity, affecting its receptor, the growth hormone secretagogue receptor (GHS-R1a), and by targeting ghrelin directly.
Studies observed these methods’ effects on insulin secretion and sensitivity as well as blood glucose concentration. The
octanoylation of ghrelin, which activates it, is catalyzed by ghrelin Oacyltransferace (GOAT). Therefore GOAT inhibitors
are one way of minimizing ghrelin’s effects on metabolism. Additionally, cAMP concentrations decrease in islet cells of the
pancreas in the presence of ghrelin. Using cAMP analogs can counter ghrelin’s consequences as well. On the other hand,
targeting the GHS-R1a receptor with an antagonist can also help enhance insulin secretion. Another research option
entails using immunoneutralization to build antibodies against endogenous ghrelin. Lastly, studies have examined ghrelin
knockout models in mice, by deleting the ghrelin gene, to examine the results that the lack of ghrelin has on insulin-glucose
metabolism. Each of these methods has been proven to affect insulin and glucose metabolism. Further advances in the
clinical application of these methods may lead to viable treatment options for obesity and diabetes.
Introduction
A big problem facing the world today is the rise of obesity.
According to the CDC, approximately one third of the American
adult population is obese. Obesity is characterized by a Body
Mass Index (BMI), of 30 or higher, while healthy weight BMI is in
the range of 18.5-24.9 (CDC, 2012). One possible con-sequence
of obesity is the development of type 2 diabetes. Diabetes is a
disease characterized by elevated glucose levels as a result of
insufficient insulin production or a malfunctioning insulin system.
Of the Americans population 29.1 million or 9.3%, had diabetes
in 2012. This number was an increase from 2010 when the statistics were 25.8 million and 8.3% (American Diabetes Association,
2014). In type 1 diabetes mellitus, the β cells of the pancreas that
are responsible for producing insulin are destroyed. In the absence of insulin, these individuals are at risk for hyperglycemia, or
dangerously elevated blood glucose levels.Type 2 diabetes usually
has a later onset. People with type 2 diabetes experience insulin
resistance so that the insulin does not help glucose enter the
body cells. Eventually the body stops producing insulin altogether
(CDC, 2014). Most cases of diabetes, 90-95% are type 2 diabetes.
Statistics show that 90% of cases of type 2 diabetes in western
countries can be attributed to excess weight gain or obesity.
Improving glucose tolerance while losing weight is the aim of
new treatments for diabetes. Examining the effects the hormone
ghrelin has on glucose metabolism can be a valuable therapeutic
option (Rudolph, et al. 2007). Ghrelin is a 28 amino acid peptide
hormone that plays a role in many different body functions. It is
the endogenous ligand for the growth hormone secretagogue
receptor (GHS-R) and has been proven to increase growth hormone secretion.Additionally, ghrelin is known as an orexigenic, or
appetite-stimulating hormone, and is also responsible for energy
bal-ance. It is produced predominantly in the stomach but is also

produced in other places including the pancreas. One important
function ghrelin serves is the ability to control insulin release
from β cells of the pancreas. In the presence of ghrelin, insulin
secretion is reduced, and blood glucose concentration increases.
Research shows the effect of ghrelin on pancreatic islet β-cells.
Ghrelin suppresses insulin secretion from β-cells by interfering
with the K and Ca2+ channels that are stimulated by glucose
metabolism. Obese individuals and diabetics have lower levels of
plasma ghrelin than lean individuals. It is reasonable to suggest
that this may be a regulated response in order to minimize the
ghrelin activity that reinforces obesity. Subsequent research implicated possible regulation of ghrelin to treat obesity and diabetes. Since insulin levels are decreased in the presence of ghrelin,
investigation of techniques to reduce or diminish the effects of
ghrelin is in effect. Various treatment options that have undergone research and experimentation show posi-tive outcomes
in regard to treating diabetes and obesity. Many techniques that
influence ghrelin’s role in decreased insulin secretion are still in
the experimental phase but may eventually be effective to treat
diabetes and obesity. Ghrelin’s effects on insulin sensitivity are
also being explored. Can regulation of ghrelin serve as a possible
treatment option for diabetes and obesity?

Methods
The research obtained about ghrelin’s effects on the metabolism
of diabetics and obese individuals was collected from a variety
of sources. The majority of articles were collected using Touro’s
library to access databases such as Pubmed, ProQuest and more.
Additionally, other articles were found by searching Google
scholar for relevant journals on the topic. After reviewing numerous articles on ghrelin’s effects on obesity and diabetes, evidence
was compiled to answer the research question.
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Discussion
Ghrelin and its forms:
Ghrelin is a 28-peptide amino acid that is produced mainly in the
stomach. This hormone is responsible for signaling hunger and
maintaining an energy balance. Acylated ghrelin, or acyl ghrelin,
the active form of ghrelin consists of noctanoylation on the
third serine. This form of ghrelin is able to bind to the GHS-R1a,
enabling it to have a biological effect in areas such as growth
hormone secre-tion and glucose metabolism. However, most of
our plasma circulating ghrelin is unacylated ghrelin, or des acyl
ghrelin, which has been discovered to have biological effects as
well (Kiewiet, et al. 2009).
Figure 1

The effects of each form of ghrelin on insulin concentration and
sensitivity has been studied. Acylated ghrelin (AG), the active
form of ghrelin has been found to be responsible for decreased
insulin levels, while unacylated ghrelin’s (UAG) affects are being
studied. It has been noted that ghrelin levels have a preprandial
increase and a postprandial decrease indicating its role as an appetite stimulant (Kiewiet, et al. 2009). The hormone insulin acts
in the opposite way, so investigators seek to explain the relationship between the two. Some studies examined the effects of
AG and UAG on the insulin metabolism. Findings were that AG
stimulated glucose release by hepatocytes, while UAG inhibited
these effects. In addition, in an experiment done with adult-onset
growth hormone-deficient patients, AG was found to decrease
insulin sensitivity, and coinjection of UAG countered the effect.
Thus, the circulating plasma ghrelin’s two forms act in contrasting
ways (Ukkola, 2009). An experiment was conducted in order to
isolate the actions of AG and UAG. Subjects were administered
a combination of AG and UAG and then each form of ghrelin on
its own. The subject group consisted of 8 morbidly obese female
Caucasians. The mean age was 45.4± 10.3 in the range of 28-62
years old. The average BMI of the subjects was 42.4± 4.8 kg/m2 .

This experiment was a repeated measures design in which each
of the 8 subjects received all the experimental conditions with
a two-week break in between. Ghrelin was administered after
overnight fasting conditions after a saline infusion. The three experiments were: administration of 200 µg of UAG on its own,
administration of 100 µg of AG together with 100 µg UAG, and
a placebo. Subjects were then given a 595 kcal breakfast, a similar
lunch three hours later, and then they were free to eat what they
pleased until midnight. Blood samples were collected to measure
the total ghrelin, glucose, and insulin concentrations. After the
first hour of administration, while subjects were fasting, administration of UAG on its own did not change insulin levels or glucose concentrations, nor did it differ from the placebo. Receiving
the combination of UAG and AG resulted in significantly decreased insulin levels as compared to UAG administration alone
and the placebo (58.2 ± 6.3% insulin concentration when AG and
UAG were administered combined, compared to 91.8 ± 3.0%,
the insulin concentration when UAG was administered alone).
This experiment tested for insulin sensitivity using the glucose
to insulin ratio. The results indicated an almost 50% decrease in
insulin levels and almost no change in glucose concentration.This
demonstrated the effect of UAG to improve insulin sensitivity
when administered along with the AG that lowered the insulin
levels. Also, subjects with a smaller AG:UAG ratio possessed
increased insulin sensitivity indicating the combination effect of
coinjection of AG and UAG.This may lead to a possible treatment
for diabetes for many diabetics have problems with insulin sensitivity. However, further research is needed to exactly determine
insulin sensitivity, for the glucose-insulin ratio does not consider
secretion, distribution and degradation of insulin (Kiewiet, et al.
2009).
However, a recent study tested the effect of AG in combination
with UAG on insulin and glucose metabolism. Healthy volunteers
were given pharmacological doses of AG and UAG as a bolus
and at 210-minute intervals under fasting conditions and intravenous glucose administration. However, The UAG did nothing
to plasma insulin levels after AG decreased them. This study did
not examine but encourages further study on insulin sensitivity
following AG and UAG administration (Barazzoni, 2014). Previous
research tested the effects of ghrelin on inulin sensitivity by using
the insulin-glucose ratio. Although the insulin levels stayed the
same, the glucose levels decreased indicating greater insulin sensitivity (Kiewiet, et al. 2009). Although this may not give the most
reliable results because it does not consider other factors that
can contribute to insulin sensitivity, it is a start in observing the
effect that UAG has on insulin sensitivity. Nevertheless, further
research is needed to confirm this relationship.

Insulin Sensitivity
Although it may be hypothesized that obese individuals have
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elevated ghrelin levels contributing to their obesity, on the contrary, obese individuals have lower ghrelin concentrations than
normal. According to a study obese patients’ plasma active
ghrelin levels compared to lean subjects were 180 ± 18 vs. 411
± 57 pg/ml. Serum total ghrelin levels differed from 3650 ±408
in obese patients and 5263 ±643 pg/ml in lean subjects. Ghrelin
levels were correlated with insulin resistance that was calculated
using the HOMA approach which is: insulin (micro-units/milliliter)
× blood glucose (milllimoles/liter)/ 22.5 (Marzullo, et al. 2003).
Similarly, in a different study, lower ghrelin levels were found in
obese subjects. This study, shows the correlation between body
fat and circulating ghrelin levels after obese and lean subjects
were fed a weight maintaining diet and abstained from exercise
two days. The results indicated that the obese subjects’ ghrelin
levels were 32% lower than the lean subjects’. Additionally, a
negative correlation was found between ghrelin concentration
and body fat (r = -.45). Insulin was also negatively correlated to
ghrelin concentration (r = -.45) (Tscöp, et al. 2001). Since ghrelin
is responsible for energy balance and homeostasis, this study is
consistent with present knowledge. Obese individuals have stable
energy levels so the body lowers the ghrelin response. However,
although the circulating ghrelin levels are minimized, its effects on
insulin and body fat are still present.
Studying children with type 1 diabetes mellitus (T1DM) indicated
lower levels of total ghrelin in comparison to healthy subjects.
Also, higher levels of AG contributed to lower insulin levels and
greater insulin resistance. Therefore, a possible way the body
protects diabetics from hyperglycemia can be the decreased concentration of circulating ghrelin. Insulin therapy after four months
elevated ghrelin levels in twenty children with T1DM (Ukkola,
2009). This can indicate the body considering lower ghrelin levels
unnecessary due to the insulin therapy.
Although we can understand how insulin resistance is a problem
in diabetic patients, obesity can contribute to insulin resistance as
well. One way in which obesity contributes to insulin resistance
is through the immune system’s activation by obesity. Adipose
tissue macrophages produce pro-inflammatory cytokines that
can lead to insulin resistance by blocking insulin action in adipose
tissue, skeletal muscle, and liver. Therefore, ghrelin as a possible
therapeutic option can improve both diabetics and obese individuals’ health (Ota, 2014).

Ghrelin’s Metabolic Effects
An experiment examined ghrelin levels in lean, obese, diabetic
and nondiabetic subjects. Blood samples were collected after
overnight fasting and again after monitored eating. Compared
to normal weight subjects, mean plasma ghrelin concentrations
were 225% for those with anorexia nervosa and 68% for obese

50

subjects. A negative correlation exists between BMI and plasma
ghrelin concentration. The body maintains homeostasis by decreasing ghrelin levels in the presence of positive energy balance.
When the body has excess energy from nutrition, the ghrelin levels are decreased to postpone hunger.This justifies the postprandial, or after eating a meal, decrease of ghrelin levels (Shiiya, et al.
2002). Ghrelin’s effects on feeding and energy balance refer to
the ghrelin produced in the stomach; however, the pancreas also
produces ghrelin contributing to glucose metabolism. Ghrelin
is an insulinostatic hormone, meaning it controls the release of
insulin. Ghrelin levels were compared from the pancreatic vein
that leaves the pancreas and the pancreatic artery that brings
new blood to the pancreas. Results showed 8 times the amount
of ghrelin levels in the pancreatic vein, indicating the pancreas
produces that ghrelin (Yada, et al. 2014).The GHS-R1a, the ghrelin
receptor, is located on pancreatic islet cells. Ghrelin binds to the
receptor and decreases insulin release from the cell and elevates
blood glucose concentrations. When glucose concentrations rise
from 2.8 mM to 8.3 mM, insulin release from β cells is stimulated.
The intensification of Ca2+ concentrations, stimulated by glucose
metabolism is a crucial step in insulin secretion. However, insulin
release is weakened when ghrelin is exogenously administered at
a high concentration of 10 nM. Ghrelin suppresses the peaks of
Ca2+ by increasing amplitudes of Kv currents that block the influx of Ca2+ ions into the cell thereby slowing down the process
of glucose-induced insulin release (Yada, et al. 2008).
Figure 2

The binding of ghrelin to GHS-R reduces cAMP expression and increases the K+ current.This slows down the influx of Ca2+ into the
cell, leading to a decreased insulin secretion response to glucose
metabolism. (Yada, et al. 2014)
Research has proven that ghrelin’s effect on the Kv channels result from decreased cAMP levels. cAMP, cyclic AMP (adenosine
monophosphate) signaling plays one of the most vital roles in insulin secretion from beta cells (Kashima,et al. 2001). Ghrelin uses
G-protein Gαi2 to obstruct the cAMP response to glucose metabolism. cAMP activates PKA, protein- kinase-A, and suppresses
Kv currents in islet cells. Since the insulinostatic effect of ghrelin
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occurs through the cAMP pathway, one possible way to minimize
it is by presenting cAMP analogues along with ghrelin. One molecule used in testing the effects of cAMP analogs on insulin secretion is 6-Phe-cAMP. In the presence of cAMP analogs, ghrelin has
no effect on insulin secretion. Hence, by reinstating the cAMP
activation pathway in the presence of ghrelin, diabetics can experience enhanced insulin secretion (Dezaki, et al. 2011). This study
demonstrates a new remedial approach to reducing ghrelin’s effects. cAMP analogs may aid diabetes by enhancing insulin secretion in pancreas islet.

Ghrelin Antagonism
Since type 2 diabetics do not have enough insulin, anti-ghrelin
treatments can enhance insulin secretion. In obesity, insulin resistance is a problem, so eliminating ghrelin can produce a positive
effect on hyperglycemia. Ghrelin’s affects on insulin and glucose
metabolism, food intake, and body weight all need to be assessed
in order to determine if antagonism of ghrelin can relieve symptoms of diabetics and obese individuals. One popular method
used to remove ghrelin’s affects is by antagonism of the GHS-R.
If the receptor does not accept ghrelin, it has no effect on the
pancreatic islets. In an experiment using fasted mice, ghrelin receptor antagonists [D-Lys3]-GHRP-6 enhanced insulin secretion
and lowered blood glucose levels. This research indicated that a
ghrelin blockade increases insulin release to help maintain normal
glucose concentrations (Yada, et al. 2008). Experiments done with
gastrectomized mice, that lack stomach-derived ghrelin, show the
role of pancreatic ghrelin in the insulin response. After GHS-R
antagonist was administered, both groups of mice showed the
same increased insulin response. This proves that the pancreatic
ghrelin is responsible for these effects. Therefore, targeting the
GHS-R can be a therapeutic approach in enhancing insulin secretion (Dezaki, et al. 2006). Administering intra-peritoneal ghrelin
antagonist to mice also decreased food consumption (Asakawa,
et al. 2003). These findings can be beneficial in aiding obese individuals control their food intake.
Additionally, an experiment done on mice implied ghrelin’s effects
on body weight, insulin levels, and blood glucose concentrations.
Injection of ghrelin twice a day for five days increased body
weight in mice compared to the control. Depending on the diet
and whether the mouse received ghrelin or saline, determined
the increase in body weight. For example, one group of mice
were fed a high fat diet and given saline. These mice exhibited a
.60 g/day increase in body weight, while those fed a high fat diet
with ghrelin had a .92 g/day increase. Serum cholesterol and insulin levels increased and glucose concentration increased as well.
The same experiment tested how ghrelin antagonist, [D-Lys3]GHRP-6, affected the same factors. After 7 days of administration to obese mice, weight gain, fat pad mass, and blood glucose
concentrations decreased (Asakawa, et al. 2003). This study does

not seem to be consistent with other research that has linked
elevated ghrelin to decreased plasma insulin secretion; but a
moderate increase in glucose concentration was observed. This
can indicate a case of insulin resistance instigated by an increase
in free fatty acids (FFA) that are known to contribute to insulin
resistance. GHS-R antagonists increased insulin sensitivity and
reduced glucose levels. In addition, it simultaneously decreased
FFA concentration aiding in fostering insulin sensitivity (Asakawa,
et al. 2003).
One class of drugs that is being studied as possible ghrelin receptor antagonists are quinazolinone derivatives. In the lab, quinazolinone derivative 1 was discovered to have affinity to GHS-R1a.Yet,
it was found that the molecule had agonistic binding to the receptor rather than the desired antagonistic affect. Alkylation of the N
group on the molecule altered its functionality by transforming
it into a GHS-Rla antagonist. Piperdine-substituted quinazolinone
derivatives that are phenyl or phenoxy substituted were found to
act as GHS-R antagonists (Del-porte, 2011).
Figure 3

Alkylated
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In a structure-activity relationship study, many derivatives of the
compound were tested for their effects in vivo. Two quinazolinone compounds that were used for study were compounds
26 and 43. These antagonists were administered at doses 3, 10,
and 30 mg/kg. While compound 26 lowered body weight at the
10 mg/kg dose, compound 43 only was effective at 30 mg/kg.
Compound 26 at 30 mg/kg is known as the first orally administered GHS-R antagonist possible to induce weight loss in animals.
This renders it a feasible way to treat obesity, a leading cause of
diabetes. Compound 26 administered at the highest dose had
similar effects to an anti-obesity drug that is still under evaluation
by the FDA, CB1 antagonist rimonabant, 5-(4-choophenyl-1-(2,4dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide. This study also tested glucose tolerance. Both compounds decreased glucose excursion by around 20%. However,
the cause be-hind these decreased blood glucose levels, was
not tested for. The study would like to go further in confirming
that this result from the GHS-R antagonist stemmed from an
enhanced insulin secretion (Rudolph, et al. 2007). This research
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brings practical application of a drug that may be available to help
treat obesity and diabetes. As a receptor antagonist, it minimizes
ghrelin’s insulinostatic effects and enhances glucose metabolism.

Immunoneutralization
Immunoneutralization of ghrelin also is a potential method of
enhancing insulin secretion. Creating a vaccine to stimulate antibody production against acylated ghrelin may be a viable treatment for obese individuals. However, when a trial was conducted
using a CYT-009 Ghr Qb vaccine, antibodies were developed, but
weight stayed the same (Delporte, 2011). In another instance,
mice were immunized against ghrelin to produce an antibody
response. After being fed identical diets, the rats with more
ghrelin-specific antibodies gained less weight per calorie ingested.
Since their food intake did not vary from other control mice,
this experiment shows that ghrelin produces a metabolic change
rather than feeding changes. However, ghrelin has been known
to increase feeding in a high-fat diet, these mice were given lowfat, less appetizing meals. This could be a factor that might have
influenced the ghrelin-vaccinated mice’s feeding habits, so the reliability of their conclusion is questionable. Additionally, there can
be possible draw-backs to this course of treatment. Long-term
or other side effects of eliminating ghrelin are unclear. It may
have possible ramifications on energy balance that is regulated by
ghrelin.The absoluteness of inactivating ghrelin by use of antibodies is also irreversible, unlike ghrelin receptor antagonism that
can be stopped when undesired effects occur. Another obstacle
that we may be facing with immunoneutralization is the negative
feedback loop of the body producing more ghrelin to compensate for lack of ghrelin signals. Although the immediate results of
an anti-ghrelin vaccine may look promising, further research is
needed to con-firm the safety and reliability of this method to
reduce body weight. Controlling the immune response can keep
ghrelin antibodies from getting out of hand (Carl-son, Cummings,
2006). However, until research can safely develop and monitor
such a vaccine, it would be best to put this method on hold.

Ghrelin Knockout
An alternative to a ghrelin vaccine is the ghrelin knockout model.
The ghrelin gene is deleted from rats and they are then monitored for feeding habits, metabolism, weight gain, and glucose
concentration. One point to remember is the unknown effects
of ghrelin’s complete absence from the body. In one experiment,
ghrelin’s effects on insulin secretion were tested using ghrelin
knockout mice. In particular, glucose-induced insulin release was
higher in knockout mice. On the contrary, basal insulin levels
remained the same in knockout and wild-type mice. Therefore,
ghrelin knockout mice had improved insulin responses to glucose.Afterwards, an insulin tolerance test (ITT) was given to both
groups of mice. No significant differences were found between
them.The experiment advanced to testing the effects of a high-fat
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diet, known to increase glucose concentrations. When fed a high
fat diet, blood glucose levels increased in wild-type mice, and no
in-crease was identified in the knockout mice. This can be attributed to enhanced insulin secretion in response to elevated
glucose levels. After the wild-type mice did a glucose tolerance
test (GTT), mice with a high-fat diet showed higher glucose concentration levels compared to a control diet, implicating glucose
intolerance. On the other hand, the ghrelin knockout mice exhibited no difference in glucose tolerance between the high-fat diet
and the control group. However, there was an increased insulin
response in the mice fed a high-fat diet (Dezaki, et al. 2006). This
research shows ghrelin’s role in glucose-insulin metabolism. In
the ab-sence of ghrelin, increased insulin levels and improved glucose tolerance were found. Although ghrelin knockout cannot be
done to humans, it serves as an indication of ghrelin’s metabolic
effects. Regulating ghrelin levels in obese people can possibly improve their body weight and glucose tolerance.

GOAT
Ghrelin O-acyltransferase is a membrane-bound O-acyltransferace.
It catalyzes the octanoylation of ghrelin allowing it to be acylated
and able to connect with the GHS-R1a receptor. Since it catalyzes ghrelin to be in its active form, one idea is to target GOAT
to slow the process of the body producing acylated ghrelin. In
GOAT knockout models, there is no acylated ghrelin found circulating (Pulk-kinen, et al. 2010). As discussed earlier, studies show
that unacylated ghrelin counteracts acylated ghrelin’s effect on
insulin, and did nothing to insulin metabolism when administered
on its own (Kiewiet, et al. 2009). So, inhibiting GOAT action can
minimize the effects that acylated ghrelin has on insulin and glucose metabolism.
One method studied to inhibit GOAT is the administration of
GO-CoA-Tat in mice. The GHS-R binding property of ghrelin
is determined by the octanoylation on serine 3, making it acyl
ghrelin. This inhibitor was found to be most active in binding to
GOAT. After administering GO-CoA-Tat to mice at a 40 mg/kg
dose, acyl ghrelin levels decreased while des acyl ghrelin levels
remained unchanged. Additionally, after 1 month, weight gain
due to decreased fat mass was assessed in the treated mice.
Interestingly, no difference in weight was found compared to
ghrelin knockout mice. This indicates that GOAT inhibition may
have similar effects to ghrelin knockout. The mice’s response to
glucose was measured to observe the effects of GO-CoA-Tat.
The insulin response was in-creased and blood glucose levels
subsequently decreased. This did not occur in ghrelin knockout
mice thereby reinforcing the mechanism of GOAT inhibition to
prevent ghrelin’s acylation (Taylor, et al. 2012). Additionally, use of
this GOAT inhibitor may be a better option than using a ghrelin
antagonist. Some advantages that a study done by Barnett et al.
in 2010 explains that GO-CoA-Tat does not need to cross the
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blood brain barrier unlike the GHS-R antagonist which targets
receptors in the brain as well. Additionally, there is no feedback
of the body trying to compensate by producing extra acylated
ghrelin to bind to the receptors. Another reason given is that
targeting an enzyme like GOAT may be safer than targeting a
widespread receptor (Barnett, et al. 2010). However, GOAT is
still being studied and its use in treatment is not yet confirmed.
Further experimentation would need to be done to examine the
viability of such a method of treatment in humans, and the possible negative side effects of a drug using this mechanism.
Figure 4

Legend
AG: Acylated ghrelin UAG: Unacylated ghrelin
GHS-R: Growth hormone secretagogue recep-tor
GOAT: Ghrelin O-acyltransferace
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Abstract
Gene therapy is the use of genes to treat or prevent diseases. Diseases such as cancer, which are difficult to treat using
conventional methods, can be treated using gene therapy.The transport of the therapeutic transgene can be accomplished
using viral or non-viral methods. However, widespread use of viral vectors is limited due to its high cost of manufacture
and safety concern. Non-viral vectors are limited in their effectiveness.The use of transposons such as the Sleeping Beauty
transposon system can effectively deliver the transgene with less concern than viral vectors. This review discusses the
various vectors and treatment strategies using gene therapy to treat cancer.
Introduction
The molecular basis for cancer is now well understood to involve the genetic control of multiple genes that control cell cycle
and tissue growth. The random mutations that activate dominant
oncogenes or inactivate tumor suppression genes result in a cell
cloning itself with an abnormal pattern of growth control forming
a tumor. Traditional cancer therapies aim to destroy or remove
the tumor by chemotherapy, radiation or surgery. The problem
with both radiation and surgery is the ability of tumors to metastasize and spread cancerous cells to areas inaccessible to these
treatments or may not be noticeable at the time of treatment
allowing a secondary tumor to appear. The trouble with chemotherapy is its low therapeutic index for many cancers and the
rapid development of drug resistance in cancerous cells.
Gene therapy is a fundamentally different approach to the treatment of diseases. Originally proposed as treatment for inherited
autosomal recessive Mendelian disorders, such as hemophilia,
gene therapy is now being used to treat multiple acquired conditions including infections, degenerative diseases and cancer. Gene
therapy is the use of genetic material (genes) to express a specific
protein in a cell or to reduce the amount of protein by interfering
with its synthesis. Replacing a defective gene with a functional
one is the essence of gene therapy.
Cancer is widely believed to arise from mutations to the cell’s
DNA by either carcinogens or random mutations during cell
division. This genetic basis coupled with the limitations of the
traditional treatments, makes cancer a great candidate for gene
therapies. More than 60 percent of all gene targeted therapy clinical trials since 1989 aimed to treat cancer (Ginn et al, 2013).

Strategies for Gene Therapy for Cancer
Cancer is a disease that involves multiple genetic changes to oncogenes, tumor-suppressor genes and modifier genes. There is
also the intracellular interactions with multiple cells that regulate
the body’s immune response and the interaction with other cancer cells to maintain a solid tumor. Gene therapy can be used
alone or together with conventional treatments. It can be used
to sensitize cancerous cells to radiation or chemotherapy. It can
increase the body’s overall resistance to chemotherapy so larger
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doses can be used. Gene therapy can declump or shrink tumors
to allow for surgical removal. Various approaches are being examined both in preclinical studies and in clinical trials for gene
therapy for cancer.

Downregulation of Genetic Targets
To downregulate the expression of protein coded by oncogenes,
antisense molecules are used. Antisense molecules are synthetic oligodeoxynucliotides (ODN) that hybridize with the coding
(sense) mRNA of a specific gene. The antisense and sense molecules form double stranded RNA which cannot be translated
destroying the mRNA. ODNs are designed to be highly resistant
to nucleases which will destroy the mRNA (Stein et al., 1988). In
a phase I–II clinical study using antisense ODNs to target BCL2
(an anti-apoptotic oncogene) mRNA combined with chemotherapy in patients with advanced malignant melanomas, the antisense
ODN was found to successfully downregulate the target protein
and has shown anti-tumor effects in 6 of the 14 patients (Jansen
et al., 2000).

Immunomodulation by Gene Therapy
Because cancer cells originate from “self” cells, they generally do
not cause a strong immune response. However, the immune system can be augmented by gene therapy to increase their function.
Therapeutic genes can be introduced into tumor cells or into
effector cells such as T lymphocytes.
To elicit a greater immune response, tumor cells have been modified with the insertion of cytokine genes. Cytokines are small
cell signaling polypeptides involved in immunity and inflammation.
Systemic and local administration of cytokines from the interleukin (IL) family has shown significant reduction in tumor size but
have systemic side effects and short half-lives, making injection
of interleukins deficient in long term tumor control. However,
tumor cells modified to express IL-12 or IL-2 have shown the
same size reduction as well as long term remission and metastasis control (Gao et al., 2005, Tahara et al., 1995).
The receptors on T lymphocytes can be modified to target tumor-associated antigens.The most common method of creating an
artificial T cell receptor (TCR) is by protein fusion of single-chain
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variable fragments derived from monoclonal antibodies that
acts as the TCR ectodomain with the CD3-zetatransmembrane
and endodomain. The endodomain can be further modified
with co-stimulatory receptors to increase immunologic activity.
Leukemias from B cell linages are suitable targets for this therapy.
The CD19 antigen is expressed in differentiated cells with B cell
linages and is rarely lost in cancerous cells. Anti-CD19 T cells can
safely target and destroy cells expressing CD19 including cancerous cells, and they will later be replenished with healthy cells
(Scheuermann & Racila, 1995).
For effective activation of T cells, non-specific signals are needed
as well as the antigen-specific signal received by the T cell receptor. Co-stimulatory molecules interact with receptors, such as
CD28, on the T cell to provide the non-specific signals. Martinet
et al. (2000) has shown that transfection of both IL-12 and 4-1BB
ligand genes into tumor cells resulted in long-term remission
of liver metastases in mice. The 4-1BB ligand, a co-stimulatory
molecule that binds with the 4-1BB receptor on T cells, synergizes with the CD28 pathway to increase the immune response
(Melero et al., 1998).

‘Suicide’ Gene Therapy
A commonly used idea for gene treatment of solid tumors is
‘suicide’ gene therapy, where the cells expressing the therapeutic
gene are killed. Suicide genes code for enzymes that can activate a drug with an otherwise low toxicity. When suicide genes
are expressed only in the targeted cancer cells, the healthy cells
avoid the drugs toxic effect. One enzyme commonly used is herpes simplex thymidine kinase, which converts the nontoxic drug
Ganciclovir, into a toxic form by phosphorylation (Song et al.,
2009).The suicide gene can be placed under the control of tumor
specific promoters such as c-erbB2 in breast cancer, ensuring specific drug activation in the tumor (Pandha et al., 1999). Because
the enzyme can bleed into and kill neighboring non-transduced
cells in what is termed the bystander effect, suicide genes can
be optimized to only require ten percent transduction in a solid
tumor greatly increasing its efficiency (Xiong et al., 2012).
Apoptosis-inducing genes One of the problems involved in treating solid tumors by conventional therapies is that cancerous cells
are often resistant to apoptosis and will not die with chemotherapy or radiation therapy alone. The gene that codes for the
anti-tumor protein p53 is either mutated or deleted in more than
50 percent of human tumors (Hollstein et al, 1991). Inserting a
copy of wild type p53 into cancerous cells has been shown to
induce apoptosis and make the cells more susceptible to chemotherapy and radiation therapy.

Anti-angiogenesis
Tumors, just like any tissue, require a constant supply of nutrients,
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oxygen, hormones and growth factors for their growth and progression. This is provided by the formation of new blood vessels or angiogenesis. Therefore, inhibition of angiogenesis would
stunt tumor growth. Patients with glioblastoma multiforme, a
highly vascularized form of brain cancer that does not respond
well to conventional treatments, would benefit greatly from an
anti-angiogenic treatment. Even poorly vascularized tumors can
be reduced by anti-angiogenic treatment (Beecken et al., 2001).
Clinical trials involving systemic administration of angiogenic inhibitors such as angiostatin and endostatin showed no dose-limiting toxicity. However, they did not show marked signs of tumor
regression due to the continuous release of pro-angiogenic
factors released by the tumor (Ohlfest et al., 2005, Shepherd &
Sridhar, 2003). Therefore, the delivery of angiogenic inhibitors by
gene transfer is favored over systemic administration.

Gene Transfer Techniques
The success of gene therapy lies in the efficient delivery of the
gene of interest to the target cell. The therapeutic gene is cloned
into a vector together with appropriate regulatory regions (promoters/enhancers) as well as any supporting proteins needed.
Selecting the right vector is a crucial part of gene therapy. The
ideal vector will protect and easily deliver the genetic information across the cell membrane and into the nucleus. It should
have the ability to regulate the expression of the gene of interest
and be able to successfully target specific cells to minimize toxicity. It should be easy and inexpensive to produce in large quantities. Once the gene is cloned into the vector it can be introduced
to the target cell. The gene can be delivered in vitro or in vivo.
In in vitro transfer, cells from a specific tissue are removed from
the patient and exposed to the gene-carrying vector. The transformed cells are selected by biomarkers and are reintroduced
into the patient’s body. In in vivo transfer, the vector is injected
into the patient’s body directly, usually into the target tissue or
the tumor if a tumor is the target.

Viral Vectors
Currently, the most effective method of gene transfer is though
viral vectors.Viruses have evolved over the years to enter the cell
and efficiently hijack the cell’s machinery to produce its own viral
proteins. An ideal viral vector uses the viral infection pathway but
avoids the expression of the viral genes that facilitate replication
and the subsequent host cell death. This is achieved by deleting
most of the viral genome, leaving intact the sequences (usually
the long terminal repeats) required for capsid packaging and integration of the vector DNA into the host’s chromatin.The most
commonly used viruses for gene therapy are retrovirus, lentivirus
and adenovirus.
Retroviruses carry their genetic material as RNA and integrate
their genome into host DNA using the viral enzymes reverse
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transcriptase and integrase. The integrated DNA acts as a provirus which replicates to make multiple copies of the virus and
is released outside the cell. Therapeutic retroviral vectors are
made replication-deficient by replacing the structural genes with
the therapeutic gene. Since retroviruses only gain access to the
host’s DNA when the nuclear membrane is broken down, they
only infect actively dividing cells and integrate the gene of interest
into the target cell.
Lentiviruses, a subclass of retroviruses, have recently been adapted to be used as gene transmission vectors. Lentivirus vectors
can naturally enter an intact nuclear membrane and integrate
their genome into non-dividing cells, which a retrovirus vector
cannot do. HIV-1 is the most common lentivirus used in gene
transfer. Because of its dangerous nature, lentivirus vectors do
not carry the gene required for replication. As an added precaution, self-inactivating (SIN) lentivirus vectors are being developed
which contain deletions in the downstream LTR.
Adenoviruses carry their genetic material as double stranded
DNA, but as opposed to the other viruses mentioned, the DNA
is not integrated into the host’s genome. However, adenovirus
can successfully infect broad range of cell type and is not limited
to dividing cells. In 2003 the first gene therapy to be approved for
commercial production was a recombinant adenovirus-p53 gene
therapy for head and neck squamous cell carcinoma approved by
China’s State Food and Drug Administration and is sold under
the name Gendicine (Pearson et al., 2004).

disease developed a form of leukemia. The cause in at least two
of the patients appeared to be the integration of the therapeutic
murine leukemia virus retroviral vector close to the LMO2 oncogene (Kohn et al., 2003).
Adenovirus vectors, since they do not integrate the gene into the
host’s genome, carry no risk of insertional mutagenesis. However,
since adenovirus vectors to not integrate the gene into the cell’s
DNA they are only expressed transiently and require multiple
administrations to be effective and repeated delivery may compromise efficacy and might induce a severe immune response
(Hartman et al, 2008).
While self-inactivating (SIN) retroviral vectors may reduce the
risk of insertional mutagenesis (Ellis, 2005), the clinical use of retroviral vectors is curtailed due the limited packaging capacity of
viral vectors. Most retroviral vectors can carry a transgene of up
to 8 kb, as larger genes would compromise the efficiency of viral
reverse transcription (Thomas et al,. 2003). This excludes the
transport of multiple or large transgenes. Finally, the high costs
involved in the manufacture of clinical-grade retroviral vector and
regulatory issues keep viral vectors from widespread translation
into clinical practice.

Non-viral Methods
The simplest method of gene delivery is injecting naked DNA
directly into the target tissue. Since naked DNA lacks any mode
of transport through the cell membrane, there have been various
methods developed to increase the efficiency of cellular uptake.

Limitations of Viral Vectors
The obvious concern regarding the use of viral vectors is the
possibility of the virus eliciting a strong immune response. In
1999, an 18-year-old male died due to an extreme immune response triggered by the administration of an adenoviral vector.
He was participating in a phase I clinical trial to determine the
safety of a gene therapy for ornithine transcarbamylase deficiency, an X-linked genetic disease of the liver (Raper et al., 2003).
Since then most work with adenovirus vectors used genetically
crippled constructs which would minimize the likelihood of an
immune response.
The integration of the therapeutic gene when using retroviral
or lentiviral vectors carries a possibility of oncogene activation.
Since the point of insertion is mostly random, the transgene can
insert into the upstream regulatory region of an existing gene
and activate or upregulate the existing gene due to the proximity
to the promoters in the downstream LTR of the transgene. The
transgene can also insert itself into a transcriptional unit of an
existing gene causing a loss of function in that gene. This was
shown to be a real threat when four patients in a clinical trial that
successfully treated X-linked severe combined immunodeficiency

In smaller animals, hydrodynamic injection can overcome the low
efficiency of cellular uptake.This procedure involves the injection
of a large volume, about 10% the weight of the mouse, of DNA/
saline solution through the tail vein in less than 10 seconds, with
most of the protein being expressed and accumulating in the liver
(Liu et al., 1999). In larger animals, the volumes required for hydrodynamic injection become prohibitive. This limitation can be
overcome by isolating an organ’s blood flow using catheters or
part of a limb using external tourniquets.
The efficiency of delivery can be enhanced by physical methods
such as microinjection directly into the cell, electroporation, sonoporation and the use of microparticle in gene guns and magnetofection. Most of these methods are only feasible in in vitro
gene delivery. Electroporation has been used successfully in gene
delivery to mice skeletal muscle in vivo (Miyazaki et al., 2002), but
the larger energy required to increase the permeability of the
cell membrane across a human limb risks destroying too many
cells. Sonoporation is limited to acoustically accessible organs.
Although these methods are efficient, they require expensive
specialized equipment reducing their benefit over viral vectors.
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The efficiency of delivery can also be increased by chemical
methods. The negatively charged phosphate on DNA can bind
to a variety of cationic polymers to form a DNA-polymer complex called a polyplex. The polyplex interacts with the cell membrane and is absorbed into the cell by phagocytosis where the
polyplex is released and the DNA can migrate into the nucleus.
Polyethylenimine (PEI) is one of the most commonly used non-viral vectors based on polycations for DNA delivery both in vitro
and in vivo. PEI is a polymer with repeating units composed of an
amine group and two carbon spacers. PEI can be linear, branched
or as a highly branched dendrimer, though linear PEI is more
commonly used. The exact mechanism my which the DNA-PEI
polyplex escapes the endosome is unknown but is thought to
be a result of the increased influx of protons, chloride ions, and
water during endosome acidification causing it to rupture from
the high osmotic pressure. Using confocal laser scanning microscopy, Merdan et al. (2002) observed the dispersal of the genetic
cargo soon after the rupture of the endosomes on living cells.
Cationic lipids are also used to condense the DNA into a liposome.These liposomes can protect the DNA from damage during
transport, something that the other non-viral delivery methods
fail to do. Suzuki et al. (2010) successfully transfected murine
ovarian tumors in vivo with IL-12 using self-prepared bubble liposomes combined with ultrasound applied to the tumor. The bubble liposome protocol was more effective than using the more
expense commercially available transfection agent, Lipofectamine
2000. However, the Lipofectamine control in the study was not
conducted together with ultrasound.
Non-viral methods present many advantages over viral vectors.
Most non-viral methods are simpler and cheaper to produce
and elicit a smaller host immune response. The transfer capacity of non-viral methods is functionally unlimited compared to
viral capacity. Low levels of transfection used to be the limiting
disadvantage, but advances have resulted in methods with transfection rates that are clinically viable and can compete with viral
vectors. However, the efficient delivery of DNA to the nucleus is
not enough for long-term transgene expression if it cannot integrate into the host genome.Transposable elements (transposons)
could potentially offer such an alternative.

Transposon Systems for Gene Therapy
Transposons or transposable elements (TE) are mobile regions
of DNA that can change their position in the genome. DNA
transposons rely on a transposase enzyme to cut the TE from
the donor site and insert it at the receiving site in a ‘cut-andpaste’ like manner. The transposase gene is the trans-acting element of the transposon system. The cis-acting element is a pair
of inverted repeats at either end of the gene which are the target
sites for the transposase as well as associated enhancers and
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promoters. Most regions coding for transposase also contain the
cis-acting elements and are considered autonomous TEs. While
transposons seem to have played a large role in evolution with
close to fifty percent of the human genome made up of TEs, most
species have accumulated mutations in the transposase genes.
One family of transposons, the mariner/tc1-like superfamily, has
members in a wide range of species including nematodes, insects,
fish, and humans with analogs reported in prokaryotes. This is a
result of horizontal gene transfer between species. Unfortunately,
not a single autonomous element has been isolated from vertebrates. Ivics et al. (1997) reconstructed the first man-made transposon system called the Sleeping Beauty (SB) transposon system
based on the consensus sequence of members of the mariner/tc1
family isolated from fish. The reconstructed SB transposase was
successfully able to transfer elements not only in fish but also in
other species including human cells. The use of a SB transposon
based system of gene transfer was proposed in 2000 when successful integration and long tern expression using SB was shown
in mice (Yant et al., 2000).
Because transposons have to survive along with the host cell,
traits that posed less of a threat to the cell were selected evolutionarily. A transposase with a high activity increases the chance
of insertional mutagenesis. Therefore, early iterations of the SB
tranposase had lower activity that could not compete with the
fast acting retroviral enzymes. It was known early on that exchanging certain amino acids in SB transposase could increase its
efficiency, but guessing the right combination of changes needed
to construct a hyperactive transposase would be near impossible.
Mates et al. (2009) conducted a large scale genetic screen of SB
mutants and yielded a transposase (SB100X) that was ~100 times
more efficient than first generation SB transposases. This hyperactive transposase allows the SB transposon system to compete
with viral vectors and was awarded the title of “Molecule of the
Year, 2009. ”
Since SB transposon based vectors integrate the transgene into
the host’s DNA, just as retroviral and lentiviral vectors do, they
also pose the risk of insertional mutagenesis. Statistical analysis
of the integration sites of both viral integrase and SB transposase
suggests the SB vectors are safer. SB transposons integrate at
TA dinucleotides and shows a preference (p<0.01) for a short
TA palindromic consensus sequence. This preference can be
explained by the greater bendability at TA sites that is possibly
required to allow the transposase access, but with ~108 TA sites
in the human genome this can still be considered random on a
genomic level. A study mapping over 1,300 SB integration sites
found 39 percent (p=0.02) integrated into known genes with a
weak preference for regions slightly upstream or within 5kb of
the start site (Yant et al., 2005). These results were compared to
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10,000 computer-simulated insertions that showed truly random
insertions would only result in 33 percent of genes. It is hard
to avoid any preference for transcriptionally active genes since
those are accessible due to chromatin modification such CpG
islands. Even though SB transposon shows a statistically significant preference for genes, the percentages are low compared to
viral vector insertions. Schröder et al. (2002) reported 69 percent (p<0.0001) of in vivo integration sites using HIV-1 vectors
were in known genes. Adding insulator sequences to the ends of
transposable element can further reduce the risk of unwanted
activation of neighboring genes (Walisko et al., 2007).
Long term expression of the transposase gene can result in the
transposon being excised and reinserted in a different location in
what is known as “re-hopping”, increasing the risk of insertional
mutagenesis. To limit the amount of time in which transposase
will be produced the transposase gene can transported on a second plasmid that will be transcribed ectopically and destroyed.
The use of mRNA as a source of transposase in also being explored (Wilber et al., 2006).
The greatest weakness of the SB transposon system is its inability
to infect cells. Any of the non-viral delivery methods mentioned
above can be used to transport the SB-containing plasmid. There
is also the possibility of using hybrid vectors that transport the
transposon packaged into virions.These hybrid vectors may prove
more effective than either method alone. The integration sites
of an HIV-1/SB hybrid was shown to be closer to truly random
integration profile with only 30 percent inserting into known
genes (Staunstrup et al., 2009), and a herpes simplex virus/SB hybrid has successfully increased the capacity of the SB transposon
(de Silva et al., 2009). SB transposon have also been successfully
delivered to target tissue using modified liposomes that used
Asialoglycoprotein receptor (ASGPR)-mediated endocytosis to
target hepatocytes in vivo (Wang et al., 2009) and hybrid vectors
may be employ similar targeting techniques being researched for
viral vectors (Waehler et al., 2007).
Since transposons simply ‘cut-and-paste’, they do not have to rely
on reverse transcriptase which has a tendency to incorporate
mutations.The transposase can possibly be modified in the future
to target a specific region of DNA using a synthetic zinc finger
domain (Yant et al., 2007). SB transposons are easier and cheaper
to manufacture than replication-incompetent viral vectors, allowing researchers without the resources required to produce viral
vectors to continue exploring transposon based systems.

and resultant bureaucracy has limited the widespread use of
commercially licensed gene therapy treatments. There are only
two approved gene therapies worldwide in over 25 years of
clinical trials, mostly due to safety and toxicity concern and not
effectiveness. There is a need for a safer delivery system and the
SB transposon system may be it. Most of its early limitations have
been resolved to the point that it can compete with viral vectors.
SB-mediated gene transfer has been shown to be effective in a variety of treatment strategies including anti-angiogenesis (Ohlfest
et al., 2005), suicide therapy (Song et al., 2009), and others.
The first human clinical trial using SB transposons is under way.
The trial will attempt to transfect T cells ex vivo with engineered
receptors against the CD19 antigen as described above (Williams,
2008). Regardless of what the results of this trial will be in terms
of efficacy, the trial will prove the safety of this method and provide the data necessary for further improvement in future trials.
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Abstract
The hygiene hypothesis provides an explanation for the sharp increase in atopy over the past several decades by proposing
that it is inversely related to the lack of infectious diseases in our society. Although atopy, as well as other hypersensitivity
reactions, do have a genetic basis; studies clearly show that environmental and socioeconomic factors play a large role in
determining which people will develop allergies. Proposed mechanisms leading to this disorder include an imbalance in
the Th1/Th2 complex in the immune system, and a deficiency in Regulatory T cells which controls excessive T cell activity.
Introduction
The immune system is a continuously adapting organ system
with many defense mechanisms in place to prevent infection.
Thousands of microbes are constantly trying to find a way to
infiltrate and take residence in the body and the components of
the immune system together find a way to prevent infection from
penetrating, or killing it once it does pierce the initial barrier.
Throughout history, the persistence of different infections has
constantly evolved to reflect our continually changing ecosystem.
As we learn to adapt to a specific disease, a new one will fill the
void that was left.Yersinia pestis, the bacteria responsible for killing hundreds of millions of people throughout the 14th century is
now almost completely eradicated (Haensch, et. al., 2010).
Many methods have been discovered which successfully wiped out
several illnesses plaguing the globe for many years. Vaccinations,
healthier diets, and personal hygiene have all had a positive effect
in reducing the number of bacterial and viral infections throughout the past century. Mumps, measles, polio, and diphtheria are
all examples of sicknesses that have practically been eliminated
in most developed countries resulting in a healthier environment.
Despite the decreased incidence of microbial infections, many
other disorders have quickly filled the void left by these infections. Crohn’s disease, type 1 diabetes, and allergies have seen
exponential growth over the past seventy years, indicating an
increase in hypersensitivity reactions. This paper explores the
recent increase in hypersensitivity reactions, specifically atopy, to
see if it is a direct result of the decreased number of microbial
infections.

Materials and Methods
Materials for this paper were mined using Touro College’s library to access databases such as Proquest, Pubmed, and Ebsco.
Additionally, some research was done using Google Scholar as
well.

Discussion
The number of cases of autoimmune disorders skyrocketed over
the past half century. Asthma, diabetes, and Crohn’s disease are
all examples of hypersensitivity disorders which have increased

exponentially in recent years while bacterial infections have
steadily decreased.
Bacterial infections and autoimmune disorders are believed to
be inversely related. Evidence for this theory first appeared in
1989, in a paper written by David Strachan who conducted a
study showing the relationship between the number of children
born and the likelihood of receiving hay fever. Strachan found
that children born into large families were less likely to contract
the disease. He suggested the reason was that children born into
large families were more susceptible to bacterial infections being
transmitted by older siblings, preventing them from contracting
allergies (Strachan, 1989). He did not provide an explanation for
this correlation.
Strachan’s hypothesis opened a door for many others who followed in his footsteps trying to explain the relationship between
autoimmune disorders and bacterial infections. This theory
later became known as the “hygiene hypothesis,” and scientists
today are still trying to find the mechanism which causes this
correlation.
In order for scientists to properly study the mechanisms of infections leading to these disorders, it is important to understand
what causes autoimmunity. Is a person’s genetic makeup the primary factor causing the disease, or do socioeconomic factors
determine if a person will develop the disorder?

Genetic Factors
It seems that there definitely are genetic factors that contribute
to an individual’s susceptibility to contract the diseases. Many
human autoimmune diseases have a tendency for familial clustering. Familial clustering, represented by λs in Table 1 (Vyse & Todd,
1996), gives the ratio of clustering in families relative to the rest
of the world. A λs of 15 means that a sibling is at 15 times greater risk of developing the disease than a member of the general
population (Vyse & Todd, 1996). All of the autoimmune diseases
listed contain a high rate of clustering, indicating that genes do
play a role in autoimmune disorders. For type 1 diabetes, the
MHC linked locus IDDM1 was the primary allele affecting the
disorder, although other alleles played a smaller role as well.
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Crohn’s disease, another autoimmune disease affecting different
areas of the gastrointestinal tract, is the result of many single
nucleotide polymorphism (SNPs) throughout a person’s genome
(Mao & Jeonghwa, 2008).
Such evidence would disprove Strachan’s hypothesis. If autoimmunity is solely a genetic disorder, it is impossible that environmental factors would be able to change an individual’s chances of
getting infected.
However, there are numerous studies that counter the notion
that autoimmunity is affected exclusively through genetics. Firstly,
evidence from observing distinct groups of individuals as they
migrated from one region to another shows that the rate of
developing diabetes is directly related to the location. A study
regarding Jews emigrating from Yemen to Israel showed that the
number of cases of type 1 diabetes sharply increased with the
duration of their stay in Israel. In fact, the numbers were higher
than any other ethnic group in Israel (Airaghi & Tedeschi, 2006).
Additionally, many studies have indicated that autoimmune
disorders are not evenly distributed amongst the continents.
Geographic data concerning Crohn’s disease, multiple sclerosis,
and type 1 diabetes demostrates that a north-south gradient
exists (Bach, 2002). In the northern hemisphere, the incidence
of autoimmune disease decreases towards the equator. One example of this is seen with the incidence of Crohn’s disease in
the US which shows a clear geographic pattern of occurrence.
Data collected from hospital discharges suggests that Crohn’s
disease clearly occurs more often in northern parts of the country (Sonnenberg, et. al., 1991). Data exists showing similar results
regarding type 1 diabetes, multiple sclerosis, and atopy as well
(Bach, 2002). Genetic factors alone would not be enough to explain all of these phenomena.

type 1 diabetes (du Prel, et. al., 2007). This study would support
Strachan’s theory that infections play a direct role on autoimmunity. Less living space would explain a child’s susceptibility to get
an infection which would inhibit his chances of developing type 1
diabetes. A similar study was done in Chile pertaining to asthma.
The results supported the belief that overcrowding was associated with less asthma symptoms (Corvalan, et. al., 2005).
The general consensus is that although there are genetic variables in an individual that will determine if he is prone to develop
an autoimmune disorder, these can be triggered based on socioeconomic conditions. A child raised in an environment that
was exposed to infections was more prone to develop infectious
diseases which in turn provided a sense of protection from developing autoimmune disorders.

Hypersensitivity
Although asthma and allergy are both subsets of hypersensitivity
reactions, they are caused by very different mechanisms. Allergy is
an immediate hypersensitivity reaction (Type 1 Hypersensitivity)
caused by activation of Th2 cells (a subset of T cells) which release cytokines to produces IgE antibody. When atopic individuals
encounter certain foods or pollen, they produce a dominant Th2
response which stimulates unchecked IgE production leading to
an allergic response.
Autoimmunity is a delayed type (or Type 2) hypersensitivity reaction resulting from the immune system acting on self tissue.
Although the direct cause for this disorder is still unknown, it is
believed Th1 activity, normally responsible for activating this pathway, may be involved in causing this disorder (Lohoff, et. al., 1998).
Most of this paper focuses on allergy, because this is where most
of the research on the hygiene hypothesis occurred, though some
of the information may shed light on autoimmunity as well.

Socioeconomic Status
Many studies have indicated that environmental factors, as well
as socioeconomic status play an even greater role in determining
one’s chances in developing autoimmune disorders (du Prel, et.
al., 2007). We already stated that autoimmunity is not evenly distributed among the continents. Developed countries usually have
a higher rate of autoimmunity than developing ones (Corvalan, et.
al., 2005). Even in developed countries, there are several factors
that will determine an individual’s chances of developing such a
disorder. Socioeconomic factors can include a number of different variables. A study regarding type 1 diabetes in Germany went
into greater detail to determine which factors will have a greater
influence. The results indicated that some aspects have a greater effect than others. Income level, education, and other similar
trends had a small effect while living space per person was a
much larger influence in determining a child’s risk of developing

A simple explanation regarding why less infections are correlated with a higher rate of autoimmune disorders is that the more
infections an individual undergoes in his lifetime causes a certain
amount of pressure on the immune system, which has to fight off
the antigen. Fewer infections means a delayed pressure on the
immune system, which is free to mount inappropriate responses against self antigens as occurs in type 1 diabetes (Airaghi &
Tedeschi, 2006).
This explanation would not fit into any of the mechanisms previously explained in triggering autoimmunity. Just because the
immune system is not pressured to fight off antigens, this doesn’t
explain why it would fight self antigens. The hypothesis would be
consistent if the immune system was weakened against foreign
microbes but not for an entirely new disorder. Nothing in this
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theory explains the inverse relationship between bacterial infections and autoimmunity.

Th1/Th2 balance
The immune system consists of T cells and B cells. T cells can be
either CD8+, cytotoxic, which are responsible for killing viruses,
or CD4+ helper T cells which assist in other immune functions.
The CD4+ T cells can be either a subset of Th1 or Th2. Each subset helps the adaptive immune system in its own way.
Th1 cells are primarily instrumental in killing intracellular infections. Neutrophils are the immediate response to the body’s
defense against an attack. However, under some circumstances,
these neutrophils are not successful in phagocytosis of the pathogen. Either the pathogen has evolved to evade the neutrophil, or
the neutrophil has not been activated properly. These situations
require help from Th1 activated T cells. These T cells recruit
macrophages to kill the microbe through ROS (Reactive Oxygen
Species). Although this is an effective way of destroying a pathogen, there are certain drawbacks. One issue is that the agent that
kills the microbes may harm healthy tissue as well. Macrophages
do not discriminate which species they attack so tissue damage
is usually accompanied with hypersensitivity to an infection. One
way of inhibiting this response is through Th2 activation.
The Th2 subset of T cells has an entirely different role than Th1.
While Th1 is effective in activating macrophages, Th2 cells are primarily responsible for producing cytokines that signal antibodies
such as IgE and activate eosinophils, which are responsible for
killing Helminthic parasites (Abbas & Lichtman, 2009).
Th2 cells also secrete cytokines that activate the alternative macrophage pathway, which inhibits the classical macrophage pathway.
When Th1 cells activate macrophages to kill a pathogen, they kill
host tissue as well. Th2 cells are responsible for inhibiting this
pathway, as well as producing cytokines to express mannose receptors to aid in tissue repair to the host.
A proper immune response to an infection requires Th1 cells
to activate macrophages to fend off the infection and Th2 cells
to slow down this response. Different organisms have different
amounts of Th1 and Th2 which will directly affect how they respond to infections (Cohn, et. al., 2004).
An overabundance in Th2 response is what causes an allergic
reaction. When a person is exposed to certain pathogens, namely Helminth parasites, Th2 cells secrete cytokines to bring IgE
and mast cells to the area to kill the infection. Atopic individuals
mount an especially strong immune response to these antigens
causing an allergic response, known as type 1 hypersensitivity.
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Th1 and Th2 develop from a common precursor termed Thp.
Development into mature Th cell depends on the conditions
present during maturation. Several cytokines such as IL2 and
TGF-β have a tendency to cause Th2 proliferation. However in
the presence of a normal amount of antigen in the host, antigen
presenting cells produced IL-12 which caused Th1 proliferation
(Lohoff, et. al., 1998).
Thus, a healthy balance of Th1 and Th2 is necessary for a proper
immune response. Th1 is necessary to fend off pathogenic microbes at the site of infection while a proper Th2 response is
necessary to prevent too much tissue from getting affected by
the macrophages. Different amount of Th1 and Th2 in the body
determines the outcome of an infection. An experiment with
different strains of mice with different amounts of Th1 or Th2
helps determine the outcome of an infection. Leishmania major,
an infection normally killed by activated macrophages, was placed
in a strain of mice that had effective Th1 cells. The infection was
successfully eradicated. However, when placed in a strain of mice
that has a dominant Th2 presence, the mice succumbed to the
infection (Elso, et. al., 2004). Mycobacterium leprae as well, if
dominated by a Th2 response will lead to a much more severe
form of leprosy.
This imbalance of Th1/Th2 might explain why less infection may
cause more allergic hypersensitivity. Developed countries are
certainly more hygienic and individuals are less prone to develop
infections. The body has less of a need for Th1 cells and may suppress Th1 production. Once an imbalance is formed,Th2 secretes
cytokines which further inhibits Th1 and cause an overabundance
of Th2 production (Holt, 2000).

Regulatory T cells
In healthy individuals, regulatory T cells (Tregs) are responsible
in suppressing dominant T cell activity. In response to infection, T
cells often cause heavy responses that can cause serious harm to
the individual if left unchecked. Activation of these Tregs, such as
CD4+CD25+, were shown to suppress the Th2 response leading
to a decrease of atopic responses in individuals exposed to pollen.
Studies show that individuals who experience atopic symptoms do
not express sufficient amounts of CD4+CD25+ (Ling, et. al., 2004).
Additionally, lack of Tregs are also responsible for several disorders
such as type 1 diabetes, multiple sclerosis, and inflammatory bowel
disease.
Tregs utilize different mechanisms of control in response to different
infections. In response to airway hypersensitivity reaction (AHR),
Tregs secrete IL-10 along with TGF-β which controls the Th2 response. In NOD mice, evidence showed that Tregs were instrumental in preventing type 1 diabetes through activation of CTLA-4 (a
cell surface molecule) together with TGF-β (Workman, et. al., 2009).

Hygiene Hypothesis

Alternatively, there are a number of factors that lead to healthy
Treg development. FoxP3 is the transcription factor that develops immature T cells into regulatory cells. A mutation in this may
lead to several autoimmune diseases such as diabetes, anemia,
and eczema. Another cell necessary for healthy Treg development
is IL-2. IL-2 is not secreted by Tregs but it is necessary for Treg
survival. IL-2 is secreted by activated T cells and a healthy balance
of is needed to maintain homeostasis. Effector T cells compete
with Tregs for IL-2 so Tregs can upregulate CD25 production to
suppress effector T cells, providing a healthy feedback mechanism
between responder T cells and Tregs (Goleva, et. al., 2005).
The mechanism leading to this deficiency in Tregs is unclear. One
theory suggests that the effector T cells in individuals with asthma may be toxic towards Tregs in these individuals (Thorburn &
Hansbro, 2010).

change in human behavior may have a direct effect on how people develop certain microbiota as shown in Table 3. The changes in the conditions listed have had a direct effect on many of
the known microbes that reside in the human body. Although
reduced colonization of H. pylori from the gastrointestinal tract
is beneficial in the sense that reduces susceptibility to gastric
cancer, it is also shown to contribute to many metabolic disorder
as well as childhood asthma. Blaser and Falkow (2009) maintain
that the recent epidemic of autoimmune disorders is not due
to the lack of pathogenic infection as much as it is due to the
human microbiome as a whole (Blaser & Falkow, 2009). Other
research supports this premise by saying the hygiene hypothesis
may not a product of less exposure to pathogenic infections itself,
as much as it is caused by lack of exposure to all microorganisms
(Bloomfield, et. al., 2006)

Conclusion
Another theory is that Tregs may actually be induced by pathogenic infections as indicated in Table 2 (Thorburn & Hansbro,
2010). Antigen presentation by the lungs was shown to promote
TGF-β dependent induction of Foxp3 expression. Lack of infection may lead to an uncontrolled immune response. Several
infections are known to have a direct link to regulatory cells so
by inhibiting these cells; it would lead to an increase in allergic
response.
One particular study tried to find if there is a direct correlation
between asthmatic infection and H. pylori- a common bacteria
found in the gut. Experimentally induced asthma in mice had
fewer symptoms when the mice were previously infected with
H. pylori. The study also showed that these mice had significantly
higher numbers of Tregs leading to the belief that Tregs is one
of the underlying mechanisms controlling an asthmatic response
(Arnold, et. al., 2011).

Microbiota Theory
Although this study definitely supports the theory that Tregs are
one of the most influential factors in developing asthma, it also
supports a different belief entirely in what causes the hygiene
hypothesis.
In an essay concerning the diminishing numbers of microbiota in
the body, Blaser and Falkow postulated that the main cause in the
increased numbers of autoimmune disorders is related to the
number of microbiota in body, rather than the number of pathogenic infections a person encounters throughout life. For the
past several centuries, humans have adapted to allow a diverse
subset of microbial organisms to live inside the mucosal surfaces of the intestines and lungs, forming a symbiotic relationship
between host and microbe. Humans provide a home for these
microbes while they are helpful in digestion and metabolism. A

Despite all the evidence supporting the hygiene hypothesis, there
still is a fierce debate whether less hygiene will in fact cause a
downward trend in autoimmune diseases. The direct mechanism
remains elusive, and without definitive evidence demonstrating
what causes the rise in allergic diseases, the microbial exposure
hypothesis may be just as plausible in explaining the rise in atopy.
And considering the many benefits our modern ecosystem provides for us on a daily basis, the pros of less microbial exposure
far outweigh the cons. Clean drinking water and Cesarean sections are just a few examples that have saved many lives over the
past few decades. So although decreasing the number of allergy
cases is a priority, the current evidence should not support exposing oneself to additional microorganism than those already
prevalent in society.
Table 3
Change

Consequence

Clean water

Reduced faceal transmission

Increase in Caesarean section

Reduced vaginal transmission

Increase use of pre-term antibiotics

Reduced vaginal transmission

Reduced breastfeeding

Reduced cutaneous transmission and a
changed immunological environment

Smaller family size

Reduced early life transmission

Widespread antibiotic use

Selection for a changing composition

Increased bathing, showering and use of antibacterial soaps

Selection for a changing composition

Increased use of mercury-amalgam dental filling

Selection for a changing composition

Changes in human ecology that might affect microbiota composition
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Abstract
Alzheimer’s disease is a neurodegenerative disorder that is the 6th leading cause of death in the United States. More than
5.5 million People over the age of 65 are currently diagnosed with Alzheimer’s disease with predictions of 13.8 million to
be diagnosed by the year 2050 (Sultana, et al., 2013) (Hebert,Weuve, Scherr, & Evans, 2013).With few treatments available,
scientists are desperately looking for a solution to this growing epidemic. Creutzfeldt-Jakob disease is also a neurodegenerative disorder, but with a far less prevalence of only 4.6 persons per million per year. It was discovered that Alzheimer’s
and Creutzfeldt-Jakob disease share many pathophysiological mechanisms with each other. Being that both of these
illnesses are currently incurable, a thorough critical analysis of mechanisms and potential treatments were preformed to
ascertain if knowledge in one disorder can help find a cure for the other. With the strong relationship between these two
disorders, it was found that many treatments intended for one illness had positive results for the other (some with slight
modifications). The discovery of this correlation improved scientist’s knowledge of the pathological mechanism of these
ailments along with finding new and creative ways for treatment. Experiments geared towards the relationship between
Alzheimer’s and Creutzfeldt-Jakob disease has brought researchers closer to finding a cure for several neurodegenerative
disorders.
Introduction
Alzheimer’s Disease (AD) and Creutzfeldt-Jacob Disease (CJD)
are two disorders characterized by their neurodegenerative
symptoms. These ailments are both considered forms of dementia consisting of phenotypes portraying a patient’s loss of memory, mood irregularities, paranoia, and several other neurological
symptoms. Physiologically, AD is characterized by its Amyloid-β
and Tau protein plaques while CJD is characterized by its prevalence of misfolded prion proteins throughout the brain. Albeit
these two diseases are believed to have different modes of physiological symptoms, they share many similarities with each other
and other neurodegenerative disorders causing many scientists
to theorize a possible correlation between their mechanisms. It is
partly due to these similarities that physicians often misdiagnose
various dementia relating disorders as either CJD or AD. In a
study of 304 autopsies that showed no prion disease prevalence,
71 (23%) of the patients had Sporadic CJD (a variant form of CJD
characterized by unknown cause) as a possible diagnosis in their
medical records (Chitravas, et al., 2011). Another study showed
that “between 12% and 23% of patients diagnosed with AD do
not have sufficient AD pathology at autopsy to account for the
presence of dementia (“misdiagnosed”) (Gaugler, et al., 2013).”
Due to the vast likeness between many dementias, there has not
been a definitive noninvasive procedure to precisely diagnose disorders such as CJD and AD (Mayo Clinic Staff, 2014).
Although AD and CJD share similarities, their prevalence in
American society is far dissimilar. AD is the 6th leading cause
of death with an estimated 5.5 million people over the age of
65 who are afflicted with this neurodegenerative disorder in the
United States (Sultana, et al., 2013). CJD on the other hand, displays a prevalence of a mere 4.6 cases per million people over the
age of 60 ( Centers for Disease Control and Prevention , 2014).
This is far fewer than the thousands of people who are diagnosed
each year with AD.

Despite the rarity of CJD, numerous research endeavors have
been conducted in understanding this prion disease. One explanation for this attention is due to the unique properties of a
prion; a protein which acts as an infectious pathogen misfolding
other proteins into additional prions (Wadsworth, et al., 2008).
What is more surprising is that prions have been found in patients diagnosed with AD (Armstrong, et al., 2005). This would
further suggest a possible correlation between pathogenic mechanisms of AD and CJD. Today various treatments for AD and CJD
are currently in clinical trials to try to treat these incurable diseases. If there is a correlation between pathological mechanisms,
further research into one of these neurodegenerative disorders
can help scientists better understand and treat the other.
The purpose of this research article will be to define and explain
the physical and physiological symptoms and mechanisms of AD
and CJD, suggest possible correlations between the two, discuss
current treatments, and lastly, the different forms of possible
treatments will be compared to postulate a possible venue to
determine if they would be effective to treat the other illness.

Methods
Several online databases were used such as: Google Scholar,
PubMed, and Jstor which were accessed through Touro College’s
online library. Additional references were gleaned from papers
found in these databases

Discussion
CJD Pathophysiology
CJD is quite unique due to its pathophysiological mechanism.
While most infectious diseases are viral or bacterial based, CJD
uses a prion to spread its illness. In actuality, every individual contains Prion Proteins (PrPc) which are believed to be necessary
for normal synaptic function (Collinge, et al., 1994). It is when
this human-coded PrPc is post-translated and converted into
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an abnormal isoform (PrPsc) that it starts to exhibit pathological tendencies. Data suggests that this abnormal protein is the
main, if not the solitary, component of the transmissible disease
(Wadsworth, et al., 2008). Once the PrPsc comes into contact
with a normal PrPc, it causes a transmutation of residue 129
turning it into a pathological agent. This replaces the amino acid
by residue 129 on the protein into either valine or methionine.
Whereas many scientists agree that the prion protein is the main
constituent of CJD, there is debate over the validity of this claim.
Manuelidis, et al (2007), argue that the abnormal PrPsc form of
the prion protein is a result, not the cause, of CJD. They claim
that a 25 nm virus is the cause of the abnormal prion isoform.
They discredit the long accepted hypothesis, that prions are the
sole pathological constituents of CJD, for several reasons. Studies
show, “high PrP-expressing transgenic brains, as well as abnormal
recombinant PrPs, have failed to show significant or reproducible
infectivity”. Additionally, the authors claim that after several decades of research, scientists found no “infectious conformation”
of PrPsc. Furthermore, sheep with scrapie showed signs of these
25 nm viruses while uninfected controls showed no prevalence
of these particles. These facts caused many researches to share
doubt on the prion-only hypothesis.
Another theory with tangible evidence suggests a different mode
of pathological mechanism. Several studies suggest that non-proteinaceous cofactors are needed to facilitate the infectious properties of PrPsc, hypothesizing that prions work via multiple components in order to function (Deleault, et al., 2012). While there
are studies that show that purified PrPcs which were folded
chemically into amyloid fibrils showed little infectivity, a combination of PrPc, liver RNA, and synthetic 1-palmitoyl-2-oleoyl-phosphatidylglycerol (POPG) lipid molecules facilitated the production of authentic infectious prions. The contrasts between the
infectivity of PrPc obtained from amyloid fibrils and from PrPc
combined with lipids and RNA support this theory (see figure
1). However, further study should be conducted to determine
whether the cofactors are required for pathology or are merely
a catalyst for a slow progressive disorder (Supattapone, 2010).
These experiments cast doubt on the viral hypothesis of prion
disease. If viruses were the cause of prion pathology, why were
scientists able to reproduce CJD symptoms with only PrPc and
various cofactors?
There are several ways for an individual to contract CJD. Factors
include ingestion of prion-infected tissue, contamination during a
procedure (most commonly a contaminated tissue transplant or
equipment), inheritance of a mutation in the PrPc gene (PRNP),
or sporadically (no apparent cause). When tissue infected with
abnormal prions is ingested, such as meat from a cow infected
with Bovine Spongiform Encephalopathy (BSE, also known as Mad
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Extra ingredients:Two different biochemical protocols yield recombinant PrPc
with different infectivity. (Left) Minimally infectious amyloid ﬁbrils are formed
by incubating recombinant PrPc with chemical denaturants. (Right) Mixing
recombinant PrPc with phospholipid and RNA produces highly infectious prions.
(Supattapone, 2010)

Cow Disease), a variant form of CJD is contracted named variant CJD (vCJD). Contamination via a procedure causes a form
of CJD termed Iatrogenic CJD while a genetic mutation that is
inherited is called Genetic CJD. CJD that is acquired sporadically
is referred to as Sporadic CJD (sCJD) (Wadsworth, et al., 2008).
According to Wadsworth et al (2008), approximately 85% of cases
with CJD occur as the sporadic variant (sCJD) while 15% are associated with a pathogenic mutation in the PRNP gene (Genetic
CJD). Wadsworth further explains that the rare iatrogenic form
of CJD occurs most frequently due to the transmission of prions
via contaminated growth hormones from cadavers or by implementation of contaminated dura mater grafts. Additionally, it has
been speculated that iatrogenic CJD can be transmitted via blood
transfusions although it is extremely rare (Ricketts, et al., 1997).
Prion disease prevalence has been tied to vCJD in the United
Kingdom by the consumption of cattle with BSE. Another unique
variant of CJD, named Kuru, is found in the Eastern Highlands of
Papua New Guinea where members of the community would
feast on the deceased relatives as a sign of respect and grief. From
the community in Papua, scientist discovered that the incubation
period of individuals infected with PrPsc could exceed 50 years
(Wadsworth, et al., 2008).
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Individuals with CJD often exhibit phenotypical signs of dementia and various other neurodegenerative symptoms. The primary indication of CJD is the observation of sponge-like holes
in a person’s brain giving the appearance of a sponge; for this
reason, many scientists refer to prion diseases as transmissible
spongiform encephalopathies (TSEs). Additionally, patients have
been known to portray feelings of anxiety, depression as well
difficulties of cognition such as impaired thinking, memory loss,
personality changes, insomnia and difficulty speaking. Blurred vision, difficulty swallowing and sudden jerky movements are also
typical signs of CJD. As the progression of the illness takes its
course, cognitive phenotypical symptoms worsen. A majority of
individuals lapse into a coma and eventually die due to cardiac
arrest, respiratory failure, or an infectious pathogen. The duration of duress is typically 7 months for classical CJD and 12-14
months for variant CJD; however, patients have been known to
live up to 2 years after diagnosis (Mayo Clinic Staff, 2012).
Currently, the only way to verify the diagnosis of CJD is via an
autopsy to confirm the presence of PrPsc plaques and to observe
the formation of spongy-like holes and structures within the patient’s brain; however, doctors can accurately identify this disease
via several diagnostics. First, a physician might asses the patient
to determine if he/she portrays any of the symptoms of CJD.
Additionally, doctors may administer an Electroencephalogram
(EEG) to measure the individual’s brain’s activity. People with
CJD typically portray an abnormal pattern. Magnetic resonance
imaging (MRI) may be used to produce a high resolution image
of a person’s brain in order to determine a signs of abnormality. Another known method of testing is a spinal tap where a
physician withdraws a small amount of cerebral spinal fluid that
surrounds an individual’s brain and spinal cord. The presence of
several proteins in the CSF may be an indication of illness (Mayo
Clinic Staff, 2012). A simple blood test to detect trace amounts
of PrPsc may be an additional venue to test for CJD, but further testing is needed to determine if this is a viable method of
diagnosis (Castilla, Saa, & Soto, 2005). Furthermore, in a study
conducted by Moda et al (2014), 13 out of 14 patients with vCJD
showed signs of PrPsc in their urine samples suggesting a future
possible diagnostic for vCJD.

AD Pathophysiology
AD is a form of dementia characterized by the formation of
Amyloid-β protein (Aβ) plaques or the hyperphosphorylation of
Tau proteins along with neuron degradation in the brain. This is
accompanied with numerous cognitive relating symptoms. While
the symptoms of AD are well documented, there is much debate
over the exact mechanism in which the disease carriers out its
pathology.
One suggested mechanism is through the formation of Amyloid-β

proteins which in turn form amyloid-β plaques. The Aβ is formed
from a far larger protein called the β-Amyloid Protein Precursor
(APP). The cleavage to the Aβ form is catalyzed by the enzyme
β-CITE APP cleaving enzyme-1 (BACE1) (Small & Cappai, 2006). It
is believed that when there is an overproduction of Aβ, either via
a faulty Aβ production mechanism or a failure of the body’s clearance of the protein, Amyloid plaques are formed (Verkhratsky, et
al., 2014). These aggregations of Aβ are believed to be toxic and
are the main cause of AD.The conclusion that Aβ is involved with
the pathogenesis of AD is strongly supported by an experiment
involving APP transgenic mice. These mice contained human APP
and when induced with an amyloid disease, showed very similar pathophysiological symptoms as AD. However, within recent
years, studies have shown that Aβ plaques are not the most toxic
form of Aβ. Experiments have shown that a low molecular weight
diffusable form (non-plaque forming) of Aβ is more toxic. This
would explain why in APP transgenic mice, abnormal cognitive
symptoms are seen before Aβ plaque formation (Small & Cappai,
2006).
Another well-known hypothesis to the pathological mechanism
of AD is the formation of toxic hyperphosphorylated tau proteins.
Normal or dephosphorylated microtubule-associated protein
(MAP) tau aid in the assembly and stability of microtubule networks in neurons. If an abnormality in the MAP tau arises, there
are two other MAPs (MAP1A/B and MAP2) that can compensate;
however, when the dephosphorylated tau turns into the hyperphosphorylated form, it turns toxic. This pathological form of tau
sequesters normal tau (MAP1A/B and MAP2) while inhibiting
and disrupting microtubule structure. The neuron that has been
afflicted with this pathogenic MAP tries to dispose of the toxic
substance by synthesizing additional normal tau and by turning
the hyperphosphorylated form into an inert polymer. Eventually,
this afflicted neuron begins to degenerate at a progressively slow
pace. Aggregation of this abnormally hyperphophorylated tau has
been linked to dementia and neurofibrillary degradation. This
abnormal MAP tau appears to be the main contributor to tau
pathologies, or tauopathies, for dephosphorylation returns the
protein back to its normal functioning state. One possible reason for this abnormality may be due to a conformational change
in the MAP tau. This causes it to be a better substrate to be
phosphorylated or a worse substrate for dephosphorylation. In
either case, these conformational changes appear to cause the
pathology of AD (Iqbal, et al., 2005).
AD is typically defined via 3 diverse categories: early-onset AD
(EOAD), late-onset AD (LOAD), or early-onset familial AD
(EOFAD). With increasing age as a known risk factor, patients
who contract the disorder past the age of 65 are said to have
LOAD which resembles the majority of all AD cases. People who
are diagnosed with AD before the age of 65 is said to have EOAD
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which encompasses up to 5 percent of all cases (WebMd, 2014).
EOFAD is a form of the disorder where the onset of duress
is under 65 years of age and where the individual has one or
more of the genes associated with AD. These genes are believed
to cause the person to attain a genetic disposition towards AD
(Bird, 1999).
Genetic linkage studies have identified three different genes
associated with EOFAD. The first gene identified was the APP
gene (the gene that is responsible for APP production). It is believed that a missense mutation within this gene is a risk factor
for EOFAD. Another gene found to be correlated with AD is
PSEN1. Family studies have shown that mutations in this gene are
pathogenic. The third gene found injunction with AD is PSEN2.
Although it is far rarer than the PSEN1 mutation, it is believed
that mutations in this strand of the gene are a precursor for
pathogenesis of EOFAD. It is believed that the PSEN1 and PSEN2
genes are involved with γ-secretase, an enzyme involved with the
cleavage of APP, and a mutation in these genes cause pathology
via this pathway. The majority of EOFAD cases (81%) can be accounted for by a mutation in the PSEN1 gene, the second most
(14%) by a mutation in the APP gene, and the least (6%) associated with the PSEN2 gene (Ertekin-Taner, 2007).
Similar to EOFAD, a gene has been found to be associated with
LOAD. The Apolipoprotein (ApoE) gene codes for a protein that
transports cholesterol in the bloodstream. It is found as different
forms named ApoE ε2, ε3, and ε4. The ApoE ε3 form is the most
common form of the gene while ApoE ε2 and ε4 are less prevalent. It is believed that ApoE ε2 reduces the risks of AD and ApoE
ε4 has the contrasting effect of increasing AD pathogenesis. If
an individual attains two sets of the ApoE ε4, it greatly increases
his/her chances of AD. Unlike other known genetic mutations,
inheriting both sets of the ApoE ε4 gene does not guarantee AD
pathology (Alzheimer’s Association, 2014).
While there is no definitive method of ascertaining if an individual will contract AD, there are several disease-modifying factors
that decrease or risk factors which increase one’s probabilities of
pathology. Nam Hu et al (2013) characterizes a list of nutrients
and their risks towards AD. Antioxidants obtained in an individual’s diet were shown to reduce the risks of AD. Studies show
that maintaining a healthy level of vitamin C in a person’s diet can
have a protective effect towards AD. In regards to metals, Iron is
believed to be a risk factor for dementia while Zinc is believed
to be a cause in the delay in AD pathology. In regards to fats and
carbohydrates, while there is an assumption that these can pose
as risk factors for AD, not enough reliable evidence is available to
make a firm conclusion. Hu et al made a graph (figure 2) illustrating the effects of various everyday foods if whether or not they
increase or decrease a person’s risk towards AD.
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Figure 2
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Foods and beverages that influence the incidence of AD. Fish, vegetables,
fruits, coffee, and light-to-moderate alcohol intake are reported to
reduce AD incidence. Milk and tea are reported to influence cognition,
but their influence on AD is not clear. (Hu, et al., 2013)

Various other theories about the pathophysiology of AD contribute to our understanding of the disease. One proposed hypothesis is the degradation of the blood brain barrier (BBB). The
BBB protects the brain from various pathogens and unwanted
particles within the bloodstream. The deterioration of the BBB
can cause various proteins in the blood to enter the cerebral
spinal fluid and form plaques (Sardi, et al., 2011). Another theory
involves the metal aluminum.While the correlation is not entirely
known, it is believed that a high level of aluminum in the brain is
a cause for AD (Shcherbatykh, 2007). Further research suggests,
as mentioned by Moulton and Yang (2012), that air pollution too
plays a role in AD. While the pathogenesis of AD is multifactorial, air pollution can accelerate “age-related oxidative changes
observed in the brain”, increasing one’s risk of contracting the
disorder.
Analogous to CJD, patients who suffer from AD share many similar phenotypical symptoms. Patients have been known to exhibit emotional symptoms such as depression, anxiety, and mood
swings and cognitive symptoms such as loss of memory, difficulty
speaking, and difficulty thinking. Additionally, those who contract
AD are known to have delusions, such as paranoia, change in
sleeping patterns, and loss of inhibitions. Towards the late progression of the disorder, important skills such as reading, hobbies,
and reminiscing are lost (Mayo Clinic Staff, 2014).
Currently, there is no specific diagnostic to confirm the presence
of AD. A physician determines whether you meet the criteria of
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dementia and often they can determine if it is due to AD. Doctors
have an arsenal of diagnostic tests that they can perform to assist
in narrowing the diagnosis. One possible test is a neuropsychological test where they can identify cognitive changes. Different
types of dementia can have different cognitive patterns. A blood
test can be administered to rule out other causes of memory
loss such as vitamin deficiencies. Frequently, brain imaging is used
to identify any abnormalities within the brain. An MRI can be
used to produce a high resolution image of the brain for further
study. A computerized tomography (CT) scan uses x-rays and a
computer to generate cross-sectional images of the brain. This
can help rule out head injuries and tumors. A positron emission
tomography (PET) scan is used in conjunction with an isotope
tracer which is injected into an individual. With this machine, a
doctor can track the movement of this tracer and determine
which areas of the body are dysfunctional. All of these diagnostics
aid in the identification of AD; however, similar to CJD, the only
way to confirm illness is to perform an autopsy and to observe
plaque buildup within the brain (Mayo Clinic Staff, 2014).

Pathophysiological Comparison of AD and CJD
AD and CJD are diagnosed via their dissimilar pathological mechanism and symptoms. AD is associated with Aβ plaques and Tau
proteins and CJD with abnormal PrPsc. AD is a slow progressive
disorder with an extremely high prevalence, afflicting a third of
octogenarians, while CJD is rapidly progressing with an extremely low prevalence, afflicting one per million per year. However, no
matter the dissimilar characteristics between the two disorders,
there is evidence that there is an analogous mechanism between
the two.
It was shown in a study that PrPc prevalence affects the function of BACE1. BACE1 is a cleaving enzyme which catalyzes the
cleavage of APP to either Aβ-40 or Aβ-42, two versions of the
Aβ differing in residue length. A high expression of PrPc reduces
the severing of the APP into peptide fragments by more than 95.
This in turn reduces the secretion of Aβ-40 by 92% and Aβ-42 to
undetectable levels. The support for this conclusion arises from
the study that showed that reduced PrPc prevalence showed an
increase in Aβ-40 and Aβ-42 production. This provides strong
evidence between the correlation between AD and CJD mechanisms (Hooper & Turner, 2008).
These findings increase the probability that a slight reduction in
PrPc at a young age could cause an inconsequential accumulation
of Aβ-40 and Aβ-42 over many years, furthering the accumulation
of Aβ plaques and the onset of AD. Patients with AD showed
lower levels of PrPc in their occipital lobes with an increased
activity of BACE1.Additionally, studies show that a polymorphism
in codon 129 of the PrPc gene is a risk factor for early-onset AD.
This polymorphism changes the peptide coded in that location

to a valine or methionine causing the transconformational alteration to the PrPsc pathogenic form. This is consistent with our
assumed PrPc-BACE1 relationship. Hooper and Turner (2008)
suggest that if PrPc affects Aβ production, we can assume that
the absence of PrPc would lead to early-onset AD.
If prion proteins regulate Aβ accumulation thus preventing AD,
does Aβ regulate and/or prevent prion pathology? In an experiment involving mice infected with scrapie, a form of prion disease
in animals, it was found that in the terminal stages of the disease
there was a considerable increase in the concentration of Aβ.
Hooper and Turner comments on this that, “[i]nterestingly, the
amounts of Aβ peptides were high in scrapie-infected mice, with
a shorter disease incubation time raising the possibility that the
higher levels of Aβ might exacerbate the disease process.” If this
theory is correct that high Aβ levels contribute to the rate of
prion pathology, then this can be used as a way to slow down
the progression of these ailments. However, they point out that
we cannot rule out that the increased levels of Aβ are perhaps
a result of the scrapie pathology, as stated before, and that further study is necessary to confirm this hypothesis (Hooper &
Turner, 2008). Furthermore, Debatin et al (2008) point out that
the increased levels of Aβ could be the result of the saturation of
clearance mechanisms; since the body is preoccupied with PrPsc
maintenance, the same mechanism that also deals with Aβ accumulation becomes saturated leading to a buildup of the AD associated protein.This theory is supported by evidence that suggests
a common pathway for protein degradation of PrPsc and Aβ.
Alternatively, there are those that argue that overexpression of
PrPc increase Aβ plaque production. Lara Ordonez-Gutierrez et
al (2013) disregard the evidence that suggest that PrPc directly inhibits Aβ production by altering the activity of BACE1.They state
that most of these tests were performed in cell cultures while
studies involving older animals showed no change in the expression of BACE1 in regards to PrPc concentrations. Furthermore,
in vivo experimentation conducted by Ordonez-Gutierrez et al
(2013) discovered that older animals that expressed a high level
of PrPc expression also illustrated a high level of Aβ deposits
with no significant consequence on BACE1 levels. They speculate
that since BACE1 levels stay the same while Aβ deposit levels
increase, perhaps this surge in plaque formation is a result of
increased protein degradation and/or production via an alternate
pathway involving PrPc.
Its been suggested that a divergent reasoning for the accumulation of Aβ deposits in patients with a high PrPc expression.
They explain, given the fact an unaltered expression of PrPc is
observed during the pathology of prion disease, it is unlikely prions are the cause for Aβ accumulation in specific sCJD patients.
Being that the aggregation of misprocessed proteins is caused by
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the differences between de novo generation and its elimination, it
is a possibility that the increased levels of Aβ deposits in sCJD are
a result of a saturation of common clearance mechanisms. This
is validated by studies that show a similar clearance mechanism
is in place for both PrPsc and Aβ. Furthermore, in a group study
of sCJD patients, individuals who exhibited high levels of Aβ-42
showed little deposits of PrPsc while individuals with high levels
of PrPsc had low amounts of Aβ-42. The correlation between
Aβ-42 and PrPsc concentrations clearly indicates a shared mechanism between the two (Debatin, et al., 2008).

cortical degradation of the two disorders (Armstrong, Lantos, &
Cairns, 2005).” With all of these similarities, including the ones
mentioned earlier, it is hard to deny the correlation between
these two neurodegenerative diseases.

There are also reports discussing a few intriguing similarities
between AD and CJD. Both AD and CJD are characterized by
their peptide aggregations resulting in plaques; Aβ in AD and
PrPsc in CJD. Additionally, the authors explain how AD and CJD
can coexist in the same individual and that the Aβ and PrPsc
plaques in sporadic AD and sCJD share a similar spatial distribution throughout the brain, “suggesting a consistent pattern of
Figure 3

innervation to the spinal cord and brain (Figure 3). Cashman and
Caughey point out that replication of these prions occur in locations accessible to immunotherapy and antibody neutralization.
Due to the pathogenic pathway observed in vCJD, it is a possibility to artificially induce an autoimmune response against prions
affecting its replication. This can effectively slow down or block
pathogenesis of the disease. It has been illustrated in studies that

Villus

Possible Treatments for CJD
In persons with vCJD, it was observed that when ingested orally,
infectious prions aggregated towards gut-assisted lymphatic tissue and the spleen (Cashman & Caughey, 2004). From this location, the prions are transported via splanchnic
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Possible spread of scrapie infectivity from the gut lumen to the nervous system following oral infection (route indicated by dotted line). Soon after ingestion,
the abnormal prion isoform (PrPSc) is detected readily within Peyer’s patches on follicular dendritic cells (FDCs), within macrophages, within cells with
morphology consistent with that of M cells and within ganglia of the enteric nervous system (ENS).These observations indicate that, following uptake of
scrapie infectivity from the gut lumen, infectivity accumulates on FDCs in Peyer’s patches and subsequently spreads via the ENS to the central nervous
system. FAE, follicle-associated epithelium. © Elsevier Ltd (2000). (Cashman & Caughey, 2004)
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antibodies targeted against PrPc, cleared cells that were scrapie-infected with PrPsc in vitro. However, in vivo, antibodies targeted against normal PrPc can have adverse effects since these
cells in their non-pathogenic configuration are detrimental to
normal neurological function. The autoimmune response to PrPc
can prompt complement-dependent lysis in many cells disrupting
normal function leading to apoptosis in the brain. It is entirely
possible for an induced antibody response to reduce the immunological tolerance of PrPc with the subsequent induction of an
autoimmune disease (Cashman & Caughey, 2004).
Often when a protein misfolds causing pathology, a sidechain
of peptides that originally was sequestered within the molecule
becomes exposed providing a means of distinguishing between
pathogenic and non-pathogenic conformational isotopes. This
specificity can aid in devising a means of targeting PrPsc alone
without affecting the normal PrPc. The therapeutic potential of
this approach is immense with the benefit of leaving non-pathogenic proteins unharmed (Paramithiotis, et al., 2003).
There are several chemical inhibitors of CJD progression in vitro.
Cyclic tetrapyrroles have been shown to slow the progression of
scrapie in mice; however, this was only if treatment began immediately after infection due to its inability to cross the BBB. Other
tetrapyrroles that do cross the BBB could prove to be efficacious
further in the stages of infection. It is believed that cyclic tetrapyrroles inhibit PrPsc by direct interaction with the protein.
Polyene antibiotics and dimethlysulphoxide are also thought to
inhibit PrPsc pathology. Polyene antibiotics target prions while
dimethlysulphoxide helps reduce accumulations and excretion of
PrPsc. Unfortunately, no chemotherapeutic drug has been shown
to significantly alleviate the pathology of CJD once clinical symptoms are present (Cashman & Caughey, 2004).
Several other therapies have been suggested for CJD treatment.
One is through gene therapy via a lentiviral vector-mediated
RNA interference (RNAi). A lentivirus is a genus of viruses that
can be modified to implement specific genes within a host’s genome or silence others. This is achieved through short hairpin
RNAs (shRNAs) that can silence select genes. A study conducted
with scrapie-infected neuronal cells that involved shRNAs that
suppressed the PrPc gene, PRNP, showed an efficient suppression
of PrPsc aggregation. Mice infected with lentivirues with shRNAs
showed a reduced expression of PrPc and an extended lifespan
of those infected with scrapie. Although further testing needs to
be done, a lentiviral vector-mediated RNAi appears to be a valid
approach for the treatment of CJD (Pfeifer, et al., 2006). However,
reducing PrPc expression may hinder CJD pathogenesis but it
may also contribute to various adverse effects. additional research will need to be conducted to attain a viable solution to
these concerns.

Another suggested therapy is by the use of antihistamines, specifically astemizole. Experiments involving astemizole indicated that
it prolonged the lifespan of scrapie-infected mice. Additionally,
astemizole has the capabilities of crossing the BBB making it a
favorable drug for the treatment of CJD. Except for a rare case of
heart arrhythmia, astemizole is an over-the-counter drug that is
relatively safe in recommended doses. It is theorized that astemizole’s antiprion properties arises from its activity on autophagy,
which is the degradation and recycling of cells and proteins. It
is suggested that individuals containing mutations in the PRNP
gene and who are genetically susceptible to CJD should take astemizole regularly as a preventative measure against disease. The
effects of astemizole on autophagy could provide new methods
for treating other neurodegenerative diseases (Karapetyan, et al.,
2013).

CJD treatments vs AD pathology
Can several potential treatments for CJD be administered or
modified to treat AD? AD is associated with the accumulation of
abnormal proteins (Aβ and/or Tau proteins). It is possible to target these molecules via an induced autoimmune response such
as that observed in CJD treatments (Cashman & Caughey, 2004).
However, this can initiate a negative cascade in which the body
targets normal functioning Aβ or Tau proteins resulting in cell
lysis and the reduced immunological tolerance towards normal
cells causing autoimmune disease.
Abnormal proteins are often accompanied by the exposure of a
previously sequestered side chain. This side chain can be used to
target pathogenic proteins alone without interfering with normal function. These findings can be applied to AD in treating Aβ
and Tau fibril accumulations. Although further experimentation is
needed to produce a safe autoimmune induced treatment, this
can be a viable method to combat AD pathology (Paramithiotis,
et al., 2003).
Lentivector-mediated RNAi can be used to treat AD as well.
ShRNAs that repress specific gene expression could be used to
suppress a faulty gene that causes pathology. For instance, if an
individual has two genes coding for a molecule involved in the
pathogenic AD pathway with one of the genes corrupted and the
other in its normal function, shRNAs can be utilized to silence
the faulty gene’s expression without affecting the normal one.
However, Lentivector-mediated RNAis can suppress the function
of both normal and faulty genes causing unwanted adverse effects
(Pfeifer, et al., 2006). This prototype treatment for CJD can ultimately be utilized to treat other disorders such as AD.
Direct modification of PrPsc/PrPc levels is another option for
AD treatment.With a theorized mechanism correlation between
PrPc and Aβ proteins, it is possible to indirectly treat AD by
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inducing prion production. For instance, Hooper and Turner believe that PrPc regulates Aβ levels by inhibiting enzyme catalyzed
cleavage of APP to Aβ-40 and Aβ-42. The greater the PrPc levels,
the lower the levels of Aβ in the body. If a patient has AD due
to high levels of Aβ, according to Hooper and Turner (2008), it
should be possible to reduce these levels by increasing expression of PrPc production (see figure 4). Ordonez-Gutierrez et al
(2013) argue that increased levels of PrPc increase Aβ plaque
formation. This suggests that reducing PrPc concentrations is the
viable method in treating Aβ aggregations in AD. More data has
to be obtained to procure the exact mechanism between PrPc
and Aβ. It seems that both Hooper and Turner and OrdonezGuiterrez et al agree that a related mechanism exists between
the two proteins, it is the effect one has on the either that is
in question. Either way, understanding how these two molecules
interact can be important in treating either of these two neurodegenerative disorders. Prion diseases can offer scientists a
prototype on the processes of other neurological disorders such
as AD (Cashman & Caughey, 2004).

Possible treatments for AD
Currently, AD patients are treated with two different types of
drugs, either acetylcholinesterase inhibitors or memantine.
Acetylcholinesterase inhibitors act by increasing cell-to-cell
communication chemical levels that were diminished during AD
onset. This is accomplished by inhibiting enzymes that facilitate
the breakdown of acetylcholine, a neurotransmitter found within the brain. Progression of symptoms is usually maintained for
Figure 4
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The role of the prion protein in Alzheimer’s disease prevention: In the amyloid
cascade hypothesis of AD, a genetic mutation (for example, in the genes
encoding APP or the presenilins), ageing or some other environmental trigger
(e.g. oxidative stress) causes an accumulation of the neurotoxic Ab peptide,
which aggregates to form the characteristic amyloid (senile) plaques found
post-mortem in the brains of AD patients.Through mechanisms that are
poorly understood, the increased levels of Ab peptides, particularly oligomeric
and fibrillar forms, cause neuronal cell death and dementia. The normal
cellular form of the prion protein, through inhibiting the production of the
Ab peptide, might help to prevent the development of AD (Hooper & Turner,
2008).
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a time before AD pathology continues to worsen. Memantine
works via a different pathway within the brain, slowing the development of symptoms relating to AD. The mode of action for
memantine is to target and inhibit NMDA receptors which has
shown to improve cognitive function compared to a placebo.
Unfortunately, medication only forestalls pathology since there is
no cure for AD (Gotz, Ittner, & Ittner, 2012) (Eubanks, et al., 2006)
(Mayo Clinic Staff, 2014).
Research into the immunization against Aβ showed promising
results. Mice immunized with Aβ-42 showed reduced Aβ burden
and preserved cognitive function. In an interrupted clinical trial,
patients who were injected with one, two, or three immunizations of Aβ-42 showed decreased levels of tau proteins with
postmortem reports of diminished Aβ in the neocortex.The trial
was interrupted because 6% of the patients developed meningoencephalitis (Gilman, et al., 2005). Using natural anti- Aβ antibodies derived from healthy humans may provide a better method
in reducing adverse effects such as encephalitis in patients (Sardi,
et al., 2011). Although the clinical trial was suspended, immunotherapy seems to be a viable method in treating AD (Gilman, et
al., 2005).
In a recent pharmaceutical study, a monoclonal antibody aimed
at Aβ named Bapineuzumab was intravenously administered for
78 weeks. It was found that there was a diminished phosphorylated tau along with a reduced accumulation of Aβ in the brain
of AD individuals carrying the pro-pathological gene, ApoE ε4.
These findings show promise in the treatment of AD through reductions of plaque buildup. Interestingly, these reductions of the
disease-inducing molecules were not able to forestall the rate of
pathological progression in the disorder. One suggested hypothesis is that Bapineuzumab was administered too far along in the
AD pathology. To remedy this concern, the drug would have to
be administered before the appearance of clinical symptoms.This
poses an issue since it is extremely difficult to diagnose a patient
before symptoms appear; however, it may be able aid those who
are high risk for AD. Another hypothesis is the actual pharmaceutical mechanism of the drug. As of yet, Bapineuzumab does
not target phosphorylated tau that aggregated into neurofibrillary tangles, another hallmark of AD (Cedernaes, et al., 2014).
While further study is needed to improve the efficaciousness of
antibodies against AD, immunotherapies are strong contenders in
discovering a feasible treatment for neurodegenerative diseases.
Non-steroidal anti-inflammatory drugs (NSAIDs) have been
shown to be a preventative measure for AD. There are reports
that suggest that BBB degradation plays a central role in AD.
As the BBB degrades, many previously unwanted molecules
cross into the fluid surrounding the brain possibly eliciting a response of inflammation. Inflammation can further increase the

Creutzfeldt - Jakob and Alzheimer’s Diseases: Overlap of Treatment Methods?

permeability of the BBB allowing circulating Aβ to enter the brain
where it can start a degenerative and inflammatory process.
NSAIDs are drugs that reduce pro-inflammatory responses in
the body. Studies have shown that patients who were medicated
with NSAIDs over a long period of time exhibited a reduced
incidence of AD. This indicates the presence of pro-inflammatory
molecules in the pathology of AD (Sardi, et al., 2011).

may be an alternative route in AD treatment. Studies involving
an induced increase in metabolic activity by administering a concoction of glucose and several Krebs cycle intermediates into
patients showed an increase in cognitive function with less neurodegeneration. Improving a deficient mitochondrial spiral may
prove to be effective in treating AD (Blass, 2001).

AD treatments vs CJD pathology
Many therapies for AD focus on ameliorating Aβ levels in the
brain without much focus on tau proteins concentrations.
Treatments aimed at pathogenic tau proteins produced reasonable results. Abnormal tau proteins are phosphorylated versions
of the normal tau form. One method of treatment is to inhibit
this phosphorylation. Administered lithium chloride inhibited glycogen synthase kinase-3, an enzyme that catalyzes the transfer
of a phosphate group onto other molecules, and reduces the
levels of hyperphosphorylated tau, insoluble tau, and behavioral
impairment in various mice models. Inhibition of other kinases
also showed promising results. Furthermore, immunization with a
tau phospho-peptide prevented pathology in tau transgenic models with no apparent adverse effects (Gotz, et al,, 2012). With the
promise of tau directed therapies, it is worthwhile to formulate
treatments involving both Aβ in conjunction with tau proteins.

With AD and CJD sharing many pathological pathways, it seems it
may be possible to treat CJD via techniques previously reserved
for AD. Acetylcholinesterase inhibitors that reduce the enzymatic degradation of acetylcholine perhaps can be used to alleviate
symptoms of dementia found in patients with CJD (Cummings,
2000). With the increased levels of the neurotransmitter acetylcholine in vivo, there can be an increased level of cell-to-cell
communications within the brain possibly easing several cognitive
symptoms. However, inhibition of this enzyme is most likely not a
viable method of treatment for there is little research conducted
on the effects of acetylcholinesterase inhibitors on CJD. There is
some evidence that memamtine, another drug used to treat AD,
Figure 5

ROS

The active component of marijuana, ∆9-tetrahydrocannabinol
(THC), appears to also be an efficacious and viable method in
the treatment of AD. THC competitively inhibits the enzymatic protein acetylcholinesterase which catalyses the breakdown
of acetylcholine. It is believed that acetylcholinesterase is a key
component in the pathological progression of AD by inducing
Aβ plaque formation. THC effectively inhibits this enzyme, reducing the degradation of acetylcholine transmitters in the brain
while simultaneously diminishing Aβ plaque formation. This treats
both the progression and the symptoms of the disease. THC is
a superior inhibitor of acetylcholinesterase as opposed to other
acetylcholinesterase inhibiters that are currently used to treat
AD. Additionally, THC appeared more effective with only half the
dosage compared to these other medications. (Eubanks, et al.,
2006).

has some inhibitory effects towards PrPsc (Muller, et al., 1993).

The treatment of metabolic deficiency is another suggested alternative in treating AD. An abnormality in the energy metabolism, calcium metabolism, or free radical pathways showed to
contribute to deficiency within the other two metabolic routes
creating a “mitochondrial spiral”. This spiral forms a negative cascade effect where the defects of one metabolic pathway continue
to degrade other pathways which in turn further damage the
original faulty pathway (see figure 5). It is thought that mitochondrial spiral causes abnormities in the metabolism of the APP
and the segments of Aβ it produces. It may also be a proximate
reason for clinical debilities found in AD. Ameliorating the spiral

Immunizations for CJD have been thought of as a method of
treatment as well. Similar to AD, antibodies targeted against proteins associated with CJD have showed some promising results.
However, being that adverse effects were found with immunizations, research has to be done before it is safe for public use as
a treatment for CJD (Cashman & Caughey, 2004). NSIADs have
been suggested as a treatment for CJD. Inflammation has been
associated with both AD and CJD. In contrast to AD, there is
little data available on the effectiveness of NSAIDs on CJD. In
vivo studies showed that NSAIDs may have some effect on prion
pathology, nevertheless, experiments using patients showed

Energy
insufficiency
Ca++
The mitochondrial spiral. Impairments of energy metabolism, alterations in
cellular calcium homeostasis, and excess free radicals (ROS) interact with
each other in mitochondria; inducing any one of them leads to abnormalities
in the other two.The interaction can set up a deleterious, downward cycle
(Blass, 2001).
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disappointing results. It is possible that the NSAIDs were given
too late in the disease pathogenesis. Further study is needed to
determine if antiinflammatory drugs are a suitable treatment for
CJD (Eikelenboom, et al., 2002).
Treatment of the “mitochondrial spiral” may play a role with individuals with CJD. In regards to AD, it was found that a deficiency
in one of three different metabolic pathways can cause deficits
in the other two creating a mitochondrial spiral. Attempts to
alleviate the stress on this spiral showed to improve cognitive
symptoms in patients (Blass, 2001). In CJD, some studies show
oxidative abnormalities plays a role in pathogenesis (Petersen, et
al.).This can cause defects in one of the three metabolic pathways
mentioned earlier. Alleviating these deficiencies may be a viable
venue of treatment. It should be mentioned that other studies
found no role of oxidative stress in CJD (Bleich, et al., 2000).
Further study is needed on the topic to fully understand the
effects of the mitochondrial spiral on disease pathogenesis.
It was suggested that it is possible that Aβ contributes to CJD
pathology. It has been hypothesized that Aβ exacerbated the disease process by possibly accelerating the pathology (Hooper &
Turner, 2008). If this hypothesis proved to be correct, any treatment formulated towards AD can in turn be prescribed for the
mitigation and delaying of symptoms in CJD. Additionally, it was
found that the other protein linked with AD, tau proteins, were
associated with prion pathology (Han, et al., 2006). As additional
experimentation is required to determine the exact impact of
one protein on the other, treatments made to diminish tau pathology may ameliorate symptoms of CJD. These hypothesized
venues of remedy will not cure prion pathology but can most
likely hinder CJD neurodegenerative impacts on the brain. The
correlation between these two diseases is too strong to suggest
otherwise. Furthering research into understanding CJD is a viable method of ascertaining a feasible treatment for the growing
epidemic that is AD.

Conclusion
AD and CJD are both neurodegenerative disorders that share a
common pathophysiological mechanism. PrPc and Aβ, proteins associated with pathology in CJD and AD respectively, are believed
to interact with each other. There is a slight debate whether they
interact directly by contact or indirectly by affecting enzymatic
proteins, such as BACE1. Additionally, there is an argument how
they influence each other in regards to inhibiting/promoting pathology; for example, does PrPc induce or inhibit Aβ aggregations
that cause pathology? Either way, there is a strong correlation of
pathologies that most scientists agree with. It is this connection
that helped researchers discover new and creative treatments
for AD and CJD. Treatments that were previously reserved for
either disease are now being tested against the other. This is
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enhancing the understanding of the mechanisms of each ailment,
bringing researchers one step closer to discovering a cure for
both neurodegenerative diseases. Perhaps, discovering the means
of pathologies for AD and CJD will lead to cures for many other
forms of dementia.

Abbreviations
AD – Alzheimer’s Disease
ApoE - Apolipoprotein
APP – β-Amyloid precursor protein
Aβ – Amyloid-β protein found in excess amounts in patients with
AD
BACE1 - β-CITE APP Cleaving Enzyme-1
BBB - Blood Brain Barrier
CJD – Creutzfeldt – Jakob Disease
EOFAD – Early-Onset Familial Alzheimer’s Disease
LOAD – Late-Onset Alzheimer’s Disease
MAP - Microtubule-Associated Protein
NSAIDs - Non-steroidal anti-inflammatory drugs
POPG - 1-Palmitoyl-2-oleoyl-phosphatidylglycerol
PrPc – The normal form of a prion protein
PrPsc – the abnormal variant of a prion protein associated with
CJD
RNAi - RNA interference
sCJD – Sporadic Creutzfeldt-Jakob Disease
shRNAs - Short Hairpin RNAs
THC - ∆9-Tetrahydrocannabinol, the active component in
marijuana
TSE - Transmissible spongiform encephalopathies
vCJD – Variant Creutzfeldt-Jakob Disease
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Abstract
Baseball is currently the fourth most popular sport in high schools across the country. However, pitchers are at a high
risk to develop career ending injuries. Overuse can result in SLAP tears as well as torn rotator cuff muscles that can end
a dream of pitching professionally. Major League Baseball has teamed up with leading sports medicine researchers to determine safe pitch-count guidelines for pitchers of all ages. Articles were found using Touro’s e-Journal database as well as
Pubmed.gov to find pertinent research on this topic. Studies on ball velocity and scapular kinematics were done on three
different levels of pitching. Data showed that over time fatigue sets in and pitching mechanisms change. It is important for
pitchers to realize this and to act in a safe manner.
Introduction

Methods

Baseball,America’s Pastime, is a sport enjoyed by men and women
of all ages. The look of joy on a young child’s face when receiving his first baseball glove is testament to the love of the game.
Who doesn’t remember going to their first baseball game? The
glamour of the game as well as the part time relaxation of lazing
around in the field allows for baseball and softball to be among
the most popular sports for adolescents in the United States.
A survey from the National Federation of High School Athletes
(NFHS handbook) found in the 2013-2014 academic year, that
a total of 15,789 schools listed baseball as a sport of choice for
men (behind basketball and track), with 541,054 students participating (behind football as well). Fast pitch softball for females
was listed as the fourth most popular sport as 15,225 schools
list it as a sport (behind basketball, track, and volleyball), with
364,297 students participating (behind soccer as well). However,
contrary to popular belief, as well as studies classifying baseball
as a safe sport, baseball and softball are not without their fair
share of injuries. Although not as prevalent or life threatening as
football injuries can be, the results can be season ending, or at
times, even career ending. A study done by Conte et al. (2001)
on Major League pitchers has shown that 57% of pitchers suffer
from a shoulder injury during a season. The study also showed a
growth in injury occurrences over an 11 year period from 1989
to 1999. Estimates of injury rates for youth (ages 9-14) are a 5%
risk of serious arm injury (shoulder or elbow) within 10 years
(Littleleague.org).

Journal articles were found by searching the terms “pitcher
fatigue causes”, “pitch-count”, and “fatigue related injuries”.
Articles were accessed using the Touro Library databases of
EBSCO, ProQuest, and Sage Premier Collection. As the topic is a
sports medicine related issue, the index of The American Journal
of Sports Medicine was utilized as well. Search terms were later
refined to specify shoulder injuries and pitching biomechanics. A
final method of research was an interview with a biomechanical
shoulder researcher at the Hospital for Special Surgery (HSS).

Pitching Biomechanics
Biomechanical studies have determined that the arm is not the
Figure 1

(b)

(a)

(d)

(c)

(e)

Pitch-count Recommendations
As a result of such injury rates there has been an increasing emphasis on the pitch count during a game, as well as cumulative
pitch count throughout the season. Pitch count is more strongly
enforced in younger populations due to concern over how the
repetitive stress that occurs with pitching alters both structural
as well as functional mechanics of the young shoulder complex.
Arm pain is common in youth pitchers with studies showing that
risk of pain increases after 75-80 pitches per game (Lyman et al
2002). This has led to recommendations by little-league baseball
for the following daily pitch maximums: ages 7-8, 50; 9-10, 75; 1112, 85; 13-16, 95; and 17-18, 105

(f)

(i)

(g)

(j)

(h)

(k)

Sequence of Motion in Pitching (Dillman et al 1993)

79

Alexander Malek

only body part involved in pitching. A pitch can be split into 6
separate sections: wind-up, stride, arm-cocking, arm acceleration,
arm deceleration, and the follow through (Dillman et al 1993),
with the upper and lower limbs working in tandem for a proper
pitch.
For purposes of this paper the focus will be on the shoulder, but
details from other locations are needed in moderation. During
the windup stage the pitcher takes a step backward with the
front foot, or stride foot.As the pitcher begins, he rotates 90° and
slowly lifts, elevates, and flexes the stride leg. The stride stage follows with the other leg slightly flexing, and the stride leg moving
toward the catcher. This phase is most important to a safe pitch,
as a key element is to control proper trunk location to contribute to a pitch. If the trunk is not as back as possible it would affect
the pitch velocity. Additionally, the landing spot of the stride leg
contributes to hip rotation which will interfere with the contribution of the trunk to the pitch. As the hips start to rotate, the
arm is flexed at the elbow, and the shoulder undergoes maximum
external rotation (arm-cocking stage). The humerus then internally rotates along the glenoid as the arm accelerates toward the
plate. During the release of a pitch the scapula rotation goes from
a maximum of 178° to 105° in approximately 0.029 seconds. It is
important to note that a decrease in lower extremity force will
often result in either a decrease in momentum or an increase in
upper extremity force leading to injury.
To date there have been three studies that compared ball velocity
and shoulder kinematics over the duration of a game. Murray et
al (2001) studied major league pitchers, Escamilla et al (2007) collegiate, and a recent yet to be published study from HSS, studied
high school pitchers. Each study has advantages over the other,
with specific revelations into pitch-count related injuries.

Major League Pitchers
Murray et al (2001) was the first attempt to compare pitch velocity
and pitcher kinematics over a period of time. They studied 7 pitchers (mean age 26) during spring training. 5 pitchers pitched for 5
innings with 2 pitching for 7. Cameras were placed in three different
locations of the stadium to capture different angles of the pitcher. A
computer program was used to manually digitize 20 different landmarks to compare over time.The program compared a fastball from
the first inning as well as one from the last inning pitched.

Collegiate Level Pitchers
Escamilla et al (2007) chose a slightly different approach to study
fatigue. They studied 10 Division I collegiate baseball pitchers with
a mean age of 20. Each pitcher threw 15 pitches per “inning” with
a rest period in between to simulate an actual baseball game. Five
pitchers pitched the entire 9 innings (135 pitches), 2 pitchers pitched
8 innings (120 pitches), and 3 pitchers pitched 7 innings (105 pitches).
Along the lines of a simulated game, the catcher called for a variety
of pitches-not just fastballs. At the end of each inning pitchers were
asked to scale their level of fatigue. Kinematic data were recorded
using reflective markers on the pitcher to be studied using motion analysis software (more accurate than video markers used by
Murray et. al). (2001)).
Although pitch velocity decreased from the first inning to the last,
the only significant kinematic difference was trunk position, as the
trunk was more vertical at the end than the beginning. This led
Escamilla et al. to conclude that there cannot be a specific amount
of pitches that determine fatigue and therefore injury. They hypothesized that in real game scenarios there are more than 15 pitches
during some innings, as well as an increased level of motivation that
may lead to harder throws.

High School Pitchers
A recent study from HSS (unpublished data) focused on young
adults (average age was 15) during a simulated game. Participants
were initially tested for range of motion in three different positions:
45° internal rotation, 0°, and 45° external rotation.After the average
peak torque was determined the pitching sequences began. Once
warmed up, the pitchers threw 90 fastballs in 6 sets (1 set = 15 pitches) with five-minute breaks between sets to simulate a game length
situation. After the completion of the innings, participants were retested for range of motion. Kinematic data was recorded using the
same method as Escamilla et al but with one major addition. They
used a specialized scapula marker for more exact scapula tracking.
Figure 2

They observed significant changes in the maximum external rotation
angle of the shoulder as well as a decrease in ball velocity.A decrease
of an average of 9° was noted with a 5 mph drop in velocity.Although
fatigue is the probable cause for these discrepancies, the possibility
of protective measures taken by the pitchers cannot be ruled out.
Average normalized pitching speeds across sets (unpublished data).
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Although each pitcher threw with different velocities, normalized
data showed that the second set of pitches were thrown the
fastest, with the fifth and sixth being the slowest (Figure 2).
Isometric strength tests demonstrated decreased internal (19%26%) and external strength (13% to 16%) for neutral and 45°
internal rotation testing positions. No significant differences in
strength were detected when participants were tested in 45° of
external rotation.
Kinematic measurements at five pitching events (foot contact,
maximum external rotation, release, and maximum internal rotation) revealed significant changes in scapulothoracic measures at
maximum internal rotation. There was a 3.8° decrease in scapula
backward tilt in set 6 compared to both sets 1 and 2 and scapula
elevation increased by 3.6° in set 6 when compared to set 1.
Abnormalities in scapula kinematics with increased scapula elevation are very common for symptomatic shoulders with possible
rotator cuff tears.
This study shows that even before a pitcher feels fatigued, there
is a drop in strength and velocity. Although no one complained
about feeling fatigued when questioned, there were clear indications of muscular fatigue amongst the athletes, which was reflected in the reduction of the arm rotational strength and the
decrease in ball speed between sets 2 and 6.

Discussion
There are only a few studies that have examined baseball during
an extended number of pitches to investigate how fatigue affects
upper extremity kinematics. Escamilla et. al. (2007) defined fatigue as the point at which the athletes could no longer continue
pitching due to a subjective perception of muscular fatigue. This
resulted in a variable number of pitches for each athlete that
ranged from 105 to 135 pitches (7 to 9 innings). Although the
subjects in that study didn’t report fatigue, the rotational isometric strength post pitching in the HSS study clearly showed that
the subjects experienced muscular fatigue during the simulated
game of 90 pitches. The difference may be attributed to the higher age and level of competition of collegiate participants as studies have demonstrated that there are great differences in pitching
kinematics between different levels of competition (high school,
college, major league) (Fleisig 2009). An advantage in Escamilla’s
study over previous research was the introduction of an artificial
game, allowing researchers to more accurately measure shoulder
kinematics. However, this also opens a possibility of lack of effort
on behalf of the pitchers leading to inaccurate data.
The advantage for Escamilla is a disadvantage for Murray et. al
(2001). Since Murray was analyzing major league pitchers in real
game scenarios, (albeit spring training) the actual motion capture

can be inaccurate. However, a major clinical advantage was the
conclusion of minimal kinematic variability as changes in external
rotation can be attributed to protective measures. This shows
that there is hope for young pitchers. Proper strength and conditioning, as well as being coached in proper mechanics can minimize injury risk to pitchers.
The study from HSS was advantageous in not letting pitchers
wait until they felt fatigued, or let them complete a simulated
game. Their research shows how fatigue affects strength and velocity before the pitcher realizes it. Add the fact that the study
was done in a meaningless simulated game, and one can see the
probable effect during a game. However, a major disadvantage
was the type of pitch allowed. They only allowed fastballs which
does not accurately portray real-life scenarios.
Muscular fatigue was also reflected in the ball speed results, as
all three studies revealed a decrease in ball velocity from start to
finish. This is to be expected as when one overworks any muscle
there tends to be fatigue. However, the main implications are not
just the ball velocity. Lyman et al (2001) surveyed a little league
over the course of a season. Careful pitch counts were collected
and players were interviewed at the end of each game, as well
as the end of the season regarding pitch type and injuries. The
results of the study led Lyman et al to recommend a maximum
of 75 pitches per game as mentioned above. Interestingly enough,
they also found that the more a person pitched the lower the
risk of injury. This is due to lack of experience when it comes to
pitchers, or possibly lack of conditioning. However, more than
600 pitches a season led to elbow pain as well, so that should
be avoided.
Fleisig et al. (2011) added to this study by linking pitch type
and amount to injury frequency. The American Sports Medicine
Institute concluded that the players who pitched more than 100
innings in at least 1 calendar year had about 3.5 times as much
chance of serious injury as those who pitched less. They also
recommended not starting to throw curve-balls before the age
of 13, to take a break of 2-3 months annually, and not to pitch on
consecutive days (American Institute of Sports Medicine, 2013).
However, subsequent reports have found that a large percentage
of youth pitchers do not follow these guidelines (Yang et al. 2014).

Specific Injuries
During the release of the ball the shoulder goes from 178° to
105° in approximately 0.029 seconds.This quick motion can cause
the greater tuberosity to come near the acromion. Unfortunately,
the biceps tendon or supraspinatus (rotator cuff) can get caught
in between. Impingement pain is easily treated with rest and physical therapy (Hawkins 1980).
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The sudden interior rotation of the humerus also leads to biceps
tendinitis, or a frayed long head of the biceps tendon. Although
this injury alone can be treated surgically, it is also treated with
rest and therapy. However, a frayed biceps is the start of a cascade
of injuries. If the biceps gets frayed or torn the shoulder loses
some stability. When the shoulder loses some stability it applies
stress on the labrum. This leads to tears in the superior part of
the labrum an injury called a superior labrum anterior and posterior, or SLAP, tear. Instability can also lead to torn rotator cuff
muscles, specifically the supraspinatus. Both SLAP tears and torn
rotator cuff muscles require surgery to fix.

39(2):253-7.
Hawkins RJ, Kennedy JC. Impingement syndrome in athletes. Am J Sports
Med. 1980;8(3):151-8.
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Lyman S, Fleisig GS, Andrews JR, Osinski ED. Effect of pitch type, pitch
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Conclusion
Literature has shown a correlation between high pitch-counts
and shoulder injuries. Although pitchers may think they are not
fatigued, this has been shown to be false. Younger pitchers, who
are not yet developed, both physically and in pitching mechanics,
are at a higher risk for injury. This has led the American Sports
Medicine Institute together with Major League Baseball to institute guidelines for young pitchers.
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Abstract
Neurodegenerative motor neuron disorders (MNDs) have devastating effects. Spinal Muscular Atrophy (SMA), for example, is a debilitating and sometimes lethal disease in children. SMA is monogenic, autosomal recessively inherited disorder
caused by a loss-of-function mutation of surviving motor neuron 1 (SMN1). SMN2 is an identical copy of this gene and
produces abbreviated transcripts without exon 7 though some full transcripts are produced that ameliorate the disease.
Previous clinical trials for this disease have not produced consistent results. However, in a recent cross-sectional study,
biomarkers for SMA (BforSMA), protein candidates and metabolite markers were identified (Finkel et al., 2012). These
markers can be used for clinical assessment, identification of molecular pathways, and may guide response to treatment.
Clinical trials of amyotrophic lateral sclerosis (ALS), another motor neuron disorder, have been uniformly disappointing
without the benefit of a full understanding of ALS’s mechanisms. Numerous theories attempt to explain ALS’s selectivity
for motor neuron degeneration, but none are conclusive. One hypothesis, gem depletion, emerges from the studies of
superoxide dismutase 1 (SOD1) transgenic mice that have been discovered to contain low levels of SMN, thereby potentially linking SMA and ALS. Furthermore, SMN1 and SMN2 are seen as risk factors for ALS (Andersen & Al-Chalabi,
2011). Biomarker identification may also help in identifying ALS’s pathogenesis and pathophysiology as it has begun to do
for SMA. ALS and SMA may be more similar than previously thought. Both MNDs may interact in a variety of genetic and
mechanistic pathways unknown at present. If so, this may serve to link seemingly disparate crippling diseases, and thereby
promote efforts by government agencies and pharmaceutical companies to pursue research and development for these
“orphan” diseases.
Introduction
Progressive muscular atrophy (PMA) was first described in 1848 by
F. A. Aran, who reported 11 cases of weakness and paresis of the
upper limbs (Bonduelle, 1989). However, it was not until 1869 that
French neurologist Jean-Martin Charcot classified amyotrophic lateral sclerosis (ALS) as a separate neurodegenerative motor neuron
disorder (MND) from PMA. It was not until 1874 that ALS was given
the name of amyotrophic lateral sclerosis in Dr. Charcot’s “Oeuvres
Completes.” In his earliest studies, he noted that, “lesions within the
lateral column in the spinal cord resulted in chronic progressive paralysis and contractures (no atrophy of muscles), while lesions of
the anterior horn of the spinal cord resulted in paralysis without
contractures (with atrophy of muscles)” (Goetz, 2000). ALS shares
many clinical symptoms to other MNDs such as: spinal muscular
atrophy, primary lateral sclerosis and bulbar palsy. The key to ALS’s
understanding was due to Dr. Charcot’s unique method known as
“anatomo-clinical method.” Using this technique he was able to determine the correlation between clinical signs detected during life
and anatomical lesions seen at death. Furthermore, post-mortem
studies revealed both the anterior horn cell lesion typical of acute
amyotrophy, and also the distinctive bilateral and symmetric sclerosis
of the lateral spinal cord columns. Hence, he named the syndrome
ALS, since it incorporated the two aspects of gray matter involvement (amyotrophy) and white matter damage (lateral sclerosis). Dr.
William Gowers, though, argued with Charcot’s terminology since
it suggested that lateral sclerosis was primary and amyotrophy was
secondary, and instead, postulated they are one event (Goetz, 2000).
This is still debated over a century later.
ALS is an incurable disease that has an incidence of approximately
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2 in every 100,000 people.The mean age of onset for ALS is 55-60
and affects men more than women. No diagnostic test exists for
ALS. Physicians only diagnose ALS when both upper and lower
motor neurons are affected and after ruling out all other causes
. At first, one may notice weakness in an arm or leg, described as
“limb onset” of ALS, or difficulty with speech production, known
as “bulbar onset” ALS, which quickly spread to other parts of the
body. Eventually, all limbs and movement cease, leading to complete paralysis. Since ALS shares several common symptoms with
spinal muscular atrophy and other neurological conditions, several tests are required to diagnose. Presently, the only tests, aside
from limited genetic testing, vary from electromyography (EMG)
and nerve conduction study (NCS) to magnetic resonance imaging (MRI). After all these tests are performed, physicians still may
not know until later stages of the disease.
Presently, the cause of ALS is unknown. Some research points
out that ALS results from inaccurate protein formation. Other
research demonstrates there is an excess of glutamate in the synapses causing neurite toxicity. Still other research shows changes to RNA processing. A fourth theory suggests environmental
factors since U.S. military personnel in the Gulf War had higher
incidence of developing ALS (Haley 2003).
Genetic mutations in ALS are numerous, for instance, superoxide dismutase 1 (SOD1), chromosome 9 open reading frame 72
(C9orf72), TAR DNA-binding protein 43 (TDP-43), senataxin
(SETX) and fused in sarcoma (FUS) are a few of the growing list
of genetic mutations associated with ALS. In contrast, spinal muscular atrophy (SMA) has only one genetic mutation in survival
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motor neuron 1/2 (SMN1/2). SMA shares some common features with ALS, such as lower motor neuron degeneration, gem
depletion and possibly biomarkers.
ALS and SMA share a biochemical pathway in gem depletion related to each disease’s respective genetic mutation (TDP-43 and
SMN) (Yamazaki, 2012; Groen et al., 2013;Turner, 2014, Rafałowska
et al., 2014). Also, both selectively target motor neurons although
SMN1, SMN2,TDP-43, SETX and FUS are ubiquitously expressed
(Cauchi, 2014; Achsel et al., 2013; Tsuiji et al., 2013). A project
called: Biomarker identification for SMA (BforSMA) has yielded
significant results for future clinical studies (Finkel et al., 2012).
ALS biomarker identification would also accelerate future clinical
trials. SMA has had much more success in diagnosis and prognosis than ALS due to its monogenic nature, while many of ALS’s
genetic mutations are still being discovered (Keller et al., 2014).
Nonetheless, there appears to be a strong relationship between
these two disparate MNDs. By researching the overlap of these
two MNDs a common therapeutic approach may be possible.
As of yet, it remains unknown why ALS and SMA, which have
genes that are ubiquitously expressed, selectively destroy motor
neurons.

Methods
Peer-reviewed articles from PubMed and UptoDate (a division of
Wolters Kluwer Health) using keywords “Amyotrophic Lateral
Sclerosis” “ALS” “Genetic basis of ALS” “Biomarkers for ALS”
“Spinal Muscular Atrophy” “SMA” “SMA and ALS” were utilized
as background for this paper. Dr. Alex Pearlman and Dr. Harry
Ostrer also provided guidance in developing this thesis.

Theories on Targeted Motor Neuron
Degeneration in ALS
ALS is a heterogeneous disease with multiple pathogenic mechanisms and variable sites of disease onset and progression.
Researchers currently are searching for the starting point of the
disease and the reason why motor neurons are specifically targeted. Present research focuses on aberrant protein formation in
axons, excess glutamate activity in neuromuscular synapses and
gem depletion in cells as being responsible for ALS pathology.
The first hypothesis on ALS pathogenesis is faulty protein formation in axons. According to Dr. Zhang, at the University of
Madison-Wisconsin, misfolded protein in neurons causes a
cascade of events (Chen et al., 2014). Eventually, the protein is
shuttled to the distal part of the axon, but becomes tangled in
transport and axonal degeneration occurs. This may also explain
Alzheimer’s and Parkinson’s disease and their pathophysiology.
Through use of induced pluripotent stem cells (iPSCs), Dr. Zhang
formed new nerve cells in vitro and tested his hypothesis (Chen
et al., 2014). Indeed, when patient iPSCs were used, neurofilament

84

(NF) aggregation together with neurite swelling in spinal motor
neurons (MN) resulted. “Such MN-selective NF changes were
mimicked by expression of a single copy of mutant SOD1 (D90A)
in human embryonic stem cells (hESCs) and prevented by genetic
correction of the SOD1 mutation in patient iPSCs” (Chen et al.,
2014). “A4V is the most common SOD1 mutation in the US and
D90A is most common in Europe” (Giannini et al., 2010; Saeed
et al., 2009). In ALS MNs bead like structures form along neurites.
These bead like structures have heavy immunostaining for plasma
phosphorylated neurafilament-H. Plasma phosphorylated neurafilament-H levels closely reflect disease progression in SOD1
(G93A) mice and are regarded as an ALS biomarker (Calvo et
al., 2012). Therefore, the bead like structures that were heavily
phosphorylated with plasma phosphorylated neurafilament-H,
indicated pathogenicity. As opposed to control MNs and nonMNs that have an even staining pattern.This finding highlights the
possibility of targeting NF regulation for therapeutic intervention.
A second hypothesis on the pathogenesis of ALS is excess
glutamate accumulation, which causes neuro-degeneration.
“Glutamate is generally acknowledged to be the most important transmitter for normal brain function” (Purves et al., 2001).
Glutamate is an excitatory neurotransmitter. However, high
extracellular glutamate can have toxic effects on neurons. It is
synthesized in neurons from precursors. In a Human Molecular
Genetics paper by Dr. Guo he explains that glial glutamate transporter, excitatory amino acid transporter (EAAT2 also known as
GLT1), is responsible for removing glutamate from the synaptic
cleft (Guo et al., 2003). In ALS patients, the glutamate transporter
EAAT2 has been found inactive. Defective glutamate transport
and loss of EAAT2 protein have also been observed in affected brain regions of patients with Alzheimer’s disease (Masliah
et al., 1996). Overactivation of glutamatergic neurons can result
in a neurodegenerative process known as excitotoxicity i.e. cell
death. (Guo et al., 2003). “However, it is still unknown whether
it is a primary cause in the cascade leading to neuron degeneration or a secondary event to cell death” (Guo et al., 2003). After
experimentation with transgenic mice, containing increased expression of EAAT2 and SOD1 variation (G93A) degeneration of
neurons was slowed, but did not cease. The results “suggest that
the loss of EAAT2 may contribute to, but does not cause, motor
neuron degeneration in ALS” (Guo et al., 2003). Transgenic mice
with the common mutations of SOD1 exhibit neurodegeneration comparable to ALS. The SOD1 mutation results in a toxic
gain of function rather than a loss of enzymatic function (Wong
et al., 1995). Furthermore, in a Nature paper by Dr. Rothstein
he demonstrates β-lactam antibiotics, for example, ceftriaxone,
a semi-synthetic, third generation cephalosporin antibiotic, has
been used to treat bacterial infections (Rothstein et al., 2005).
These antibiotics also show no substantial toxic CNS effects.
Additionally, they have found it to increase gene expression
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of GLT1. Leading to neuroprotection by increasing glutamate
transporter expression. The mechanism of this overexpression
appears to be activation of the genetic promoter for GLT1, although the pathway for promoter activation is, as yet, unknown.
(Rothstein et al., 2005). This too provides another possible intervention of ALS, which is currently in phase 3 clinical trials (Berry
et al., 2013). Note that the only drug currently available for ALS
is Riluzole. It provides no relief of symptoms, but slows the progress of the syndrome by decreasing glutamate accumulation.

ALS and SMA Overlap
A third hypothesis for ALS disease onset is gem depletion. Gems
or gemini of Cajal bodies are protein products of SMN, TDP-43,
FUS and SETX located in nuclear foci and in the cell cytoplasm
responsible for the assembly of small nuclear ribonucleoproteins
(snRNPs) (Tsuiji et al., 2013; Achsel et al., 2013; Cauchi, 2014). In
spinal motor neurons with TDP-43 mutations there are depleted
gems, snRNPs and small nuclear ribonucleotides (snRNAs) (Tsuiji
et al., 2013).TDP-43 and FUS localize within nuclear gems together with the SMN complex and are involved in the maintenance
of the spliceosome by controlling levels of snRNA (Tsuiji et al.,
2013). It was further shown that accumulation of spliceosomes
cause aberrant splicing of mRNAs resulting in motor neuron
death in ALS and SMA. To clarify what gems are, how they relate
to SMN,TDP-43 and FUS and the link between spliceosomes and
motor function, Dr. Ruben Cauchi explains succinctly the RNA
processing pathway. The pathway starts with the SMN-Gemins
complex consisting of a nine-membered union of diverse proteins. More specifically, these are SMN, seven Gemin proteins
(Gemin2-Gemin8) (Carissimi et al., 2006) and Unrip (Carissimi
et al., 2005). The SMN-Gemins complex establishes the snRNP
assemblyosome. “SnRNPs are composed of one or two short
noncoding RNA molecules (snRNAs) bound to a set of seven
Smith (SM or Sm-like (Lsm) proteins, and a unique set of snRNP-specific proteins” (Matera, Terns, & Terns, 2007).
Working together with numerous non-snRNP splicing factors,
U1, U2, U4/U6 and U5 snRNPs form the more abundant spliceosome that is responsible for splicing introns from pre-mRNA;
as opposed to, U11, U12 U4atac/U6atac and U5 snRNPs that
constitute the less available spliceosome (Patel & Steitz, 2003).
The Lsm-class U6 and U6atac snRNPs, though, are synthesized
in the nucleus while the core structure of the remaining Smclass snRNPs is assembled in the cytoplasm. The published work
on these interactions is fairly recent, and it is still is not fully
understood why in vivo requires the action of the SMN-Gemins
complex (Otter et al., 2007) and involves the uploading of a heptameric Sm D1/D2/E/F/G/D3/B ring-shaped core domain onto
the “Sm site,” a conserved uridine-rich sequence motif intrinsic
to snRNAs (Cauchi, 2014).

The snRNAs expelled from the nucleus following transcription
are tagged by SMN-Gemins complex-independent Gemin5 protein. Once Gemin5 is charged with snRNAs it binds with SMNGemin complex, proximate to Gemin2, to form the Sm core
assembly. Gemin2 is essential for the majority of Sm proteins recognition to form the ring-shaped domain. It also blocks foreign
RNA binding supposedly until bona fide RNA substrates, snRNAs,
are identified. (Zhang et al., 2011) (Figure 1). SMN’s function in
snRNP assembly, according to many, is the most decisive of all the
SMN-Gemins complex members (Cauchi, 2014) and is probably
linked to axonal mRNP trafficking (Fallini, Bassell, & Rossoll, 2012;
Briese, Esmaeili, & Sattelle, 2005). Proper Sm core assembly is
necessary not only for stability and function of snRNPs, but also
for snRNP biogenesis, including cap hypermethylation, 3` terminal
trimming and eventual import into the nucleus. Once in the nucleus, snRNPs mature in Cajal Bodies (CBs) prior to pre-mRNA
splicing. After multiple splicing procedures, snRNPs return to the
CBs where they are regenerated or recycled (Staněk et al., 2008).
Mutations in the copy numbers of SMN1 and the identical gene of
SMN2 are the principal etiologic basis of SMA cases. The number
of copy numbers in SMN2 is inversely correlated with disease
severity. One of the main theories explaining SMA is improper
mRNA processing. According to the above, the fewer normal
SMN proteins cause a lack of SMN-Gemins complex essential
for pre-mRNA splicing (Borg & Cauchi, 2013; Briese et al., 2009).
Phenotypic SMA effects have been modeled in fly, zebrafish and
mouse models with insufficient levels of SNM protein (Burghes
& Beattie, 2009; Briese et al., 2009). Gemins mutations, however,
have not been associated with SMA. Investigators hypothesize
SMN is unique in human genetics and a SMN2-like pseudogene in
any of the Gemins would be incompatible with life. Dr. Cauci conducted an experiment with organisms containing reduced levels
of Gemins selectively in motor neurons. Organisms with this
defect develop similar motor deficits found in the attenuation of
SMN. Therefore, inadequate levels of any member in the SMNGemins complex can cause motor deficits. Decreased capacity
of the SMN-Gemins complex can account for neuromuscular
selectivity, based on sequencing of RNA from microdissected
motor neurons of presymptomatic SMA mice; there are specific
transcriptome abnormalities that link SMN deficiency to motor
neuron pathology in SMA (Zhang et al., 2013).
The function of Gems is thought to colocalize with CBs in later
developmental stages. Gems are viewed as storage depots for
supplementary SMN-Gemins complexes since upregulation of
SMN or Gemins induces gem formation or increases gem numbers (Cauchi 2011, Turner et al., 2014). Additionally, when there
is loss of SMN or Gemins there is substantial decrease in gems
and CBs.
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ALS and SMA phenotypes affect lower motor neurons in the
anterior horn of the spinal tract. There is a common tract and
biochemical pathway that both MNDs share. ALS can also affect
the upper motor neurons.Two of the more common genetic mutations found in ALS are TDP-43 and FUS. (Millecamps et al., 2010;
Tsai et al., 2011). Surprisingly, these two genes engage in RNA
processing. Under pathogenic conditions, the proteins of each
are found concentrated in the cytoplasm and not in the nucleus
in both neuronal and glial cells. This suggests there is a loss of
proper nuclear function or toxic gain of function pertinent to
ALS pathogenesis (Andersen & Al-Chalabi, 2011; Ferraiuolo et al.,
2011; Lagier-Tourenne, Polymenidou, & Cleveland, 2010).
SMN has been found in decreased levels in transgenic SOD1 murine models (Turner, 2009) and SMN protein levels were reduced
in ALS patients (Turner, 2014).This agrees with previous evidence
relating decreased copy numbers of SMN2 to increased severity
of ALS. (Veldink, 2005). Furthermore, loss of the SMN2 protein
caused gem depletion in motor neurons, and knockout mice of
TDP-43 showed altered numbers of gems (Shan et al., 2010). In
ALS patient derived cells with TDP-43 or FUS mutations, the gem
numbers are significantly reduced too (Yamazaki et al., 2012).
Also, biochemical experiments have shown that TDP-43 and FUS
interact with the SMN-Gemins complex (Yamazaki et al., 2012,
Tsuiji et al., 2013).

Biomarker Identification
Since both ALS and SMA are swift and crippling diseases, early
diagnosis is essential for prognosis and future treatment options.
Although, genetic testing is a current diagnostic tool for SMA,
it does not test for all mutations in SMA, and is a premium that
most cannot afford. Additionally, it does not provide a test for
treatment response. Previous clinical trials for both ALS and SMA
have produced no complete treatments for humans. There is a
need to develop biomarkers that can help deliver quicker results
from research into practice. At the same time, biomarkers facilitate the discovery of novel targets and pathways in pathogenesis.
One of the most successful approaches for diagnosis is biomarker identification, incorporating: proteomics, metabolomics and
transriptomics. Biomarker identification is not new to translational medicine. Biomarkers have been used tremendously in
the cancer field and they are beginning to show promise in SMA
too. After a recent cross-sectional study in Biomarkers for SMA
(BforSMA), the top 5 biomarker candidates: CILP2,TNXB, COMP,
ADAMTSL4 and CLEC3B may be used for diagnosis and testing
response to treatment after further testing (Finkel (2012). A longitudinal study will be necessary to qualify the results of BforSMA.
The BforSMA isolated the candidate plasma proteins, metabolites
based on type of SMA presented since type I will produce possible differences than type II or III. Transcripts, though, did not
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provide significant candidates in the BforSMA.The potential from
the BforSMA is tremendous for future clinical trials and reduction in patients and costs associated with studies. ALS would also
benefit from biomarker identification.
All of the BforSMA are only from peripheral blood mononuclear
cells. As a result, there was an absence of change in gene expression or splicing suggesting that the degree of reduction of
the SMN protein in this tissue is not enough to cause dramatic
changes. This would be consistent with the fact that blood and
other tissues do not exhibit the change of cellular or organ function except in Type I SMA. Since SMN protein is known to have
reduction concurrent with genetic mutations in ALS, some of the
biomarkers not tested for in BforSMA may serve as an interesting study for a common biomarker between these two seemingly
disparate diseases.
Following the BforSMA study, a publication by Dr. Robert Bowser
outlines biomarkers that have been discovered recently in transgenic models that may best represent ALS patients, along with
prognostic determinants for ALS. Some of the biomarkers highlighted are SOD1 in the cerebrospinal fluid (CSF), increased
levels of NF in blood/CSF, increased expression of CD4+ T
cells (Bakkar, Boehringer, & Bowser, 2014). Some of the positive
prognostic markers for ALS are low pNF-H, high sCD14 and low
S100B in blood/CSF (Bakkar, Boehringer, & Bowser, 2014). A disadvantage of these biomarkers is that they are only tested from
transgenic models unlike the BforSMA, which tested human SMA
patients. As with the BforSMA, longitudinal studies are necessary
to qualify these findings.
There is significant evidence of genetic and mechanistic interaction between SMA and ALS. Unfortunately the low rate incidence of ALS – approximately 2 in every 100,000 people – has
limited the expenditure of resources into the understanding of
the pathogenesis and treatment of this disease. Thus any linkage between ALS and the more common disorder of SMA may
prove extremely beneficial. With further research on the shared
pathways and possible common biomarkers of ALS and SMA,
therapies of MNDs may emerge that may combat the devastating
consequences of both of these neurodegenerative disorders.

Future Directions
To further clarify the potential linkage, between SMA and ALS,
both the limb- and bulbar- onset types of ALS must be brought
under a more uniform classification scheme that recognizes the
homogeneity of these diseases which may then be applied to
SMA.The elucidation of the genetic make-up of ALS may also lead
to a common gene for multiple sites of origin. Moreover, some
genetic mutations in ALS may also be shown to augment symptoms common in SMA. The fact that both of these MNDs affect

ALS and Spinal Muscular Atrophy: A Genetic Linkage?

lower motor neuron function and share a common biochemical
pathway in pathogenesis may lead to other insights into the interaction between these MNDs. Biomarker identification will
likely prove extremely useful in future clinical trials as a potential
possible diagnostic tool.
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Abstract
Nanoparticles are gaining immense popularity in the medical world, specifically in its use in drug delivery systems.The objective of this paper is to study, based on available published literature, how nanoparticles are utilized in drug delivery and
more importantly to identify the potential toxic effects of nanoparticles. Based on textual research, it is clear that there
are benefits to nanoparticle use, but new studies are showing that there are many potential hazards of nanoparticle-like
particles. In order to fully determine the toxicity of the hundreds of types of nanoparticles, a clear method to categorize
these particles is needed and more research using empty nano-carriers needs to be done.
Introduction
The U.S. National Nanotechnology Initiative defines Nanomaterial
as materials that have at least one dimension in the 1-100 nm
range. Despite its size, you can see things with the effects of
nanoparticles all around you. They give the sunset its red color,
allow birds to navigate, and help geckos stick to trees. All around
us, there are nano-sized materials present form volcanoes, forest
fires, viral particles, biogenic magnetite and combustion products (Nano.gov). What has taken the scientific world by storm
in the last few years is not the naturally existing nanoparticles,
but rather, it is the newfound ability to create new materials on
a nanoscale. The term “Nanotechnology” by the material science
standard refers to the creation of these new particles and its
usage. In the physical sciences, nanotechnology is associated
with the quantum behavior of subatomic particles in nanoscale
structures. In the biomedical sciences, nanotechnology is used
in imaging, diagnosing, monitoring diseases, gene delivery, artificial implants, and targeted drug delivery (Nasimi, Haidari 2013).
Engineered nanomaterials are useful, specifically in drug delivery,
because of their large surface area to mass ratio (Oberdorster
2004). When a drug is encapsulated in a nanoparticle, there is
a more accurate delivery to the targeted tissue. Drug permeability will also increase, thereby reducing the dosing frequency.
For instance, an intravenously administered hydrophilic drug has
poor reabsorption after glomerular filtration, often caused by the
rapid renal clearance of the drug; whereas, encapsulating the drug
in a nanoparticle reduces renal clearance and allows for better
absorption. An orally administered drug has to endure enzymatic
degradation in the gastrointestinal tract and a pass through the
liver before it enters systemic circulation. By encapsulating the
drug in a nanoparticle, the exposures to harsh conditions on the
digestive tract are minimized (Kadam, et al 2012).
The key to using nanoparticles in drug delivery systems is ensuring that the drug can be released at the proper time. In that vein,
a biodegradable nanoparticle formulation would be needed, as it
is the intention to transport and release the drug in order to be
effective. However, model studies to the behavior of nanoparticles have largely been conducted with non-degradable particles. Most data concerning the biological behavior and toxicity
of particles comes from studies on inhaled nanoparticles. This is
part of the unintended release of ultrafine or nanoparticles by

combustion-derived processes such as diesel exhaust particles
(Oberdörster, Oberdörster et al 2005). Research has demonstrated that exposure to these combustion derived ultrafine particles/nanoparticles is associated with a wide variety of effects,
including vascular thrombosis, peripheral thrombosis, increased
plasma fibrinogen levels and cardiovascular effects (Radomski,
Jurasz et al 2005; Oberdorster, Oberdörster et al 2005). Since
the size for both ultrafine and nanoparticles (100 nm) is relatively the same, many use both terms as equivalents. Based on the
similarity of character and size between the two, researchers are
speculating that the adverse effects of ultrafine particles, as part
of environmental pollution, may be similar to the negative effects
of engineered nanoparticles.

Methods
The NCBI PubMedCentral database, the Touro College library
Database, Proquest, and Google Scholar were search engines used to find information. The following key words were
searched to obtain research related to this paper: nanotechnology, nanoparticles, nano-medicine, nanotechnology and medical
uses, nanotechnology and drug delivery, toxic effect of nanoparticles, negative effects of engineered nanoparticles, toxicity and
nanoparticles, applications of nanoparticles, and hazards of nanotechnology. Further sources were found by using appropriate
references cited in various journals and reviews.

Nanoparticles and Drug Delivery
Nanoparticles are formed through natural or human facilitated
degeneration of larger structures or by controlled assembly
processes. These procedures occur either in the gas phase, in
a plasma, in a vacuum phase or in the liquid phase (SCENHIR
2006). Naturally occurring nanoparticles are found in the air
in surprisingly high concentrations - approximately 106 to 108
nanoparticles per liter of air depending on conditions. They originate from the oxidation of volatile compounds, diesel and car
engines, and photo-oxidation. The most significant concentration
of particles and smallest particle size are associated with highspeed road traffic, apparently due to the subtle conditions during
concomitant cooling and dilution of the exhaust gases (SCENHIR
2006).Although there are many naturally occurring nanoparticles,
the ones that are man-made and biodegradable are the ones that
are used in drug delivery systems (Oberdorster 2004).
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Preparation of Nanoparticles
Before choosing a method to prepare nanoparticles for use in
drug delivery, many factors have to be taken into account. Some
of these factors are the size of the nanoparticle required, the
inherent properties of the drug (ex. solubility, stability), surface
characteristics and the degree of biodegradability, biocompatibility and toxicity (Mohanraj, Chen 2006). The following are the
three main methods used to prepare nanoparticles for drug
delivery:
Dispersion of preformed polymers: A polymer is dissolved in an
organic solvent, which is also used as the solvent for the hydrophobic drug. This mixture is then emulsified in an aqueous
solution containing a surfactant.After a stable emulsion is formed,
the organic solvent is evaporated. Some of the polymers used in
this method include poly- lactic acid, poly(D, L-glycolide), poly(D,
L-lactide-co-glycolide) and poly(cyanoacrylate) (Mohanraj, Chen
2006).

carboxyl) (Govender, et al 1999). Once the drug is loaded, the
next step is to ensure an opportune release. In general, the release of the drug is dependent on the solubility of the drug, drug
diffusion through the nanoparticle matrix and nanoparticle matrix degradation. (Mohanraj, Chen 2006). Very often, the drug is
released by interactions between intracellular chemicals and the
nanoparticle matrix. For example, the cationic surface of some
nanoparticles allows penetration through the cell membrane
and the drug is then released after the nanoparticle matrix is
triggered by intracellular glutathione. Another example is the reduction of cadmium sulfate or ferric oxide (which are used to cap
silica nanoparticles) by thiols that release the molecules inside
the nanoparticle (Nasimi, Haidari 2013). An alternate mechanism
for release is the use of pH-responsive nanomaterials. A further
achievement in the area of drug release was reached when a
method was developed to use multifunctional super-magnetic
nanoparticles that can be released remotely (Derfus, et al. 2007).

Passing the Blood Brain Barrier (BBB)
Polymerization method: Monomers a polymerized and form
nanoparticles in aqueous solution.The drug is encapsulated either
by dissolving it in the polymerization medium or by absorption
onto the nanoparticles post- polymerization. The nanoparticles
are separated from the suspension by ultra-centrifugation (Reis,
et al 2006).
Coacervation or ionic gelation method: A significant amount of
research has been focused on the preparation of nanoparticles
using hydrophilic, biodegradable polymers such as chitosan, gelatin and sodium alginate. A method was developed by P. Calvo, et
al. for preparing hydrophilic chitosan nanoparticles by ionic gelation. They mixed two aqueous solutions together- one was the
polymer chitosan and the other was the polyanion sodium triphosphate.The positively charged group of the chitosan interacts
with the negatively charged triphosphate to form coacervates
(an aggregate of colloidal droplets held together by electrostatic
attractive forces) with a size in the range of a nanometer (Calvo,
et al 1997).

From several standpoints the brain is a challenging organ for
drug delivery. First, the occurrence of progressive diseases in
the brain will increase with the aging population. Secondly, the
blood brain barrier (BBB) is well known as the best gatekeeper
in the body toward exogenous substances. Generally pharmaceuticals including most small molecules do not cross the BBB.
The BBB is formed by tight junctions between the cerebral endothelial cells, which abolish all aqueous diffusion pathways, and
by biochemical systems consisting of enzymes, which specifically
metabolize many drugs. However, the barrier properties may be
compromised intentionally or unintentionally by allowing the
passage of nanoparticles (Kreuter, et al. 2002). Many studies were
done that show coating of the nanoparticles with the polysorbate (80) surfactants resulted in transport of drugs across the
blood brain barrier (Schroder 1996). It is interesting to note that
studies were first done using engineered nanoparticles to cross
the BBB; however, with increased research it was discovered and
published that natural ultrafine particles can cross the BBB and
cause damage.

Drug Loading and Release

Toxicological Hazards of Nanoparticles

The ideal nanoparticle for drug delivery should have a high
drug loading capacity, thereby reducing the quantity of matrix
materials (Mohanraj, Chen 2006). The two main ways to load
a drug into a nanoparticle is by incorporating it at the time of
nanoparticle production, or absorbing the drug after formation
of the nanoparticles by incubating the nanoparticle carrier with
a concentrated drug solution. The efficiency in loading the drug
is very much dependent on the solubility of the drug in a solid
state into the matrix material or polymer.The solubility is related
to the polymer composition, molecular weight, the drug-polymer
interactions and the type of functional group present (ester or

General concepts
To effectively tap into the potential of Nanotechnology in
Nanomedicine, full attention is needed to focus on safety and
toxicological issues. For pharmaceuticals, precise drug delivery
formulations may be used to increase the so called “therapeutic
ratio” which is the margin between the dose needed for clinical efficacy and the dose that would induce adverse side effects
(toxicity). Also, for these specific formulations, a toxicological
evaluation is needed. The US Food and Drug Administration approval is crucial for clinical applications of nanotechnology, but
considerable problems come into account when it comes to
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approving nanotechnology-based products. The Food and Drug
Administration regulate pharmaceuticals and biological devices
differently, and it is not yet clear how emerging nanotherapeutics
will be evaluated. It is important to have a safety guide particularly in the applications of nanoparticles for drug delivery. In these
applications, particles are brought intentionally into the human
body and environment (Buxton, et al 2003). Opinions started to
divert when toxicologists claimed that new science, methods and
protocols are needed (Nel et al 2006). However, the need for
a safety guide is now underlined by several expert reports and
more importantly by the following concepts:
1) Nanomaterials are made for their unique surface properties
as opposed to the similar properties of bulk materials. Since the
surface is the layer that interacts with the body tissue, and an
essential factor of particle response, these unique properties
need to be investigated from a toxicological perspective. When
nanoparticles are used for their distinctive reactive characteristics, it may be probable that these same characteristics also have
an impact on the toxicity of such particles. Although existing
tests and procedures in drug and device assessment may work
to detect many risks related to the use of these nanoparticles,
it cannot be presumed that these assays will detect all potential
risks. (SCENIHR 2006) The toxicity may differ depending on the
type of particles used, i.e., biological versus non-biological origin.

2) Nanoparticles are recognized as having different physical and
chemical characteristics from micron-sized particles. This may
result in changed body distribution, passage of the blood brain
barrier and triggering of blood coagulation pathways. In view
of these characteristics, specific emphasis should be on testing
and studying the distribution of nanoparticles. What is currently
lacking is a basic comprehension of the biological behavior of
nanoparticles in relation to the distribution in vivo both at the
organ and cellular level.
Using nanoparticles as a drug carrier may reduce the toxicity of
the incorporated drug. In general, research focuses on the toxicity of the entire formulation.The results of the nanoparticles itself
are not described, so differentiation between drug and nanoparticle toxicity cannot be made.There should be a specific emphasis
on the toxicity of the “empty” non-drug loaded particles. This is
especially important when slow or non-degradable particles are
used for drug delivery. (Oberdorster, Maynard, et al. 2005)

Evidence for Nanoparticle Toxicity
The largest database on the toxicity of nanoparticles comes from
the PM10 literature (particulate matter with a size below 10 mm),
where studies on inhalation and the ‘Nanoparticle hypothesis’
have proved to be a powerful drive for research (Oberdörster,
Oberdörster et al 2005). Therefore it is relevant to discuss this

Table 1

Particle type

Description

PM10, PM2.5

Particle mass fraction in ambient air with a mean diameter of 10 or 2.5 μm
respectively. Basis of current standards for ambient particles in Europe and USA

Coarse particles

The mass fraction of PM10, which is bigger than 2.5 μm

Ultrafine particles
(PM0.1)

The fraction of PM10 with a size cut-off at 0.1 μm. Contains primary particles and
agglomerates smaller than 100 nm

PSP

Poorly soluble particles with low specific toxicity. Maybe be fine or ultrafine.
Terminology used in relation to bulk synthetic particles. Examples TiO2, carbon
blacks, Amorphous silica, Iron oxides (Fe2O3), Zinc oxides (ZnO)

CDNP

Combustion derived nanoparticles, such as diesel exhaust particles (DEP)

DEP

Diesel exhaust particles

Various denominations of particles in inhalation toxicology and drug delivery in relation to their source (ambient, bulk, engineered)
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evidence with the expectation that it will shed light on the toxicity of engineered nanoparticles. The adverse health effects of
particulate matter (PM) are measurable as causes of respiratory
disease and deaths as well as hospitalizations and deaths from
respiratory and cardiovascular disease. Many laboratory studies
have been done to investigate the effects of ultrafine and PM particles. It was found that some nanoparticles might have the extra
potential of affecting cardiovascular disease directly. Vascular
function was impaired after inhalation of diesel exhaust particles.
However, data to date is limited and not all studies of nanoparticles have shown significant translocation from lung to the blood.
Understanding clearance kinetics of inhaled ambient air nanoparticles will also be important in understanding the potential for
adverse effects. (Oberdorster, Maynard, et al. 2005)
The current standard in particle toxicology is that ultrafine ambient air particles have the potential of affecting cardiovascular
disease both indirectly via pulmonary inflammation and directly
through particle distribution. Although significant, this property
of redistribution has yet to be demonstrated for nanoparticles
present in real PM10’s. It should be noted that there are several
mechanisms whereby nanoparticles could lead to inflammatory
effects, as is the case for larger particles. These mechanisms are
either based on the large surface area of a particle core or on
soluble components released by the nanoparticles (Schins, et
al. 2004). Several toxicological studies support the argument
that nanoparticles in PM10’s could drive inflammatory effects.
There are a number of components of PM10’s that contribute
to the mass but have little toxicity, including salts such as sulfates, chlorides and ammonium salts and nitrates. In fact, within
PM10’s there are only few components that toxicologists would
identify as likely causes of adverse effects – i.e., particle surfaces,
organics, metals and endotoxins. A large surface area, organics
and metals are all characteristic of combustion–derived particles
and so these have attracted considerable toxicological attention
(Donaldson, et al. 2005).

Effects of Nanoparticle Toxicity
Many physicochemical factors can influence the potential biological
interactions and toxicity of nanoparticles. Therefore, it is important to consider the extent to which the physicochemical properties of nanoparticles have been characterized in any given study.
Without sufficient characterization, it is extremely challenging to
interpret the results of individual studies and virtually impossible
to compare the results of different studies, even in cases where
the same nanoparticle has been investigated. As a result, the ability
to identify parameters that might influence toxicity is hampered.
Although there is not yet a universally accepted standard of parameters that is deemed necessary for nanoparticle characterization, recent reports have highlighted several key physicochemical elements for which it is strongly recommended that data be
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reported (Oberdörster, Maynard, et al. 2005). These limitations
include method of synthesis, size, size distribution, shape, composition, crystal structure, aggregation and agglomeration status,
dissolution, purity, surface area, and other surface characteristics.
Classification of nanoparticles in the context of the experimental
contact media (cell culture media, dosing solution, aerosol, etc.) is
also of substantial importance, as some physicochemical parameters are likely to differ depending on whether they are determined
in the experimental media or in the bulk (i.e., “as received”) state.
Unfortunately, the inclusion of all these parameters in publications
describing nanoparticle toxicity studies appears to be rare.

Nanoparticles in The Lungs
When nanoparticles enter the respiratory system, they are thought
to cause damage that results primarily from lung particle overload.
This is due to the inability of alveolar macrophages to recognize
and/or clear particles of this size, resulting in a particle build up,
chronic inflammation, fibrosis, and tumor-genesis. However, many
studies have not shown a correlation between nanoparticles and
inflammation (Card, et al, 2008). Many studies also track whether
the particles translocate from the pulmonary system into systemic circulation. One of the studies reported to date indicate
that inhaled 99mtechnetium-labeled carbon nanoparticles, which
are man-made, are not detected outside of the lungs in significant
quantities after inhalation. However, as mentioned to by Mills et
al., these findings do not indicate that other nanoparticles will behave in the same manner, nor do they rule out the possibility that
nanoparticles may interact with and influence the vascular system
in the lungs. Moreover, the studies conducted to date have used a
single inhalation exposure protocol, and it is possible that repeated exposures may result in greater pulmonary accumulation and
transfer of significant quantities of nanoparticles to the circulation
(Mills, et al. 2006).
Fibrosis is a condition that many researchers believe is caused by
nanoparticle exposure. Many experiments were done using animals
to test the effects of primarily carbon nanotubes, carbon black,
fullerenes, silica, and metal-based nanoparticles including titanium
dioxide, silver, and nickel. Though it is known that the pathogenic
mechanisms underlying animal models of lung fibrosis and human
lung fibrosis are not necessarily the same, increased collagen deposits and structural deviations to the lungs can result in changed
respiratory mechanics that are common features of both. Fibrosis
in animal models is defined by increased collagen content and/or
histopathological evidence of structural alterations to the lung that
are consistent with fibrosis (Card, et al, 2008). It was found that
the type of carbon nanotubes, their length, and the way specific
fibers interact, all have varying effects on pulmonary inflammation
and fibrosis. Studies have found that the longer the nanotube fiber
length, the greater the toxicity, and the more likely it is to cause
fibrosis and cancer (Donaldson, et al. 2006).

Toxicity of Nanoparticle

Effects on Blood and Cardiovascular System
In a study by Radomski, et al, (2005) the effects of various
nanoparticles on platelet function were studied. In vitro studies
were done using human blood samples, and then in vivo studies
were done in rats to confirm the effects of platelet- aggregation found in the human blood. Engineered nanoparticles were
found to cause activation and aggregation of human platelets.
The efficacy of the nanoparticles in blood aggregation in vitro
was matched by the same results in the rats. Treatment with
nanoparticles caused rat vascular thrombosis. The data shows
that not all nanomaterials act similar in this test, and that surface area is not the only factor playing a role here. The data also
validates the idea that mainly cationic species have an effect on
blood clotting. Interestingly, this was the first study that allows
bridging of data, since a PM10 sample (SRM1648) was included in
the test-series, in combination with nanoparticles.The PM sample
actually showed a lower effect on platelet aggregation compared
to the carbon nanotubes (Radomski, Jurasz et al 2005). Another
study shows that repeated exposure to PM10’s causes a systemic
inflammatory response, including bone marrow stimulation, and
is related to the progression of atherosclerosis in the coronary
arteries and aorta (Suwa, et al. 2002).

Uptake and Effects of Nanoparticles in The Brain
Nanoparticles can gain access to the brain by two different
mechanisms. (1) Trans-synaptic transport after inhalation through
the olfactory epithelium. (2) Uptake through the blood-brain
barrier. The first pathway has been studied primarily with model
particles such as carbon, Au and MnO2 in experimental inhalation models in rats (Oberdörster et al 2004; Oberdörster,
Oberdörster et al 2005). The pathway via the BBB has been the
topic of research for a while, especially for drug delivery. Studies
suggest that the physiological barrier may hinder the distribution
of some proteins and viral particles after trans-vascular delivery
to the brain, suggesting that the healthy BBB contains defense
mechanisms protecting it from blood-borne nanoparticle exposure. When nanoparticles with different surface characteristics
were evaluated, neutral nanoparticles and low concentrations
of anionic nanoparticles were found to have no effect on the
BBB, whereas high concentrations of anionic nanoparticles and
cationic nanoparticles were toxic for the BBB (Nel et al 2006).
Fullerenes and C60 nanoparticles have been shown to induce
the production of reactive oxygen species, oxidative stress, and
rapid brain lipid peroxidation in marine species. Because of all the
negative effects on the brain by nanoparticles, further tests would
need to be done before using fullerenes and C60 for human and
industrial use (Oberdorster 2004).

Conclusion
Although there is a considerable amount of data on the toxicity
of nanoparticles, this data is mainly based on a small sampling

and the assumption that a lot of effects by particulate matter
are driven by the ultrafine particle fraction in it (Oberdörtster,
Oberdörster et al 2005). This small sampling doesn’t really give
enough information to adequately determine the potential hazards. Although hazard identification is the general approach for
safety evaluation of healthcare products, it is recommended to
add testing driven by the anticipated application and classification
by risk. Some engineered nanoparticles that are airborne will
pose inhalation and cardiovascular hazards, while cosmetics with
nanoparticles provide dermal exposures. Each nanoparticle formulation should be tested on a case-by-case basis in the requisite
ways focusing on their method of entry. In this respect the potential adverse effects of empty particles should also be considered.
In developing testing procedures and protocols a number of basic
issues need to be considered:
1) It needs to be determined whether noticed effects are caused
only by nanoparticles, or are the adverse effects caused by something else and only aggravated by nanoparticles. It is clear from
research that both PM and ultrafine particles can cause inflammation, cancer, etc., but these new and smaller nanoparticles may
cause different effects.
2) Most of the conclusions drawn about nanoparticles are based
on correlations made between the behavior of ultrafine particles
and PM’s to that of nanoparticles. The question is how much of
a correlation is permitted to be drawn, how many assumptions
can be made, as manufactured nanoparticles and ultrafine/ PM
particles are not identical.
3) The scientific world is dealing with a increasingly growing number of nanomaterials. All have the potential to create a new toxic
effect that has never been studied before.The current testing and
classification system for nanoparticles does not seem sufficient
to fully identify and quantify the toxicological effects of these new
nanoparticles.
For years pharmaceutical sciences have been using nanoparticles
to reduce toxicity and the side effects of drugs. Up to recently it
was not realized that these drug carrier systems themselves may
cause risks to the patient.The type of hazards that are introduced
by using nanoparticles for drug delivery are beyond what is posed
by conventional hazards imposed by chemicals. However, as of
current data, the scientific example for the possible toxic and adverse reactivity of nanoparticles is lacking and we have little understanding of the basics of the interaction of nanoparticles with
living cells, organs and organisms. A conceptual understanding of
biological responses to nanomaterials is needed in order to develop and apply safe nanomaterials in drug delivery in the future.
Furthermore, a close partnership between those working in drug
delivery and those working in particle toxicology is necessary for

93

Zisi Hursarsky

the exchange of concepts, methods and to establish a common
system for identifying the potential dangers of nanoparticles.
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Abstract
Dehydration in children and adolescents is a major concern for caretakers. Often children are not drinking enough, particularly while participating in physical activity. Utilizing data drawn from pediatricians, nutritionists, and bio-scientists, this
paper will examine whether sports drinks are a good source of fluids for the exercising child. The results of the research
indicate that the advantages generally associated with sports drinks, to achieve higher body water absorption levels,
prevent electrolyte deficits, and maintain proper electrolyte/water concentrations, are reserved for unique circumstances.
Sports drink intake should be encouraged only when the child is participating in prolonged physical activity, in intense exercise with short break intervals, or in hot/humid environments. In these instances, sports drinks adequately resupply the
lost fluids and electrolytes. Furthermore, the carbohydrates contained in sports drinks replenish energy supply. However,
under normal conditions, sports drinks are associated with health risks, primarily due to their excess of sugar. Care should
be taken to encourage children to avoid sports drinks and instead encourage them to consume plain water at a rate
equal to sweat loss. The research establishes that health risks involved with sports drink intake outweighs the benefit of
increased voluntary consumption.
Introduction
The Importance of Hydration
Water is an essential nutrient required for life. It is the most
abundant compound found in the human body and is responsible for moving nutrients along the body’s pathways. Water is
also involved in biochemical reactions as a solvent and reagent;
its physical properties affect reaction rates and mechanisms of
various processes. Dehydration, an imbalance between water
intake and body water loss, which can be caused by sweating,
respiratory process, and/or urine production, is generally defined
as a loss of 1-2% of body weight (Kliener, 1999). This level of
dehydration increases the core body temperature (Ganio et al.,
2007), impairs aerobic capacity, decreases plasma volume, and
increases cardiovascular strain (Hill et al., 2008). Furthermore,
studies indicate a correlation between insufficient fluid intake and
different forms of cancers (Kleiner, 1999). Even when the water
concentration deficit is less than 1% there can be negative effects,
such as headaches, digestive problems, lack of concentration, and
dry skin (The Expert Group on Hydration, 2005).

size, children are at greater risk of the effects of poor hydration
(Pediatrics, 2000).
Data from the U.K.’s National Diet and Nutrition Survey of 2000
are cited to demonstrate that most children are not drinking
enough and most parents are not aware of this issue. In the
study, 40% of 11-18 year olds were consuming less than the
Food Standards Agency’s minimum of 1.2 liters. In schools, 38%
of students were not offered sufficient fluids even after physical
education (The Expert Group on Hydration, 2005), despite the
fact that the effects of dehydration can be especially severe when
children exercise. They generate more metabolic heat per mass
unit than adults do during exercise, even when just walking or
running (Pediatrics, 2000).
Due to the high risk of dehydration, should sports drinks be given
to children and adolescents engaged in athletics as an effective
source of hydration?

Method
“Sports drinks are beverages that may contain carbohydrates,
minerals, electrolytes, and flavoring and are intended to replenish
water and electrolytes lost through sweating during exercise”
(Pediatrics, 2011).

Critical analyses of research articles were utilized to gather this
information. These articles were collected from online databases
and journals, such as, Touro College’s online databases, PubMed,
and Google Scholar.

Children

Sport Drinks: A Source of Hydration

The average daily total water recommendation for children aged
6 to 11 is 1.5 liters for girls and 1.7 liters for boys (National
Academy of Sciences, 2005). Children aged 11 and above should
be drinking approximately 2 liters per day. Special care needs to
be taken to ensure that children and adolescents are properly
hydrated. They are less likely to take the time to drink regularly,
especially when in school where decisions are made for them
(The Expert Group on Hydration, 2005). Due to their smaller

Many experts assert that sports drinks are an invaluable source
of hydration, as they maintain body electrolyte concentrations
and lead to greater fluid consumption.
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Electrolytes
Excessive intake of sodium-free drinks, such as plain water, can
lead to hyponatremia, a rapid fall in serum sodium concentration
and serum osmolality (Maughan, et al., 1993). Even replacing large
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fluid losses with equal amounts of pure water may dilute the plasma sodium level (Ganio et al., 2007). Water alone cannot replace
electrolytes lost through sweat. Therefore, it has been suggested
that electrolytes and water should be replaced with sports drinks
that contain the proper amounts and ratios of these elements
(Maughan, et al., 1993, Pediatrics, 2000).

Water Absorption
Dr. R. J. Maughan, a Fellow of the American College of Sports
Medicine, and his colleagues maintain that electrolytes contained
in sports drinks enhance fluid absorption in the body. Sports
drinks manufacturers frequently use this assertion when advancing their products and also claim that sports drinks are scientifically formulated to tackle dehydration. Lucozade®, a drink
manufacturer states, “Adding both carbohydrate and sodium to
a sports drink, helps your body absorb fluids more effectively”
(Lucozade, 2015).

Taste
Naturally, people, especially children, tend to consume fluids that
they enjoy. The effect of taste is found even within various sources of water. One survey found that out of 124 respondents, 43%
said taste was the primary reason they chose bottled water over
tap water (Kliener, 1999). Surely, the palatability of cool, pleasant-tasting sports drinks greatly enhance fluid intake. More specifically, sodium chloride, commonly found in sports drinks, has
been shown to increase voluntary fluid intake by 90% compared
to unflavored drinks (Pediatrics, 2000). Additionally, the carbohydrates that sports drinks contain, to various degrees, may influence palatability (Maughan, et al., 1993). Therefore, while water
is an easily available drink, flavored beverages, sports drinks, are
often the beverage of choice to increase fluid intake, specifically,
in the case of an exercising child, where the need for rehydration
and sensitivity to flavor are especially significant.

Thirst Inhibiter
The body’s natural reaction to dehydration is thirst. The hypothalamus senses fluid loss when the concentration of sodium in
the body rises. It responds by increasing renal sodium and water
conservation, which stimulates the sensation of thirst (Noakes,
2012). Drinking plain water could lead to a rapid fall in sodium
concentration which could alter the chain of reaction, ultimately
inhibiting thirst and causing a reduction of fluid intake. Sports
drinks are preferred, since they have accurate water-sodium ratios and do not inhibit thirst.

Refuting the Claims in Favor of Sports Drinks
Taste
While tap water does not have a favorable taste and can lead to
children not drinking enough fluids, palatability can be achieved
in ways other than sports drinks. For example, parents and

caregivers can supply children with filtered, purified, and/or bottled water. If this does not supply the desired fluid intake, taste
can be enhanced by adding a minimal amount of flavor, such as
lemon slices, to the water (Ahmad, 2008).

Electrolyte
Sweating is the most efficient method that the body uses to dissipate excess heat, either a result of byproducts of muscular work
or from a hot environment (Burke, 1997).The water contained in
sweat decreases the core body temperature through evaporative
cooling at the skin surface. Generally, the sweat produced by the
average exercising child or adolescent is a relatively dilute plasma
secretion containing far more water than electrolytes. Since the
main fluid lost is water, the main replacement should be water,
not sports drinks which contain electrolytes (Ahmad, 2008).
Nevertheless, to avoid incorrect electrolyte/water ratios, care
should be taken not to drink disproportionate amounts of water
(Robert Wood Johnson Foundation, 2012, Pediatrics, 2011). Most
children’s and adolescents’ daily electrolyte requirements are
met sufficiently by a healthy balanced diet, while sports drinks
offer little to no advantage over plain water. Furthermore, sports
drinks can be harmful due to excess caloric, fat, and protein intake and the potential nutritional imbalance that can ensue.
In addition, hyponatremia has been observed in cases of dehydration, maintained hydration, and over hydration. Therefore, excessive water intake cannot be correlated to hyponatremia; the
cause may be multi-faceted and circumstantial and further studies
need to be done before conclusions can be drawn (Ganio, Casa,
Armstrong et al, 2007).

Energy Source
Despite the above arguments, some maintain that sports drinks
are still advantageous for energy resupply (Maughan, et al., 1993).
However, since the average child athlete does not need quick
energy supplements, there is little need for energy-containing
beverages. The recommended daily intake of fruit juices, low fat
milk and other daily diet food supply the appropriate amounts of
carbohydrates and proteins that children need (Pediatrics, 2011).

Water Absorption
The advantage of increased total water absorption attributed
to sports drinks is only under conditions where further bouts
of exercise occur after short recovery periods. However, during
rest or low intensity exercise, sports drinks do not improve the
overall water absorption rate or the amount consumed by means
of plain water. This assertion is maintained by an innovative experiment using a deuterium dilution technique to compare the
hydration ability of commercially available sports drinks versus
water (Hill, 2008). Scientists provided three different sports
drinks solutions, as well as plain water, ingested with an isotope
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tracer, to exercising subjects (aged 18-35) at set intervals over
the course of sixty minutes. The team then analyzed their saliva samples; the appearance of deuterium in saliva indicated the
uptake of water in the body’s tissues and enabled the team to
calculate the kinetics of the water absorption. With the aid of
proven mathematical modeling, the kinetics data provided the researchers with estimates for the maximum absorption rate, the
time at which absorption was complete, and the percentage of
solution absorbed, at any given time. This innovative approach
measured the gastric emptying rate and the intestinal absorption, two major factors that affect absorption of the solution’s
water content. It is important to note that the exercise was not
intensive, consisting of walking on a treadmill at 55% of heart
rate maximum for an hour. The results of the experiment clearly
indicated that for the speed of rehydration, the maximum rate
of absorption was achieved with sports drinks rather than with
water. Nonetheless, by half of the total time of absorption there
was no difference in the rate of absorption between the sports
drinks and water. Furthermore, by the end of the total time, the
sports drinks and water solutions accomplished the same total
absorption volumes. Therefore, the study determines, “under
conditions where recovery periods occur between further bouts
of exercise, sports drinks may be favored due to faster speed
at which they reached their max absorption rate.” However, for
normal, non-intensive, conditions, since there is no advantage in
total water absorption and no need for quick rates of rehydration, there is no hydration advantage in providing sports drinks
instead of plain water.

Sports Drinks – A Bad Choice For Hydration
Excessive Sports Drink Consumption
Sports drinks contain sugars and recent studies show that most
children today consume far more added sugars than the maximum daily recommendation (Johnson RK et al., 2009). Beverage
patterns and trends among school-aged children in the United
States indicate that, between 1989 and 2008, the percentage
of American children aged 6 to 11 consuming sports drinks
increased from 2 percent to 12 percent (Lasater et al., 2011).
A study by a group of nutritionists measured US children and
adolescents per-capita daily caloric intake from sugar-sweetened
beverages (SSB) and 100% fruit juice. The authors found that SSB
consumption increased from 242 kcal/day in the years 1988-1994
to 270 kcal/day in the years 1999-2004. One hundred percent
fruit juice intake increased from 38 to 48 kcal/day. The largest
increases occurred among children aged 6 to 11 years (Wang et
al., 2008). In another study, researchers asked adolescents why
they drank sports drinks. No one claimed they did so to maintain
hydration (O’dea, 2003).
Excessive sugar intake causes weight gain, poor nutrition, displacement of healthy ingestion, obesity, and poor dental health. In
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addition, SSBs lead to type 2 diabetes and cardiovascular disease
(Robert Wood Johnson Foundation, 2012). Additionally, the gratuitous amounts of sodium found in sports drinks displace necessary nutrients and results in excessive caloric intake (Pediatrics,
2011). Therefore, to achieve optimal health, sports drinks should
not be used as a source for hydration.

The Value of Sports Drinks
In the event that the child is playing in a hot and/ or humid environment maintaining hydration is even more crucial, as children
do not adapt to extreme climatic changes as well as adults do. “A
child may need as many as 8 to 10 exposures (30 to 45 minutes
each) to the new climate to acclimate sufficiently.” Hot air temperatures and high humidity levels, even with relatively normal
air temperature, may lead to heat stress. Furthermore, children
have a large area-to-body mass ratio which results in significant
heat gain. Moreover, children’s sweating capacity is considerably
lower than adults, which diminishes their ability to dissipate body
heat via evaporation. Consequently, children exercising in hot
and humid environments are at greater risk from the effects of
dehydration (Pediatrics, 2000). More specifically, children playing
in hot and/or humid conditions for more than one hour lose
excessive amounts of electrolytes, such as sodium, potassium,
and chloride, which cannot be replaced sufficiently by plain water
(Ahmad, 2008). Under these conditions, “[s]ports drinks have
been shown to decrease fatigue and replace electrolytes lost in
sweat” (Robert Wood Johnson Foundation, 2012).
Likewise, sports drinks are appropriate for children and adolescents who engage in prolonged vigorous physical activity, as
the amount of energy and electrolytes lost cannot be regained
through plain water alone (Robert Wood Johnson Foundation,
2012). To prevent fatigue and maintain performance it is necessary to resupply muscle glycogen stores through ongoing intake
of carbohydrates. The carbohydrates and electrolytes contained
in sports drinks restore the loss, and provide the necessary nutrients in the proper ratios.

Discussion
In view of the above, for the average child, water is the best
form of hydration. Sports drinks are detrimental, in large part
because they provide children with excess sugars. Furthermore,
their added ingredients can negatively affect the proper amount
and relative proportion needed for a healthy diet. Cohen (2012)
affirms that after 38 years of research there is still no scientific
proof for sports drinks providing higher fluid intake or better absorption than water. Sports drinks were designed for committed
athletes, and they should be restricted to them.
In addition, while sports drinks may be advantageous because of
their greater palatability in comparison to tap water, which will
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lead to children consuming more fluids, parents and caregivers
should keep in mind that the bad health effects far outweigh these
benefits. Therefore, water should be the beverage of choice, and
if the child is not drinking enough, a parent should seek methods
to encourage voluntary water consumption, such as by providing
cool, filtered water and promoting the health benefits of water
(Loughridge and Barratt, 2005).
Nutritionists offer water drinking guidelines to maintain hydration. In the case of a child participating in normal physical activity,
for less than three hours and in normal air/humidity conditions,
water intake should occur every 15-20 minutes (Ahmad, 2008).
The main body fluid lost is water, therefore, water is the only
substance needed to be replenished. Still, care should be taken to
replace water at a rate equal to, not greater than, the sweat rate
(Ganio et. al, 2007). In events of intensive physical activity, water
and a balanced diet, for example, soup, fruits and vegetables, are
enough to replace the water, carbohydrates and electrolytes lost
during exercise, provided the activity does not last more than an
hour (Robert Wood Johnson Foundation, 2012). In the event of
prolonged physical exercise, children should be well hydrated before and during the activity. Periodic drinking should be enforced
throughout, even if the child does not feel thirsty (Pediatrics,
2000). Also, children and adolescent athletes should drink water
even after the activity is over (Pediatrics, 2011).
In cases of hot or humid conditions and during intense exercise
lasting over an hour, since there is a greater loss of electrolytes
(sodium, potassium, and chloride) and energy, water alone is not
enough to rehydrate and replenish energy, and sports drinks
should be provided (Robert Wood Johnson Foundation, 2012).
Ahmad (2008) advises that every 15-20 minutes the child and
adolescent should be provided with five ounces of electrolyte-replacing fluids such as water mixed with juice or sports drinks.
Also, sports drinks are commendable in situations where quick
rehydration is critical. It is important to note that the various
amounts of sodium, potassium, and magnesium, found in the different sports drinks all achieve quicker retention rates over a
short period of time, in relation to plain water (Hill et al., 2008).

Thirst as an Indicator for Hydration
In general, as mentioned in the paper, exercise raises the core
body temperature which causes the body to sweat out the heat
and to replenish fluids lost in the process by the conscious feeling of thirst (Noakes, 2012). Over the course of the research,
however, it was evident that scholars debate whether thirst is a
good indicator for fluid replacement in children and adolescents.
Some argue that thirst is not a good indicator and relying on
it for fluid intake may lead to severe dehydration. Firstly, thirst
often-times lags behind changes in hydration (Ganio, et al., 2007).

The threshold of the indication of thirst occurs at a point when
a person is already dehydrated to a level of .8 % to 2% loss of
body weight (Kliener, 2009). Secondly, drinking water creates a
reduction in plasma osmolality and reduces the drive to drink,
even before sufficient fluid has been consumed to replace loss
(Maughan RJ et al., 1993). Thirdly, children frequently do not
feel the need to drink enough to replenish fluid loss during
prolonged exercise, and if they find plain water non-appealing,
they may not drink even if they are feeling thirsty (Pediatrics,
2000). Lastly, environments may alter the thirst mechanism. For
example, swimmers may have virtually no thirst response during
immersion (Kliener, 2009).Therefore, these researchers conclude
that children should be given to drink even if they are not thirsty.
The risk of relying on just thirst to identify when to provide fluids
is greater in hot/humid environments, where the potential for hypo-hydration in children and adolescent athletes is even greater.
However, it can be argued that thirst is a reliable indicator; it is
a natural biological response to dehydration and children rehydrate voluntarily when fluid is available (Kliener, 2009). Cohen
(2012) questions the scientific validity of studies that claim thirst
to be unreliable, calling it a “war on thirst”. The article states that
scientists who invalidate thirst as an indicator of dehydration are
associated with the sports drinks industry and their results are
biased. Instead, Cohen’s article maintains that thirst is a good
indicator of when to drink. In addition, humans do not need to
immediately replace all the fluids lost during routine exercise;
humans are delayed drinkers. Individuals can rely on the next
meal for most fluid replacement. Thirst is a dependable indicator
of water and electrolyte deficits that need to be imminently rectified (Noakes, 2012).

Conclusion
The negative effects of sports drinks render them unfit to properly hydrate children and adolescents; instead plain or flavored
water should be the primary beverage. However, if an exercising
child is not drinking enough, is playing for more than three hours
in normal conditions, is engaging in repeated bouts of exercise
interspersed with short breaks, or is exercising in hot, humid
conditions for over one hour, then sports drinks would be the
best source of hydration.
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Abstract
The purpose of this paper is to better understand the methods problems and some solutions for siRNA treatments.
The benefits of this novel medical treatment are explored and its benefits are expounded on by comparing it to other
more complex and futuristic treatments. The exact process of siRNA silencing and down regulation is unknown. Some
hypotheses of how it may work are discussed giving precedence to the most widely accepted hypothesis. Although siRNA
treatments are not yet used on a major scale for many diseases, different possible treatment options are compared and
explained. Particular care was taken to give a broad range of illnesses in order to show the vast possibilities of siRNA
therapy. The common problems and some methods to overcome them are arranged in an orderly manner starting from
the time the siRNA treatment is administered, through its delivery and subsequent potency, followed finally by its degradation. SiRNAs viability as a treatment is then analyzed primarily on its large interest in many fields, as well as the enormous
progress it has made since its discovery just a short while ago.
Viability of SiRNA as a Clinical Treatment
The future of medicine is heading closer and closer to perfecting
gene therapy.While research is bringing the option to alter genes
closer to fruition, there is still a long way until it will be able to
be implemented. Simpler therapies albeit with their own set of
problems, seem to be a more realistic option for the foreseeable future. One in particular that has seen some progress is
the use of small interfering RNA (siRNA). ”Since its discovery
by Fire and Mellow in 1998, siRNA has proven to be a powerful
tool for modulating the expression of almost any gene in various
species.” (Nechaev, et al, 2013) During Göran Hansson’s speech
after receiving the noble prize for the discovery of a form of
RNA silencing, he said, referring to RNAi (more general term for
siRNA), that it “has added a new dimension to our understanding
of life and provided new tools for medicine.” (Eggleston, 2009).
It can have many applications and doesn’t necessarily require
the alteration of DNA. It allows the DNA to remain in its state
of disarray however it won’t allow the problematic gene to be
translated. This allows for control of the gene without having to
alter the DNA. The applications for this are countless. SiRNA
can treat many otherwise untreatable diseases ranging from viral
infections to complex genetic disorders (Endo-Takahashi. et al.
2012).Although the concept of siRNA is not a new one, there are
some kinks in how to use it as a treatment. One major setback
is that although it is now possible to create this aforementioned
silencing RNA (siRNA), its method of delivery is problematic.The
siRNA, if delivered indiscriminately, can wreak havoc in cells it
wasn’t intended for. It can stop crucial growth and functional elements of important life sustaining cells. It is therefore important
to deliver these potentially harmful substances only to their intended targets.This is just one of a few issues that can be a major
hindrance in siRNAs future as a treatment. It is imperative to
understand how siRNA works before an approach can be found
to tackle the issues that can arise in using siRNA as a treatment.
SiRNA silences the expression of specific genes allowing for particular cell functions to seize. SiRNA begins its life as a double
stranded RNA molecule (dsRNA). The dsRNA is cleaved into

shorter siRNAs. This process requires dicer to cleave the large
dsRNA. The siRNA is incorporated into a protein complex referred to as RNA inducing silencing complex (RISC). The still
double stranded siRNA is unwound by the protein complex via
multiple steps. The now single strand of siRNA leads the RISC to
the target RNA destroying it (Schwarz, et al, 2014).The destroyed
mRNA is no longer able to perform the function it was coded for.
This allows for a cell to continue with its other functions as long
as the specified protein isn’t crucial for the cells normal function.
The siRNA does not interact with the genome directly allowing
for less risk of creating mutant cells.

Possible Applications of siRNA
SiRNA has been studied largely for its application as a cancer
suppressor. It has however, many applications beyond that. whether in its ability to lower circulating cholesterol (Tep, et al, 2012)
by inhibiting the translation of a specific protein, or as a method
of controlling HIV-1(Zhou, et al, 2008) as well as possibly reducing any other potentially harmful protein synthesis. SiRNA can
have other non-clinical applications as well. Although the same
basic ideas and methods are used for all potential treatments
associated with siRNA the broad range of diseases it can potentially treat allows for some unique applications.
One study on the effects that siRNA can play in treating ovarian
cancer used a pretty classical method of using siRNA.The surface
protein cd44 is necessary in activating signal pathways necessary
for cancer, specifically metastasized, to continue its growth and
destruction. These pathways instruct the cell to continue transcribing proteins necessary for cell growth, as well as other factors that allow the cancer cells to live and multiply. The cd44
protein is also only found to be expressed by metastasized cancer cells, thus negating many of the issues associated with siRNA
delivery that will be discussed later.The study used siRNA as well
as an anticancer drug to see the combined effects they could
have on metastasized ovarian cancer. The siRNA was specific to
mRNA coding for cd44. It was carried out in vitro as well as in
vivo with similarly successful outcomes; the cancer cells growth
was slowed dramatically in both tests. Compared to just the use
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of the cancer drug and other chemotherapies, it was deemed
more efficient and aggressive. This is a truly great step forward
in finding a new cure with this rarely used method of treatment.
(Shah, et al, 2013).
SiRNAs use as a treatment for HIV is also being considered.“HIV1 gene expression, during productive and chronic infection, is essentially dependent upon the early regulatory genes tat and rav.”
(Caputo, et al, 1997) If a method to stop these regulatory genes
from being expressed can be found it can be used to virtually
control HIV. Although there have been many improvements in
controlling and preventing new outbreaks of HIV and the associated life altering conditions, HIV is still a still prolific disease(Centers for Disease Control, 2013) .
Working on this premise, researches created a siRNA delivery
method that is specific to the HIV strain they were interested in
controlling. The siRNA was manufactured to be specific to the
genes that coded for tat and rav. In stopping the expression of
these genes that are crucial for the viability of HIV-1 they were in
essence stopping the disease. Through methods including quantitative real time pcr, they were able to confirm that the genes
associated with rav and tat were significantly down regulated
(Zhou, et al, 2008).
The extensive range of treatments that can be possible with a
treatment involving siRNA doesn’t just apply to cases of cancer
and the HIV virus. It is being evaluated for its potential as a method of treating conditions involving an increased level of low density lipoprotein (LDL) cholesterol. “In individuals with 5-year risk
of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major
vascular events of about 11 per 1000 over 5 years” (Cholesterol
Treatment Trialists’ (CTT) Collaborators. 2012). A reduction in
ones LDL levels, specifically in the amount found in one’s blood
stream, has proven to reduce the risk of cardiovascular disease
(Manninen, et al, 1992), and might be a factor in lowering the risk
of those who have had a stroke previously from having another
(Sacco, et al, 2006) .
SiRNA can be used indirectly as a way to lower LDL cholesterol
levels. “ A novel therapeutic approach to lower LDL-c that is currently in clinical development involves blocking VLDL assembly
and secretion by inhibiting the microsomal triglyceride transfer
protein (Mtp)” (Tep, et al, 2012). By using siRNA to inhibit translation of the gene responsible for Mtp, they were able to reduce
the levels of LDL cholesterol found in the blood stream. This is
especially useful for those who don’t react well to the current
protocol set to reduce LDL levels by prescribing statins.
The broad range of application in a clinical sense for the use of
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siRNAs is apparent from the few studies mentioned. There are
many other applications that can be utilized, but those mentioned
here show how broad its ability as a drug can be. Most of these
studies however, are very theoretical. There are many hurdles
that must be overcome before being able to use it as a treatment.
The main hurdles being its delivery to a specific cell and stopping
a specific protein without affecting others.

Problems and Their Potential Answers
Delivery of SiRNA to cells has been a major problem for researchers. There are quite a few reasons that it is difficult to
deliver molecules of siRNA, or more specifically its precursor
dsRNA, to cells. The first is its really short lifespan. Even if the
dsRNA won’t degrade before reaching its desired location, the
trouble of getting it into the cytoplasm of the cell is a hurdle in
itself. However the biggest issue seems to be how to get these
crucial siRNAs to a specific cell. Once in the correct cell, problems may still arise. SiRNA can be finicky at times and down
regulate proteins that it wasn’t intended for. Basically the siRNA
has major issues with its specificity on the cellular level as well
as intercellular.
“Unmodified, naked siRNAs are relatively unstable in blood
and serum, as they are rapidly degraded by endo- and exonucleases, meaning that they have short half-lives in vivo.” (Akhtar,
Benter, 2007). This limits the ability to administer siRNAs in their
“naked” already modified form. However, chemically modifying
the siRNAs seems to prevent their untimely degradation. Studies
were done comparing siRNA in its naked, already modified form,
to siRNA that was chemically modified either by way of caging,
nanoparticles, or PEGylation. When this comparison was done
under conditions that simulated living in the blood stream, the
siRNA that had been modified showed a significant increase in
life span. Chemically modifying siRNA seems to be the way to
allow for the siRNA to survive its journey to the cell. (Shah, et
al 2013)
Surviving its journey to the cell is just the first of many hurdles
for this important new treatment. The next major stumbling
block to overcome is how to get it to the cell of choice. Although
siRNA is selective for specific proteins it can cause havoc in a cell
it wasn’t intended for. For example, even if a cell doesn’t have the
specific protein that this siRNA codes for it can cause unwanted mRNA degradation due to off targeting (B. Scaggiante, et al,
2011), a complication that will be discussed in a more general
sense in the coming paragraphs.
Some methods are being studied as ways to allow the delivery
to be more specific. The use of aptamers has been relatively successful in allowing the siRNA to reach specific cells, although it
has its own unique set of issues (Liu, Gao, 2013). Another method
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that has been used is connecting the siRNA enclosed in nanoparticles to an existing delivery system. This has shown promising
results especially when the intended drug is also used (Shah, et al,
2013). Other methods are showing promising results as well.This
leads to the next problem of the siRNA being delivered across
the cell membrane.
SiRNA can be especially difficult to deliver through the cell membrane due to its charge. The cell membrane has an affinity to
the siRNAs inherent charge causing it to be repelled. There are
several methods being studied to find the most efficient way of
allowing molecules of siRNA to penetrate the cell membrane.
The first is the physical or mechanical method. Using electroporation or ultrasound, for example, to allow for cellular uptake.
Another method being looked at is the use of chemicals either
to neutralize the negative charge of siRNA or deliver it through
other methods. (Zhou, et al, 2008)
With passage of siRNA through the cell now possible, off targeting, the last issue of delivery needs to be resolved. Although
siRNA is coded uniquely to suppress the desired protein, it isn’t
always so specific. If a similar protein is also produced in the cell
that the siRNA is delivered to, it can occasionally down regulate
that protein as well. A specific protein is one that has a similar
genetic code even though it can serve a very different and sometimes crucial role in the viability of the specified cell.
A few methods have been used to negate this off target silencing.
The methods mainly use modifications to the siRNA or dsRNA
starting material. By modifying the backbone of the strand, improved specificity was able to be reached. Although useful the
modifications tend to make the siRNA less efficient against the
target mRNA as well. There is one particularly successful option
that doesn’t affect the down regulation of the target mRNA as
much as many of the previous methods tried. This process requires adding a one nucleotide bulge on the antisense strand specifically at the second positon. The modified siRNA was found to
be more specific to the intended mRNA producing less mistaken
down regulation while still properly down regulating its intended
target. ( Dua, et al, 2011)
With its intended target found, the siRNA can now efficiently
down regulate it. However, the stable dsRNA that the RISC now
unwound to use as a mRNA inhibitor, is no longer as stable.
Due to its less stable state when joining the RISC, “Transfected
synthetic siRNA works for only a few days in mammalian cells.”
(Sioud 2004) While multiple treatments may reduce the issue of
short term effectiveness, a better solution may be available. Using
retroviral drugs the siRNA can be integrated into the genome
more specifically as hairpin RNA. This is like the naturally occurring non synthetic siRNA. Using siRNA the cell can regulate

itself post transcriptionally. By integrating the codons to produce
siRNA the time frame for siRNA longevity becomes indefinite.
This is not by it increasing in stability rather it allows for a constant dose without further intervention. (Stewart, et al, 2003)

Conclusion
The concept of using siRNA as a treatment for humans is one
that excites and can open many previously unavailable options
to those suffering many debilitating diseases. It is so promising
that any stumbling block that has arisen along the way hasn’t
deterred researchers from their final goal of using siRNA in the
clinical setting. They have attacked it from every angle and found
solutions for many problems and ideas for others.The main issue
of delivery primarily affects reaching specific cells or tissues with
specificity. There are clinical trials mainly focused on using siRNA
as a topical treatment. Although this method of treatment has
been proven successful, by eliminating many of the issues associated with delivery, it only works on areas that are able to react
to topical treatments. Topical siRNA treatments have seen much
progress and continue to pass multiple phases of their testing;
some have even been approved for clinical use. These treatments
bypass many of the issues discussed, and show the ability of
siRNA as a potential treatment for other diseases that need a
more complex delivery system.
The extensive opportunities for siRNA use are driving many to
discover new and improved methods. The way in which siRNA
has turned from a discovery into clinical trials in a mere fifteen
years attests to its great potential and likely future as a viable
treatment. There are many areas that are still unclear especially
regarding the methods in which siRNA works.With more discovery and new technology the methods of delivery and treatments
will likely improve and start the important work siRNA was intended for.
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